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The trypanosomatid parasites T. brucei, T. cruzi and Leishmania spp. are responsible for the 
‘neglected diseases’ Human African Trypanosomiasis, Chagas disease and Leishmaniasis 
respectively. In their human infective form in the bloodstream all three trypanosomatid 
parasites rely heavily on glycolysis for ATP production. Phosphofructokinase (PFK) catalyses the 
third step of the glycolytic pathway in all organisms using aerobic respiration. It facilitates the 
phospho transfer from ATP to fructose 6-phosphate (F6P) to make the products fructose 1,6-
bisphosphate (F16BP) and ADP.  RNAi knockout of T. brucei PFK has shown the enzyme is 
essential for survival of the bloodstream form parasites. Trypanosomatid PFKs have a unique set 
of structural and regulatory differences compared to the mammalian host enzyme. These 
differences, coupled with the availability of trypanosomatid PFK crystal structures present an 
opportunity for the structure-based design of specific inhibitors against the enzyme. 
Here we present an enzymatic characterisation of recombinant PFKs from T. brucei, T. cruzi and 
Leishmania infantum trypanosomatids, their regulation by the allosteric activator AMP, and 
their inhibition by drug-like inhibitor compounds. Inhibitor compounds (‘CTCB compounds’) 
were designed against T. brucei PFK with the aim of developing novel treatments against Human 
African Trypanosomiasis (HAT). We describe the testing, ranking and biophysical 
characterisation of these compounds as part of a Wellcome Trust Seeding Drug Discovery 
program. We found that CTCB inhibitor compounds bound to an allosteric pocket unique to 
trypanosomatid PFKs. We show that the compounds are specific; neither competing with the 
natural substrates ATP or F6P nor inhibiting the human PFK enzyme. 
We describe the development and testing of highly potent and specific low molecular weight 
PFK inhibitors that translate to both killing of cultured T. b. brucei parasites and a cure of stage 
I HAT in mice models. We describe the tight, 1:1 binding of these compounds with 
trypanosomatid PFKs, and the thermodynamic characteristics of binding through various 
biophysical assays. We also show the unprecedented characterisation of the reverse PFK 
reaction by trypanosomatid and human forms of the enzymes. We found that PFK can also carry 
out the reverse enzymatic reaction, under physiologically relevant concentrations of ADP and 
F16BP to produce F6P and ATP. We show that the reverse reaction is also subject to allosteric 
regulation by AMP, and can be inhibited by the CTCB compounds with a similar potency to the 
forward reaction. Finally, we describe the mechanism of allosteric activation by AMP and 





Protozoan parasites are microscopic organisms that invade larger organisms (known as the host) 
where they survive and reproduce at the expense of the host. The protozoan parasite species 
‘Trypanosoma brucei’, ‘Trypanosoma cruzi’ and ‘Leishmania infantum’ are responsible for the 
human diseases ‘African Sleeping Sickness’, ‘Chagas disease’ and ‘Leishmaniasis’ respectively. 
These diseases are caused by the parasites gaining entry to the human bloodstream through the 
bite of an insect ‘vector’ carrying the parasite. African Sleeping Sickness has two disease stages; 
In the first the parasites enter the human bloodstream and replicate. After some time, the 
parasites move from the bloodstream into the tissue of the brain and spinal cord – the second 
stage of the disease. The parasites can survive and reproduce both in the insect ‘vector’ and in 
the human ‘host’ organisms. We know that for the ‘Trypanosoma brucei’ parasites to survive in 
the human bloodstream, it relies on a pathway called glycolysis. This is an important pathway 
involving the breakdown of sugar (glucose) to produce energy in many organisms. Sugar is 
plentiful in the human bloodstream and this is the parasites main source of energy while it is in 
the bloodstream. Specifically, a protein known as phosphofructokinase (PFK) is an essential 
enzyme in the glycolysis pathway. Enzymes are proteins that speed up a chemical reaction. The 
chemical reaction involves starting molecules known as ‘substrates’. Enzymes speed up 
reactions by binding these substrate molecules and facilitating their change to the end products 
of the reaction before releasing them. PFK carries out an important step in the glycolysis 
pathway, without this enzyme, the Trypanosoma brucei parasites cannot survive in the human 
bloodstream. 
Because it is essential for survival of the parasites in the human bloodstream, this PFK enzyme 
was chosen as a target to design drugs to treat African Sleeping Sickness. This requires drug 
compounds to be designed, produced and tested for their ability to inhibit the activity of the 
Trypanosoma brucei PFK enzyme and kill the parasite. Humans also possess this PFK enzyme and 
so it is important that the drugs only inhibit the activity of the parasitic PFK enzyme. Importantly, 
the parasite PFK enzyme has a unique structure compared to the human enzyme form. This 
offers an opportunity to design drug molecules with specific properties that mean they only bind 
and inhibit the parasitic PFK enzyme and not the human form. 
 The primary aim of the work outlined in this thesis is to give a description of the effect of these 
inhibitor compounds on the activity of the PFK enzyme. This involved ranking the compounds 
according to how well they inhibited PFK activity, and providing a description of how the 




improve the design of the inhibitors to fit and inhibit the PFK enzyme better. To achieve this aim 
the Trypanosoma brucei PFK protein was produced by and harvested from large amounts of 
bacteria grown in the lab. The inhibitor compounds were then tested against the pure PFK 
protein in a number of experiments or ‘assays’ which measured the effect of the compounds on 
the PFK activity. We show that drug compounds designed against the parasitic PFK enzymes are 
effective inhibitors of the enzyme activity, and also lead to the death of living parasites in the 
laboratory. We also describe how and where the inhibitor compounds bind the PFK enzyme, and 
show that the compounds bind the parasitic PFK enzyme specifically over the human form.  
The secondary aim of this thesis was to draw comparisons between the PFK enzymes from the 
Trypanosoma brucei, Trypanosoma cruzi and Leishmania infantum species in terms of their 
activity. The aim of this work was to further our understanding of the reliance that each parasite 
species places on the PFK enzyme for survival. We show how PFKs from these three parasitic 
species differ from each other in terms of the speed at which the enzyme carries out its role in 
glycolysis.  
Biological enzymes are often regulated by certain chemicals found within the cells of organisms. 
These chemical regulators can speed up or slow down the activity of the enzyme, and in the case 
of PFK, are important in controlling the overall speed of the pathway in which they are part of. 
We describe how the PFK enzymes are regulated by a chemical activator of the enzyme, and 
compare the effect of this enzyme regulator across the PFK enzymes from the three parasitic 
species. Furthermore, we show how the parasitic PFK enzyme can run in reverse – carrying out 
the opposite chemical reaction under conditions that may occur in the parasite organism. This 
has not been reported before, and the PFK enzyme is traditionally not thought to be able to run 
in the reverse direction. 
Finally, we link together all of our observations regarding the activity and inhibition of the 
parasitic PFK enzymes to develop a model for how the enzyme works and how it is regulated on 
a molecular level. We show that the inhibitor compounds designed against the Trypanosoma 
brucei parasite PFK enzyme are effective at killing parasites grown in the lab, and that the 
compounds lead to a cure of the first stage of the African Sleeping Sickness disease in the 
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Chapter 1: Introduction - phosphofructokinase and 
Human African Trypanosomiasis. 
 
1.1. Introduction. 
The main aim of the work outlined in this thesis is to give a description of the molecular 
regulation of the glycolytic enzyme phosphofructokinase (PFK) in trypanosomatids. This 
overriding aim has two parts; firstly to investigate and describe the ‘physiological’ molecular 
regulation of phosphofructokinase by its substrates, known and potential effectors and 
metabolic intermediates. The purpose of this study was to provide an understanding of the 
underlying activity and regulation of the enzyme, as a target for developing drugs against 
trypanosomatids. This leads to the second focus of this project; to provide a description of the 
molecular inhibition of Trypanosoma brucei PFK by small molecules designed against the 
enzyme. This chapter introduces the diseases caused by trypanosomatids, explains the 
reasoning for selection of phosphofructokinase as a target for anti-trypanosomatid drug 
development and outlines the role of the enzyme within the parasites. 
1.2. Human African Trypanosomiasis. 
The work described in this thesis was carried out as part of a Wellcome Trust funded ‘Seeding 
Drug Discovery’ (SDD) project awarded to the Walkinshaw Group at the University of Edinburgh. 
This study aimed to identify and design small molecule inhibitors against the glycolytic enzyme 
phosphofructokinase in T. brucei parasites. The overall outcome was to develop novel drug 
candidates against Human African Trypanosomiasis (HAT). The work described in this thesis was 
carried out by the author in a research technician role working on the SDD project. Compound 
synthesis was carried out by Selcia Ltd, in vitro parasite culture work by Dr L. Yen and in vivo 
mouse work by Dr D. Malik at the University of Edinburgh. 
The parasitic kinetoplastid Trypanosoma brucei is the cause of Human African Trypanosomiasis 
(HAT) or ‘sleeping sickness’ – a blood-borne disease spread by the bite of tsetse flies (Glossina 
spp.) carrying the parasite (Brun et al., 2010).  T. brucei has 3 morphologically similar pathogenic 
subspecies; T. b. gambiens which causes HAT endemic to west Africa, T. b. rhodesiense causing 
an acute form of HAT in south and east Africa and T. b. brucei which is pathogenic to wild game 
and domestic mammals (African Animal Trypanosomiasis –AAT or ‘Nagana disease’) but not man 




pathogenic foci across Africa.  HAT is fatal if left untreated, and is a major cause of 
underdevelopment in countries where the disease is endemic (Brun et al., 2010; Stich et al., 
2002). Poor, rural areas are worst affected due to increased likelihood of transmission from 
hunting, fishing and farming activities, where the natural habitat of the tsetse fly vector is 
coupled with pools of asymptomatically infected animals with T. b. gambiense and T. b. 
rhodesiense (Brun et al., 2010). 
Modern vector control and population surveillance initiatives have reduced cases of the T. b. 
gambiense disease by 69% and T. b. rhodesiense reported cases by 4% between 1997 – 2006 in 
the 24 countries where the diseases are endemic (Barrett, 2006; Brun et al., 2010). 
Underreporting masks the true number of cases; a record low of 2,800 cases were reported in 
2014 however the actual number of people infected is estimated at 20,000, with 65 million 
people at risk (http://www.who.int/).  
 
Figure 1.1: Distribution map of human pathogenic Trypanosomiasis cases across Africa. 
Black line separates areas where the T. b. gambiense and T. b. rhodesiense foci prevail. 





1.2.1 Trypanosomatids and ‘neglected diseases’. 
The trypanosomatid parasites T. brucei, T. cruzi and Leishmania spp. are the causative agents of 
HAT, American trypanosomiasis (Chagas disease) and Leishmaniosis diseases in humans 
worldwide. A high proportion of affected individuals coupled with a lack of sufficient drug 
development to treat HAT, Chagas Disease and Leishmaniasis has led the World Health 
Organisation to describe these as ‘neglected diseases’(Brun et al., 2010). While HAT and Chagas 
are 2-stage diseases, three forms of Leishmaniasis occur; Visceral Leishmaniasis (VL) or ‘kala-
azar’, cutaneous Leishmaniasis (CL) and mucocutaneous Leishmaniasis (ML). Table 1.1 provides 
a summary of these three neglected diseases. 
 African Trypanosomiasis1 Chagas Disease2 Leishmaniosis3 
Parasite(s)  
responsible 
T. b. gambiense (HAT) 




Trypanosomiasis – ‘AAT’) 
T. b brucei (AAT- livestock) 
T. evansi (AAT – livestock) 
T. equiperdum (AAT – 
Horses) 
T. cruzi. 
Kala-azar disease results 
from other zoonosis 




>20 Leishmania spp.  
VL: L. donovani, L. infantum. 
CL: L. tropica, L. peruviana, 
L. mexicana, L. infantum. 
ML: L. amazonensis, L. 
braziliensis, L. panamensis. 
Zoonosis: L. major. 
Disease  
vector 
Tsetse fly (Glossina spp.) 
bite – blood meal. 
Animal reservoirs (T. b. 
rhodesiense) – wild and 
domestic. 
Triatomine ‘kissing bug’ 
– various species. Bite 
and contact with faeces. 
Animal reservoirs – wild 
and domestic. 
Female phlebotomine 
Sandfly bite – blood meal. 
Reservoirs in 70 animal 
species.  
Prevalence Estimated 20,000 new 
cases annually. 65 million 
at risk. 
6 – 7 million infected 
currently. 
0.7 – 1 million new cases 




Sub-Saharan Africa (T. b.  
rhodesiense/gambiense/br
ucei). South America and 
Asia (T. b.  evansi, T. vivax) 
4.  
Initially endemic to S. 
America. 21 Latin 
American countries.  
New cases recently in 
USA, Canada and Europe 
due to migration of 
people – vector is absent 
outside S. America. 
VL: 98 countries. Most 
prevalent in Brazil, Ethiopia, 
Kenya, Somalia, Sudan, 
Bangladesh and India. 
CL: Americas, 
Mediterranean, Middle East 
and Central Asia. 







Stage I (1.5 yrs.): 
Proliferation of parasites 





Stage II (1.5 yrs.): Parasites 
invade CNS. Disruption of 
sleep cycle, 
neuropsychiatric disorders 
and death if untreated. 
Acute stage (2 months): 
parasites proliferate in 
bloodstream. Unspecific 
symptoms, characteristic 
skin lesions and eye 
swelling. 
Chronic stage (1+ yrs.): 
Parasites invade heart 
and muscles of digestive 
system. Cardiac and 
digestive disorders. 
Sudden death in later 
years due to heart and 
CNS failure.  
VL: Fever, weight loss, 
enlargement of spleen and 
anaemia. 
CL: Skin lesions on exposed 
parts of body. Lifelong scars 
and disability. 
ML: Destruction of mucous 




Stage I: Pentamidine, 
Suramin. 
Stage II: Eflornithine, 
Melarsoprol, Nifurtimox.  
Benzimidazole, 
Nifurtimox. Most 
affective if treated in 
acute stage.  
Dependant on disease type 
and location. VL: 
Paromomycin, liposomal 
amphotericin B, pentavalent 
antrimonials. CL: 
Paromomycin, Fluconazole 
and Pentamidine.  
 
Table 1.1: Fact file on HAT, Chagas and Leishmaniosis neglected diseases. 
1. WHO factsheet 259 Jan 2017. 2. WHO factsheet 340 Jan. 2017. 3 WHO factsheet 375 Jan 2017. 
(http://www.who.int/) 4. (Morrison, Vezza, Rowan, & Hope, 2016a). 
1.2.2 AAT – Animal African Trypanosomiasis. 
Animal African Trypanosomiasis (AAT) or ‘Nagana disease’ is caused by  multiple species and 
strains of trypanosomes but two species predominate ; T. congolense and T. vivax in sub-Saharan 
Africa and T. vivax in south America are responsible for the most significant infections. T. b. 
evansi and T. b. brucei are also pathogenic to animals. Both T. vivax and T. b. evansi have 
developed mechanical transmission allowing them to spread out with the African tsetse fly 
transmission areas to South America and Asia respectively (Morrison, Vezza, Rowan, & Hope, 
2016b). The disease affects wild game animals as well as domestic cattle and pig livestock and is 
a major contributing factor to economic underdevelopment in rural areas (Brun et al., 2010; 
Stich et al., 2002).  
The majority of knowledge on African Trypanosomiasis is based on research into the T. brucei 
species and mice models of the disease. While the T. b. brucei subspecies is pathogenic in 
animals, the case for more focus on T. congolense and T. vivax studies has been made (Morrison 




traditional mice models of T. brucei infection are becoming insufficient in making advances 
against AAT. Differences in the host (bovine) immune response, the regulation of parasite 
antigenic variation (VSGs) and differences in T. congolense and T. vivax drug uptake and 
resistance require a more focused approach on these species over T. brucei to advance progress 
on vaccines or drugs against AAT.  
1.2.3 Trypanosomatidae phylogenetic tree. 
Figure 1.2 shows a phylogenetic tree of the major disease causing species of Trypanosomatidae 
responsible for African trypanosomiasis, Chagas disease and Leishmaniasis. The three T. brucei 
subspecies (T. b. brucei, T. b. rhodesiense and T. b. gambiense) are not monophyletic; while T. b. 
brucei and T. b. rhodesiense differ only by a single gene that confers resistance to a lytic factor 
in human blood serum (T. b. rhodesiense), T. gambiense has evolved on a separate phylogenetic 
branch (Richardson et al., 2017).  
 
Figure 1.2: Phylogenetic tree of main pathogenic members of the Trypanosomatidae group. 
Main causative species of African trypanosomiasis (red), Chagas disease (blue) and 





1.2.4 Epidemiology of T. brucei infection in HAT. 
Trypanosomes are protists belonging to the family Trypanosomatidae. They are unicellular 
organisms ~15 – 30 µm in length. They contain a nucleus, a single mitochondrion that spans 
from the posterior to anterior end of the parasite and a concentrated circular mitochondrial 
DNA density inside the kinetoplast. The parasite moves via a single flagellum – a semi-rigid 
structure made up of a doublet of microtubules (‘axoneme’) and a paraflagellar rod. The 
flagellum is connected to the mitochondrial genome via a basal body attached to the kinetoplast 
(figure 1.3) (Matthews, 2005). The parasite contains membrane-bounded organelles called 
glycosomes in which the first seven steps of glycolysis occur. 
 
 
Figure 1.3: Structural architecture of typical Trypanosomatidae parasite. 
Image adapted from Matthews, 2005.  
The T. brucei parasite uses both male and female tsetse flies as a transmission vector. The fly 
must take a blood meal from an infected animal. The parasite undergoes a number of complex 





Figure 1.4: Insect vector and human host life cycle stages for Trypanosoma brucei.  
Adapted from (http://www.cdc.gov/parasites/sleepingsickness/biology.html)  
In the tsetse fly gut the formerly bloodstream form (BSF) trypomastigotes differentiate for 3-5 
weeks before entering the salivary gland where they develop into an infective ‘metacyclic’ form. 
Only 0.1% of tsetse fly vectors will develop a fully mature infective parasite for transmission. It 
is the metacyclic form of the parasite that is transferred when the tsetse fly takes a blood meal 
from mammals. In the bloodstream, the T. brucei trypanosomes must overcome immune 
responses and prevent overconsumption of host resources from over proliferation; over 
proliferation will lead to host death and lessens transmission potential. 
The first hurdle (immune system detection) is overcome through antigenic variation – 
trypanosomes constantly vary the expression of variant surface glycoproteins (VSG) to prevent 
immune system detection (Vickerman, 1978)(Taylor & Rudenko, 2006). Over proliferation is 
avoided by a density-dependant developmental switch from a proliferative ‘slender’ form to a 
non-proliferative (G0/G1 arrested) ‘stumpy’ form (Silvester, McWilliam, & Matthews, 2017). 
Stumpy T. brucei parasites halt antigenic variation, but instead have a greater rate of endocytosis 














Two differentiated disease stages are a product of the trypanosomatid life cycle while in the 
human host:   
Stage I. The first stage (‘haemolymphatic stage’) of the disease is caused by parasites inhabiting 
the blood and lymphatic systems. The parasites avoid lytic factors and immune detection 
through variable expression of cell-surface glycoproteins, which are encoded by >2000 genes in 
T. b. brucei (Taylor & Rudenko, 2006). Human blood serum contains a lytic factor against 
trypanosomes. The non-pathogenic T. brucei subspecies T. b. brucei differs with the human 
pathogenic T. b. rhodesiense only by a single gene that encodes resistance to this lytic factor. 
Many of the glycoproteins are recognised by the immune system but those that are not allow 
the parasite to proliferate within the host.  This stage is characterised by generalised fever, 
headaches and lymphenopathy (swollen lymph nodes) and can last up to 1 ½ years in the case 
of T. b. gambiense. 
Stage II. The second stage (‘meningoencephalitic stage’) disease is caused by invasion of the 
central nervous system (CNS) by the parasite. The parasite remains extracellular and crosses the 
blood-brain barrier through gaps in intercellular junctions into the brain parenchyma (Masocha, 
Rottenberg, & Kristensson, 2007). Clinical characteristics include disruption of the sleep cycle 
through circadian rhythm complications, neuropsychiatric disorders and eventually death if left 
untreated. This stage can last up to 1 ½ years in the case of T. b. gambiense infections. T. b. 
rhodesiense infections cause an acute form of the disease in which the death of the host can 
occur within weeks or months from initial infection. 
1.2.5 Diagnosis of HAT. 
Initial diagnosis of first stage HAT is based on identification of the parasite in the blood in the 
form of finger pricks and laboratory testing including immunological ‘CATT card’ test and PCR 
identification (Biéler et al., 2016). Diagnosis, as well as treatment differs between the first and 
second stages of the disease. Second stage HAT requires more training and expertise as CNS 
lumbar punctures are required to identify the parasites and/or an elevation in white blood cells 
(Stich et al., 2002). Diagnosis therefore requires a high level of material and human resources 
and a stable infrastructure for screening and treatment. This is a difficulty in many of the rural 
and economically deprived areas where the disease is endemic. Increased research into better 
diagnostic methods is required and prompted the WHO’s ‘FIND’ (Foundation for Innovative New 





1.2.6 Current treatment of HAT. 
Historically, dyes such as ‘trypan red’ and arsenic-based chemicals that showed killing of 
trypanosomes were amongst the first disease-specific treatments (coined ‘Chemiotherapy’) to 
arise (Alsford et al., 2012a; Ehrlich, 1913). Amazingly, some current HAT treatments such as the 
trypan-red based drug ‘Suramin’ and the arsenic compound ‘Melarsoprol’ are still related to 
these original chemicals (Alsford et al., 2012b). The main treatments for HAT fall into those 
which can be used to treat the stage I form of the disease (Pentamidine and Suramin) and those 
which treat the stage II form of the disease as the parasites enter the CNS (Eflornithine, 
Nifurtimox and Melarsoprol). A summary of the current HAT treatments is given in table 1.2. 
As seen in table 1.2, there are many major drawbacks to the current treatments for first and 
second stage HAT caused by T. b. rhodesiense and T. b. gambiense. Generally, stage I treatments 
are relatively non-toxic but have poor blood brain barrier (BBB) penetration. Stage II treatments 
have good BBB penetration but are highly toxic and in some cases lethal (Masocha et al., 2007). 
All of the current treatments have serious drug-related side effects, and in some cases such as 
the widely used Melarsoprol, these can be fatal. Drug resistance and treatment failure rates are 
increasing, and have been reported for Suramin since the 1950’s (Pepin & Milord, 1994), 
although recently this has been disputed as treatment failure and not resistance (Wiedemar et 
al., 2017). Resistance to Pentamidine and Melarsoprol is due to a loss of a membrane 
transporter (de Koning, 2008) (Alsford et al., 2012b) (Munday et al., 2014). Side effects likely 
stem from untargeted modes of action; Melarsoprol is known to inhibit 80 assays out of a total 
of 370 listed in PubChem (Brimacombe et al., 2014).  
Difficulties also arise in drug delivery; administration requires complex dosing schemes via 
intravenous or intramuscular injection – making treatment difficult in the rural areas in which 
the disease is endemic (Brun et al., 2010; Yun, Priotto, Tong, Flevaud, & Chappuis, 2010). In 2009 
a combinatorial therapy named ‘NECT’ (Nifurtimox-Eflornithine Combination Therapy) was 
introduced. NECT offers significant advantages over Eflornithine monotherapy as a stage II T. b. 
gambiense treatment; patients are 50% less likely to develop serious side effects compared to 
Eflornithine monotherapy, and the cost of the total treatment, due to lower dosing schedules, 
is much smaller at €39 per patient compared to Eflornithine at a cost of €107 per patient (Yun 
et al., 2010).  Reported efficacy is also improved with NECT – with 98% cure rates being reported 
over 92% for Eflornithine monotherapy (Yun et al., 2010). Using combinational therapies such 
as NECT also reduce the likelihood of parasite resistance over using Melarsoprol and Eflornithine 




treatment schedule, and is much less effective for treating 1st or 2nd stage HAT cause by T. b. 
rhodesiense. The need for an orally available, targeted and selective treatment for both stages 





Drug Stage of disease Mode of action 
validated? 
Side effects 
T. b. gambiense    
Pentamidine (1940s) 
 














2nd Yes – blocks polyamine 






vomiting and anaemia 
Melarsoprol* (1949) 
 
2nd Yes – converted to 
melarsen oxide in body – 
promiscuous inhibitor of 
many metabolic 
pathways [3].  
Encephalopathic 
syndromes – 5-10 % 
fatality rate. Skin 
reaction, 
neuropathies. 
‘NECT’ – Nifurtimox + Eflornithine 
combination therapy (2009) 






symptoms 50% less 
likely than 
monotherapy [4]. 
T. b. rhodesiense    
Suramin (1920s) 
  




Melarsoprol (1949) 2nd Yes – see above See above 
Others    
Nifurtimox Ɨ 
 
2nd 2 possible MOA – see 
section 1.2.7. Current 
treatment for Chagas 
disease 
Anorexia, weight loss, 
nausea, vomiting, 
vertigo. 50% of 
patients cannot 
complete treatment. 
Fexinidazole (phase II trials 2012) 
 
Active in 1st and 
2nd stage HAT 
models 




Cure in 2nd stage 
HAT models 




Table 1.2: current treatments for human African Trypanosomiasis (HAT). 
* Where Eflornithine is not available or not currently registered as a 1st stage treatment for T. 
b. gambiense. Ɨ Where Eflornithine and Melarsoprol are not effective 
[1] (Lanteri, Tidwell, & Meshnick, 2008a). [2] (Van Bogaert & Haemers, 1989).[3] (Verlinde et al., 




1.2.7 Trypanosomatid drug uptake and mechanisms of current HAT treatments. 
Current treatments for HAT can be grouped into 2 categories; those that are used for treating 
the haemolymphatic (stage I) form of the disease, and those used for the meningoencephalitic 
(stage II) phase of the disease. They differ in both their mechanism of action (MOA) and uptake 
into the parasite cell. 
Stage I treatments: 
Suramin; Suramin is large (1.3 KDa) and has a negative charge so cannot pass through lipid 
membrane barriers by passive diffusion. Uptake is likely facilitated by trypanosome endocytosis. 
A recent study confirmed that the genes encoding 4 lysosomal proteins, an adaptin complex 
(‘AP1’) that facilitates endosomal clathrin-mediated trafficking and a BSF-specific invariant 
surface glycoprotein ‘ISG75’ were required to maintain the efficacy of Suramin against cultured 
T. brucei parasites lacking the gene (Alsford et al., 2012b). Suramin’s specific MOA is still 
unknown. 
Pentamidine; Pentamidine’s MOA involves multiple targets. It is known to bind nucleotides, and 
accumulates to millimolar concentrations in the trypanosome where it disrupts the 
mitochondrial membrane potential (Lanteri, Tidwell, & Meshnick, 2008b). Potential targets have 
been found : two P-type ATPases and a plasma membrane H+-ATPase (Alsford et al., 2012b). 
Uptake of Pentamidine was first found to be related to an adenosine transporter (‘AT1’), the 
loss of which has been observed in drug resistant strains (Carter & Fairlamb, 1993). Recently the 
role of an aquaglyceroporin ‘TbAQP2’ has been found to also play a role in resistance (Munday 
et al., 2014). 
 
Stage II treatments: 
Melarsoprol; Melarsoprol’s mode of action is related to the formation of a stable adduct with 
the kinetoplastid-specific antioxidant ‘trypanothione’. This complex is named ‘Mel T’ and its 
toxic nature that inhibits a number of metabolic pathways is also responsible for its significant 
side effects in humans (Alsford et al., 2012b). Similar to Pentamidine, Melarsoprol’s uptake and 
resistance is related to the adenosine transporter ‘AT1’ and ‘TbAQP2’ aquaglyceroporin in 
trypanosomes (Carter & Fairlamb, 1993) (Munday et al., 2014). Treatment failure rates for 




Eflornithine; Eflornathine irreversibly inhibits ornithine decarboxylase – an enzyme involved in 
Polyamine synthesis. Polyamine synthesis is essential for the trypanosome’s cell growth and 
replication (Van Bogaert & Haemers, 1989). Elfornithine’s MOA is thought to be trypanostatic 
and not trypanocidal. Its uptake and emerging resistance is facilitated by ‘AAT6’ - a member of 
an amino acid transporter family (Vincent et al., 2010). 
Nifurtimox; Nifurtimox is the primary treatment for American trypanosomiasis (Chagas disease). 
Activation of the prodrug to a toxic product and resistance is facilitated by a mitochondrial type 
1 nitroreductase (Wilkinson, Taylor, Horn, Kelly, & Cheeseman, 2008)(Hall, Bot, & Wilkinson, 
2011). Two schools of thought remain on the drug’s downstream MOA; 
 It forms a nitro-anion radical metabolite that damages the parasite’s DNA, similar to the 
MOA of antibacterial ‘nitrofuran’ compounds (Gutteridge, 1985). 
 It results in the production of toxic superoxide anions and hydrogen peroxide (H2O2) 
from the inhibition of the parasitic antioxidant enzyme ‘trypanothione reductase’ (Marr 
& Docampo, 1986). 
The unknown MOA, significant side effects and complex dosing and administration regimes of 
the current HAT treatments present the need for new, orally administered drug candidates to 
fight the disease. Coupled with evidence of emerging resistance to some of the drugs, the need 





1.3. Glycolysis as a target for anti-trypanosomatid drugs. 
1.3.1 Trypanosomatid metabolism and reliance on glycolysis. 
The glycolytic pathway is a promising target for anti-trypanosomatid drugs, as reviewed by 
Barros-Alvarez et al. (2014) and Verlinde et al. (2001). Bloodstream-form (BSF) T. brucei 
trypanosomes rely solely on aerobic glycolysis for their ATP production (Barros-Alvarez et al., 
2014).  BSF trypanosomes adapt to use aerobic glycolysis for energy production in the 
bloodstream. Mitochondrial metabolism, the respiratory chain and the TCA cycle are all severely 
repressed in this life cycle stage. In T. brucei promastigotes, 40% of the enzymes contained 
within the glycosomes are glycolytic enzymes, this proportion increases to 90% in the BSF stage 
where glucose supplies are plentiful (Barros-Alvarez et al., 2014). Each of the glycolytic enzymes 
in BSF T. brucei have been validated as essential for parasite survival through RNAi knockdown 
experiments (Albert et al., 2005; Caceres, Michels, & Hannaert, 2010). Starving BSF T. brucei  
cultures of glucose, or incubating cultures with the glucose transporter inhibitor ‘Phloretin’ 
causes cell death within minutes (Seyfang & Duszenko, 1991). Amino acids and lipids are still 
taken up in BSF trypanosomes, but are used for anabolic processes and cell material synthesis, 
not ATP production (Barros-Alvarez et al., 2014). 
In the bloodstream, T. brucei trypanosomes undergo a density-dependant developmental switch 
from ‘slender’ to ‘stumpy’ forms. Aside from the morphological and cell cycle changes associated 
with this switch, the parasites upregulate a number of metabolic proteins. In preparation for 
transmission into the Tsetse fly salivary and gut as procyclic trypanosomes, T. brucei parasites 
activate their mitochondrion. A number of metabolic proteins are upregulated in the switch to 
stumpy forms to prepare for this, and a great deal of evidence now suggests that BSF T. brucei 
parasites are capable of a rapid switch to alternate energy metabolism – reviewed by ((Zikova, 
Verner, Nenarokova, Michels, & Lukes, 2017). Stumpy form parasites have been found to be 
dominant over slender forms in late state HAT infections in mice (MacGregor, Savill, Hall, & 
Matthews, 2011). It is thought that this stage allows for immediate changes in metabolic 
pathways used once the parasite moves to a new environment, such as the fly midgut or, as 
recently reported, the host skin tissue (Tanowitz, Scherer, Mota & Figueiredo, 2017) or adipose 
tissue where fatty acid metabolism genes are upregulated (Capewell et. al, 2016). While this 
emerging evidence suggests alternative metabolic pathways are used by T. brucei parasites 
within the human host, it is clear that in the bloodstream the parasites are heavily reliant on 
glycolysis. This presents a window of opportunity for drug development against the infective 




1.3.2 The glycosome and glycolytic enzyme targets. 
Trypanosomes contain membrane-bounded organelles called glycosomes where 7 out of the 10 
glycolytic enzymes are found. Glycosomes in BSF T. brucei trypanosomes are highly specialised 
– 90% of the protein content is made up of glycolytic enzymes (P. A. M. Michels, Bringaud, 
Herman, & Hannaert, 2006). Figure 1.5 shows the compartmentalisation of glycolysis and 
related metabolic pathways in T. brucei, T. cruzi and Leishmania spp. glycosomes. The 
localisation of essential glycolytic enzymes within these organelles coupled with the 
evolutionally divergence between the enzymes in parasite and man has resulted in unique 
structural and functional differences in the glycosomal proteins that can be exploited in drug 
discovery against trypanosomes.  Compartmentalisation provides a unique glycolytic 
environment; there is no net ATP production within T. brucei glycosomes, meaning an ATP/ADP 
balance is maintained within the organelles. A constant NAD+/NADH balance is also maintained, 
and the organelle is said to be in equilibrium. Other metabolic pathways are also found within 
glycosomes, such as the pentose phosphate pathway (PPP), an extension of the glycolytic 
pathway to produce succinate, and routes for nucleotide sugar synthesis (figure 1.5). 
Glycolytic flux within the glycosomes of BSF T. brucei is very high – inhibition of enzymes 
resulting in just a 50% reduction of glycolytic flux causes cell growth arrest and death of 
trypanosomes (Barros-Alvarez et al., 2014).  The compartmentalised enzymes in trypanosomes 
are not subject to the regulatory mechanisms controlling glycolysis in many other cells (Verlinde 
et al., 2001); two examples are the regulation of hexokinase and PFK, which are heavily regulated 
in other organisms but not in trypanosomatids (Nwagwu & Opperdoes, 1982). Instead, the 
compartmentalisation of the first 7 steps of glycolysis means that net ATP production occurs 
outside the glycosome, and does not fuel hexokinase and PFK, therefore removing the need for 
regulation to prevent the ‘turbo effect’ (Haanstra et al., 2008). A long evolutionary divergence 
between trypanosomatids and mammals (Fernandes, Nelson, & Beverley, 1993) coupled with 
the unique regulatory and structural differences as a result of glycosomal compartmentalisation 
makes glycolysis an attractive target for anti-trypanosomatid drugs (Barros-Alvarez et al., 2014; 
Verlinde et al., 2001) . Each of the glycolytic enzymes in T. brucei have been kinetically 
characterised and sequence identity between human and parasite forms is as low as 21% (PFK) 




























Figure 1.5: metabolic pathways localised to the glycosome and used in BSF T. brucei, T. cruzi and 
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1.3.3 Alternative metabolic pathways as anti-trypanosomatid targets. 
Other transport and metabolic pathways linked to glycosomes also serve as targets of interest 
for developing anti-trypanosome drugs.  Many of these pathways are predominant in the 
procyclic parasite stage in the tsetse fly midgut, and not expressed or only at low level in the 
bloodstream forms.  These include the pentose phosphate pathway (PPP), an extension of the 
glycolytic pathway to allow production of succinate in the glycosome and synthetic routes for 
sugar nucleotide synthesis needed for glycosylation reactions (reviewed in Barros-Alvarez et al., 
2014).  
Glycosomal metabolism differs slightly between human pathogenic forms of T. brucei, T. cruzi 
and Leishmania spp.  A considerably higher proportion of glucose is used in the PPP and 
succinate pathways in the T. cruzi glycosome compared to T. brucei and Leishmania spp. The T. 
cruzi mitochondrion is more developed than in BSF T. brucei as it possesses a TCA cycle and 
electron transfer chain in both life cycle stages (Barros-Alvarez et al., 2014). T. cruzi also contain 
the enzymes for an extended glucose catabolic pathway to produce succinate, in contrast to T. 
brucei which has a more ‘glycolysis optimised’ glycosome (Barros-Alvarez et al., 2014). Recent 
evidence however indicates that T. brucei BSF parasites, notably in stumpy but also in long-
slender forms have a significantly more complete mitochondrial proteome than previously 
thought, although expressed at low level, in agreement with metabolic carbon products such as 
pyruvate, acetate, malate, fumarate and succinate being observed in cultured BSF T. brucei 
(Zikova, Verner, Nenarokova, Michels, & Lukeš, 2017)  
Leishmania spp. live as ‘amastigotes’ in their pathogenic human stage in phagolysosomes of 
macrophages and other phagocytotic cells, which have an acidic, low glucose and high amino 
acid environment (Barros-Alvarez et. al, 2014). As such gluconeogenesis is predominant over 
glycolysis in Leishmania amastigotes. β-oxidation of fatty acids, for which the enzymes involved 
are contained within both the mitochondrion and glycosomes, provides the main source of 
energy for the amastigotes (Barros-Alvarez et. al, 2014). Purine salvage and pyrimidine synthesis 
is also facilitated by the glycosomes in Leishmania spp. 
Targeting glycolysis remains an excellent option for developing drugs against T. brucei 
bloodstream parasites, however for T. cruzi, and Leishmania spp. alternative metabolic targets 
should be considered, as less reliance is placed on glycolysis for survival. Whether this is also 





1.3.4 Alternative metabolic pathways targeted in anti-trypanosomatid drug 
development. 
The pentose phosphate pathway has been targeted for anti-trypanosome drugs through 
inhibition of glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate 
dehydrogenase (6PGDH) (see PPP oxidative branch, figure 1.5); Human steroids such as 
epiandrosterone un-competitively inhibit the T. brucei enzymes at low µM range, but with 
limited selectivity and do not inhibit the Leishmania spp. enzyme form (Cordeiro & Thiemann, 
2010; Cordeiro, Thiemann, & Michels, 2009). Prodrug analogues of the substrate for 6-
phosphogluconate (6PDH) have been shown to exhibit trypanocidal activity with ED50’s of 0.008 
– 43 µM (Dardonville et al., 2004). Targeting the PPP in trypanosomes leads to a supressed 
oxidative stress response that leads to increased H2O2 death in T. brucei (Barros-Alvarez et al., 
2014). 
Purine salvage enzymes  Hypoxanthine-guanine phosphoribosyl transferase (HGPRT) and 
xanthine phosphoribosyl transferase (XPRT) have also been targeted with the drug Allopurinol 
showing trypanostatic activity in Chagas disease models  in dogs (Koutinas et al., 2001) and mice 
(Gobbi et al., 2007). Subtle differences observed in the active sites of crystal structures of human 
and T. cruzi HGPRT lead to a screen for compounds yielding candidates with low µM ED50’s and 
Ki’s of 0.5-17 µM against the parasite (Freymann et al., 2000). 
Low nanomolar inhibitors of the genetically validated anti-T. brucei target glycogen synthase 
kinase-3 (GSK-3) have recently been developed (Urich, Luksch, Frearson, Brenk, & Wyatt, 2014). 
The glycosomal membrane is a permeability barrier for metabolites, cofactors (ATP, NADH), 
lipids and proteins larger than ~400-500 Da. Glycosomal membrane transporters are another 
promising target for anti-trypanosome drugs therefore, preventing the shuttling of material 
important for survival.  Little is known about glycosomal transport of small molecule 
intermediates. Peroxisome protein transport has been researched extensively however (review 
available by Galland and Michels (Galland & Michels, 2010)). Low sequence similarity homologs 
of peroxisome transport proteins have been identified in T. brucei for two classes of 
transporters;  ATP-binding cassette (ABC) transporters – of which 3 have been identified in T. 
brucei (Yernaux et al., 2006), and a mitochondrial carrier family (MCF) transporter – of which 
one has been identified in T. brucei (Colasante, Peña Diaz, Clayton, & Voncken, 2009). Two 
plasma membrane glucose transporters are known in T. brucei: THT1 which is expressed in BSF 
parasites and THT2 which is expressed in the insect form of the parasite are promising inhibitor 




1.3.5 Considerations for glycolytic target choice: metabolic flux.  
The reliance of trypanosomes on glycolysis, and the rapid death of trypanosomes where the 
pathway has been blocked presents a promising target for anti-trypanosome drug compounds. 
As reviewed by Verlinde et al., there are two requirements for blocking the flux of an essential 
metabolic pathway; the targeted enzyme must exert sufficient control on the flux, and the 
affinity of the inhibitor against the target must be high enough to sufficiently block its 
activity(Verlinde et al., 2001).  
Metabolic control analysis is a technique whereby the physiological effects of blocking one 
enzyme in a metabolic pathway can be quantified. A review of the process has been carried out 
by Cascante et al. (Cascante et al., 2002) and Bakker et al. (Bakker et al., 2000). Each enzyme 
within the system is given a flux control coefficient, described as:  
Flux Control Coefficient (FCC) = change of flux / change in enzyme activity 
Due to the ‘summation theorem’ for metabolic control analysis, in an ideal pathway the sum of 
the FCC values of all enzymes making up the system equal 1.  Bearing this in mind, an ideal target 
for inhibition of glycolysis in trypanosomes should therefore have a relatively high FCC in the 
parasite, and a low FCC in the host organism. This is known as ‘differential control analysis’ and 
can be used to consider enzyme targets that may have high structural similarity between 
organisms to describe effect a drug has on one organism over the other– i.e. a drug may limit 
the flux of glycolysis in the target more than the host, killing the target organism without 
damaging the host cells (Haanstra et al., 2017). The flux control coefficients for T. brucei’s 
glycolytic enzymes are well known and data on the human counterparts is also becoming 
established (Haanstra et al., 2017)(Bakker et al., 2000). 
A study by Bakker et al. (Bakker et al., 1999) using the transport inhibitor Phloretin showed that 
under normal blood glucose levels (5mM) the glucose transporter in T. brucei had partial control 
of flux (FCC = 0.3-0.5) and full control of flux (FCC =1) under low glucose levels (0.4mM). 
Therefore under physiological conditions the glucose transporter is one, but not the sole 
controlling component of glycolytic flux in T. brucei. A 51% reduction in glycolytic flux is required 
to kill trypanosomes. It was found that the hierarchy of FCC’s corresponded to the effectiveness 
of inhibiting the glycolytic enzymes; inhibition of only 50% of the glucose transporter activity 
was required to reduce the glycolytic flux by 50%. Aldolase, glyceraldehyde-3-phosphate 
dehydrogenase, phosphoglycerate kinase and glycerol-3-phosphate dehydrogenase required 




kinase needed 93-97% inhibition for 50% flux reduction (Bakker et al., 2000). This hierarchy 
suggests the glucose transporter followed by aldolase, glyceraldehyde-3-phosphate 
dehydrogenase, phosphoglycerate kinase and glycerol-3-phosphate dehydrogenase would be 
the best glycolytic targets for anti-trypanosome drugs. A further study showed that 95% 
inhibition of aldolase, glyceraldehyde-3-phosphate dehydrogenase or phosphoglycerate kinase 
caused no clinical symptoms in human erythrocytes (Schuster & Holzhütter, 1995).  PFK and PYK 
are lower on the list of glycolytic targets ranked on FCC values only. 
The glucose transporter in T. brucei therefore appears like an interesting target – together with 
hexokinase it has a FCC value of 0.6, as well as a direct relationship between inhibition and 
reduction of glycolytic flux (Bakker et al., 2000)(Haanstra et al., 2017). Recent studies have 
shown that  glucose transporters and glyceraldehyde-3-phosphate dehydrogenase are the most 
selective antiparasitic targets in terms of flux control, when comparing BSF T. brucei over human 
erythrocytes (Haanstra et al., 2017). In reality however the trypanosomes may compensate for 
THT1 inhibition (the glucose transporter found in blood-forms) by expressing the THT2 
transporter (found in the insect-stage form) (Bakker et al., 2000). Much of the emerging HAT 
drug resistance is also related to transporter loss in resistant T. brucei strains (Alsford et al., 
2012a). 
Another major consideration for an anti-trypanosome target is the type of inhibition carried out 
by the drug molecule on the target. Inhibitors based on substrate analogues will be competitive 
and likely less effective in vivo, especially in the highly concentrated milieu of the glycosome 
(Bakker et al., 1999). If structural identity of the target enzyme is high between organisms, the 
target enzyme should ideally have unique allosteric sites or binding pockets into which a 
compound can bind and inhibit the enzyme.  
In summary, an ideal antiparasitic target is an enzyme with high flux control in the parasite, but 
low control in the host cell, one which may have a unique pocket into which specific inhibitors 
can be developed without the need to compete with substrates. Inhibition of a non-essential 
enzyme will not kill the target organism. Similarly, if a high level of enzyme inhibition is required 





1.4. Phosphofructokinase: an excellent target for anti-
trypanosomatid drugs.  
Phosphofructokinase (PFK) or (6-phosphofructo-1-kinase – PFK-1) is an enzyme that 
phosphorylates the fructose-6-phosphate sugar to fructose 1,6-bisphosphate (F16BP) in the 
third step of glycolysis. The enzyme is responsible for a limiting step in glycolysis and the 
conversion of F6P to F16BP is considered to be essentially irreversible. 
Both mammals and trypanosomes have two non-homologous PFKs – ‘PFK-1’ and ‘PFK-2’. 
Fructose 1-6-bisphosphatase (FBPase) facilitates the reverse reaction of F16BP to F6P. In both 
mammals and trypanosomes PFK-1 catalyses the conversion on F6P to F16BP. Similarly, both 
mammalian and trypanosomatid PFK-2 catalyses the conversion of F6P to F26BP and the 
hydrolysis of F26BP as a bifunctional enzyme, known as PFK2/FBPase2 in mammals and a pair of 
enzymes – PFK2 and FPBase2 in trypanosomes. The difference is that in mammals, the 
production of F26BP acts as a positive regulator of glycolysis (through PFK-1) and inhibitor of 
glycogenesis (through FBPase-1). In trypanosomatids however, the production of F26BP by PFK-
2 is strictly a positive regulator of glycolysis through stimulation of the downstream pyruvate 
kinase (PYK) enzyme. This is summarised in figure 1.6. 
PFK2 and PFK1 are not homologous – in fact the PFK2 domain of mammalian PFK2/FBPase 
enzyme has greater structural identity with adenylate kinase than PFK1 (Rider et al., 2004). A 
total of 4 isoenzymes of the homodimeric PFK2/FBPase2 enzyme exist in mammals, each 
encoded by a separate gene that expresses several isoforms with differing regulatory properties 
(Rider et al., 2004). In trypanosomes, 4 genes encode PFK2 proteins in T. brucei and L. major. 
Four pairs of genes encode the PFK2 enzyme in T. cruzi (Chevalier et al., 2005). One of the 







Figure 1.6: Roles of PFK1 and PFK2 enzymes in mammals and Trypanosomes. 
A) Roles of PFK1 and PFK2 enzymes in mammalian cells. F26BP (produced by PFK2) acts directly 
as a positive regulator of PFK1 here. All enzymes within cytosol of cell. B) Roles of PFK1 and PFK2 
enzymes in trypanosomatids – blue circle represents glycosome. F26BP here acts still as a positive 
regulator of glycolysis, but on the cytosolic PYK enzyme, not PFK1. Image adapted from  
(Chevalier et al., 2005).  
 
The target of interest in the Wellcome Trust funded SDD project is PFK-1 in T. brucei. Despite a 
relatively low control of glycolytic flux (Bakker et al., 2000), PFK-1 remains an excellent candidate 
for anti-trypanosomatid drugs. We know that PFK-1 in trypanosomes is an essential enzyme as 
part of an essential pathway; in a study of T. brucei 427 bloodstream form parasites with 
tetracycline-inducible RNAi against PFK, it was found that knockdown of PFK resulted in cell 









Figure 1.7: RNAi shows PFK is essential for BSF T. brucei survival. 
Cultured T. b. brucei 427 cell line with tetracycline (Tet)-induced RNAi against PFK. Cell lines 
deficient in 50% of their PFK expression show lack of growth (blue). Image adapted from (Albert 


















1.4.1 Evolution of phosphofructokinase-1 
Phosphofructokinases can be assigned into one of two groups – ATP dependant (ATP-PFK) and 
PPi dependant (PPi-PFK) enzymes, according to the phospho donor they use. All PFKs evolved 
from a bacterial PFK-like ATP-dependant ancestor. Gene duplication and fusion events have led 
to a number of PFK types differing in structure and regulatory properties across species (McNae 
& Martinez-Oyanedel, 2009). The evolution of PFK in yeast, mammals, trypanosomes, bacteria 
and plants is summarised in figure 1.8. Table 1.3 summarises the structural and regulatory 
properties of PFK enzymes from these species. 
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Gene duplication + fusion. 
Size effectively doubles [1]. 
Gain of effector site from 
active site () 
Gene duplication – 
resulting in 2 chains [2]. 
Gene duplication – 3 
isoenzymes + additional 40 
residues at C-terminal [3]. 






Additional 100 residues at C-terminal and 
30 residues at N-terminal. Introduction of 
functionally important ‘inserted loops’[5] 
Effector site evolved from active site Activation by 
F26BP and/or AMP/ADP 
Effector site : inhib. by citrate/ATP 
Rudimentary effector site – partial or 
complete loss of activity 
ATP-dependant active site 
Effector site : inhib. by PEP, act. by ADP 
Ppi-dependant active site 
ATP-dependent Ppi-dependent 
Figure 1.8: Summary of evolution of phosphofructokinase. 
Image adapted from McNae et. al (2009). [1] Poorman et. al (1984). [2] Heinisch et. al (1989). [3]: Dunaway. (1983). [4]: Bapteste, Moreira and Philippe (2003). [5]: 
Moore et. al (2002). [6]: Michels et. al (1997). [7]: Martinez-Oyanedel et. al (2007). [8]: Carlisle et. al (1990). 
Gene duplication – 
resulting in 2 chains [8]. 
Gain of effector site 
from active site () 
Change to Ppi dependence – 
nucleotides no longer bind, 
partial loss of effector site[4]. 
Reversion to ATP 
dependence – Ppi structural 




1.4.2 Phosphofructokinase-1 in eukaryotes. 
A great deal is known about the structure of prokaryotic PFKs from bacteria, however relatively 
little is known about the structure of eukaryotic PFKs. TbPFK was the first eukaryotic PFK that 
has been described structurally in its active form (2HIG, 3F5M) (Martinez-Oyanedel et al., 2007; 
McNae & Martinez-Oyanedel, 2009). The yeast PFK hetero-octamer from S. cerevisiae has also 
been described structurally in its active form (3O8O) (Banaszak et al., 2011). Gene duplication 
and fusion events from a prokaryotic ancestor have resulted in eukaryotic PFKs having subunits 
roughly twice as large as their bacterial ancestor (figure 1.8). One eukaryotic PFK subunit 
consists of two halves, each of which are related to one ancestral bacterial PFK subunit, and 
form hetero- and homo-oligomeric enzymes (Schöneberg, Kloos, Brüser, Kirchberger, & Sträter, 
2013). Each eukaryotic dimer corresponds in terms of size and fold to one bacterial tetramer as 
shown in figure 1.9 below. Trypanosomatid PFKs of course are an exception to this due to their 
divergent ancestral path, though do have extensions on their C and N terminals relative to the 
bacterial ancestor (figure 1.8). Plant PFKs underwent a separate gene duplication event from 
eukaryotic PFKs that, similar to yeast PFKs, resulted in 2 chains per subunit (figure 1.8) (Carlisle 
et al., 1990).  
 
Figure 1.9: Model of an ancestral bacterial PFK tetramer compared to trypanosomatid PFK 
tetramer and mammalian PFK dimer. Substrate and effector sites are also shown as described by 
Archaga et. al (Arechaga, Martínez-Costa, Ferreras, Carrascosa, & Aragón, 2010). IC, IN, IIC, and 
IIN correspond to the C- and N-terminal ends of each mammalian subunit (‘I’ and ‘II’).  
Rabbit muscle PFK was the first mammalian PFK structure to be partially solved (3O8L/N) 
(Banaszak et al., 2011). The smallest active form of a mammalian PFK has been shown to be a 
tetramer, but higher oligomeric and filamentous forms are also possible (Schöneberg et al., 
2013).  PFK is expressed in three isoforms from three separate chromosomes in humans; PFKM 




– expressed mainly in platelet and fibroblast cells (G. a Dunaway, Kasten, Sebo, & Trapp, 1988). 
Residues known to be involved in ATP and F6P binding are well conserved across all species. The 
first complete crystal structure of a homotetrameric human PFKP has recently been published 
with ATP-Mg2+ (4XYJ) and ADP (4XYK) bound forms (Webb et al., 2015). It exists as a 
homotetramer (A4). 
1.4.3 Phosphofructokinase-1 in trypanosomatids. 
To date, T. brucei PFK-1 is the only trypanosomatid PFK with published structures. Figure 1.10 
shows an identity matrix between the trypanosomatid PFK species investigated in this thesis and 
mammalian, bacterial and yeast PFKs. 
 L. inf. T. bruc. T. cong T. vivax T. cruzi E. coli S. cere. Rb (M) Hs 
(M) 
L. inf. - 70.3 69.5 70.0 71.8 23.0 22.8 25.3 24.7 
T. bruc. 70.3 - 87.7 79.8 76.9 24.8 25.5 24.4 23.6 
T. cong. 69.5 87.7 - 81.6 77.3 25.1 24.6 23.6 22.7 
T. vivax 70.0 79.8 81.6 - 78.7 26.4 24.5 24.7 24.2 
T. cruzi 71.8 76.9 77.3 78.7 - 25.7 24.0 25.0 24.2 
E. coli 23.0 24.8 25.1 26.4 25.7 - 34.4 40.2 40.8 
S. cere. 22.8 25.5 24.6 24.5 24.0 34.4 - 42.9 42.7 
Rb (M) 25.3 24.4 23.6 24.7 25.0 40.2 42.9 - 96.3 
Hs (M) 24.7 23.6 22.7 24.2 24.2 40.8 42.7 96.3 - 
L. inf. = Leishmania infantum. T. bruc. = Trypanosoma brucei brucei/ T. cong. = T. congolense 
(IL300 strain), S. cere. = Saccharomyces cerevisiae. Rb (M) = Rabbit muscle (Oryctolagus 
cuniculus). Hs (M) = Homo sapiens muscle.  
Figure 1.10: Sequence identity matrix between trypanosomatid, mammalian, bacterial and yeast 
PFKs. 
The trypanosomatid PFKs have ~70-88% identity with each other, but only ~20-25% identity with 
their mammalian counterparts. As discussed in section 3.2.1, chapter 3, the active site is well 
conserved across all PFK species. Despite this, several unique structural features beyond the 
active site of T. brucei PFK provide the opportunity for targeted inhibitor development and 





1.4.4 Structure of T. brucei PFK-1. 
T. brucei PFK is a homotetramer (dimer of dimers) of four 53 KDa subunits, 487 a.a. per subunit. 
Its crystal structure was the first eukaryotic PFK structure to be solved in its active form 
(Martinez-Oyanedel et al., 2007). Structures of the apoenzyme (2HIG) and ATP-bound enzyme 
(3F5M) have been solved. Figure 1.11 shows the crystal structure of the ATP-bound TbPFK 
tetramer.   
Each subunit consists of 3 domains; ‘A’ domain (res. 8-94, 410-441) is a loosely packed domain 
and contains a feature unique to the T. brucei enzyme - the N-terminal ‘embracing arm’ that 
links neighbouring subunits in each dimer(McNae & Martinez-Oyanedel, 2009). A tightly packed 
‘B domain’ (res. 95-233, 386-409) contains the ATP-binding portion of the active site, and a 
tightly packed ‘C’ domain (res. 234-385, 442-453) contains two more structural features unique 
to T. brucei PFK; an ‘inserted loop’ (res. 329-348) that donates two unique residues to the 
catalytic activity of the enzyme compared to other eukaryotic PFKs (McNae & Martinez-
Oyanedel, 2009), and a C-terminal extension that forms ‘reaching arms’ that make contacts with 
adjacent subunits between the dimers (figure 1.11A). This structure is disordered in the 
apoenzyme form but ordered in the ATP-bound structure. These N- and C-terminal extensions 
are unique compared to other ATP-dependant PFKs and are likely a result of T. brucei PFKs PPi 
ancestral lineage. The TbPFK inserted loop is unique to trypanosomatid PFKs, but is similar to an 
additional sequence in the B. burgdorferi bacterial PPi-PFK structure that forms a ‘lid’ over the 
active site (Martinez-Oyanedel et al., 2007). 
The active site of TbPFK is located between domains B+C. ATP binding occurs between a helix 
(‘Helix 8’) and another dynamic active site loop – the ‘Arg173’ loop (res. 170-178). Models based 
on the E. coli PFK structure show that F6P binding occurs in the cleft directly below the ATP 
binding site (Schirmer & Evans, 1990). Another dynamic loop important for catalytic activity is 
the ‘Asp229 loop’ (res. 225-257) which contributes an important aspartate residue required for 






Figure 1.11: Structure of MgATP bound TbPFK holoenzyme (3F5M).  
A) TbPFK tetramer – subunits coloured blue, pink, green and red. Orange arrows indicate C-
terminal reaching arms between adjacent subunits. Orange circle indicates embracing arms of 2 
neighbouring subunits in dimer. B) TbPFK monomer coloured according to domains; Domain A 
(res. 8-94, 410 – 411) – red, Domain B (res. 95 – 233, 386 – 409) – orange, and Domain C (res. 
234 – 385, 442-453) – brown. Other subunits in tetramer are shown in background. ATP binding 
site has been circled. 
 
1.4.5 Active site structure and catalytic mechanism of TbPFK-1. 
The catalytic mechanism of bacterial ATP-dependant PFK from E. coli and B. stearothermophilus 
has been described by Evans et. al. (Evans, 1992). An aspartate residue-Asp127 (corresponding 
to Asp229 in TbPFK) pulls the proton away from the -OH1 group of F6P, allowing the nucleophilic 
attack of the γ-phosphate of ATP (Evans, 1992) (figure 1.12). A central magnesium ion co-


















Figure 1.12: catalytic mechanism of bacterial ATP-dependant PFK.  
Adapted from Evans et al(Evans, 1992). Active site residues involved in ATP and F6P binding and 
phosphotransfer as modelled by Evans et. al using a ‘hybrid’ model of E.coli and B. 
stearothermophilus enzymes. Bacterial residues given in bold. Corresponding T. brucei PFK 
residues are given in grey underneath, as described by (Martinez-Oyanedel et al., 2007). Asp229 
(TbPFK), part of the Asp229 loop, has been circled to highlight its importance in the catalytic 
activity of the enzyme. 
 
The active site of TbPFK is formed by residues between the B and C domains. Known structural 
data suggest that the catalytic mechanism of TbPFK is ordered – ATP binds first and induces a 
conformational change that accommodates F6P binding, as well as forming the putative 
allosteric pocket into which AMP binds (McNae & Martinez-Oyanedel, 2009). Prior to ATP 
binding the active site is in a more ‘closed’ conformation; S341 (from the ‘inserted loop’) and 
N230 (from the ‘Asp229 loop’) block the α- and γ-phosphates of ATP, respectively.    
Upon ATP binding, there is a 3o conformational rotation from a ‘hinge’ point between domains 
A and C (figure 1.13). Strikingly, the C-terminal reaching arms become ordered in the ATP-bound 
structure, forming long subunit-spanning helices involved in holding the tetramer together in an 






Figure 1.13: ATP binding to TbPFK-1 induces a conformational change in the tertiary structure. 
A) MgATP-TbPFK structure (3F5M) consists of a homotetramer. ATP binding orders the C-
terminal reaching arms (circled) that hold adjacent subunits together. B) Image B shows the pink 
subunit from image A rotated 90o on the plane of the paper. The same MgATP-bound monomer 
(pink) has been overlaid onto the apoenzyme (2HIG)( (purple) monomer structure. ATP binding 
induces a 3o rotation around a hinge point. 
 
 The ATP-inducted rotation in domain C results in the movement and ordering of three dynamic 
loops near the active site; the ‘Arg173 loop’ ‘inserted loop’ and ‘Asp229 loop’ move away from 
the ATP pocket to accommodate F6P binding and γ-phosphate transfer (figure 1.14). The C-
terminal helices (reaching arms) become ordered and hold the tetramer together tighter 
(McNae & Martinez-Oyanedel, 2009).  
In the apo-enzyme structure the Asp229 loop – named so due to the catalytic importance of the 
Asp229 residue (figure 1.12) - sits in a conformation with the Asp229 residue pointed toward 
the ATP/F6P binding sites. In the ATP-bound structure the loop is repositioned away from the 










Figure 1.14: Conformational changes in TbPFK active site upon ATP binding.  
TbPFK Apo (2HIG) (purple) and ATP-bound (3F5M) (pink) crystal structures are shown in cartoon 
form. ATP (sticks with white carbons) is shown in its TbPFK crystal structure-bound position with 
Mg2+ (green sphere). The three main loops undergoing conformational change between the apo- 
and ATP-bound enzymes have been labelled and arrows (red) depict movement upon ATP-
binding. The Asp229 (‘D229’) important in catalytic activity has been shown in stick form. 
 
1.4.6 F6P binding in trypanosomatid PFKs – Cooperativity models. 
Cooperative binding of F6P has been observed at the lower concentrations of F6P titrations 
against PFK enzymes from T. brucei (Claustre et al., 2002), T. cruzi (Rodríguez, Lander, & Ramirez, 
2009) and L. donovani (López et al., 2002) trypanosomatids. Two well-known models for 
describing cooperativity in enzymes are the Monod-Wyman-Changeux (MWC) ‘symmetry’ or 
‘concerted’ model and the opposing Koshland-Nemethy-Filmer (KNF) or ‘sequential’ model 
(Koshland & Hamadani, 2002). Figure 1.15 summarises the two models. The two models have 
conflicting features regarding the mechanism of cooperativity. The ‘rules’ for each model are as 
follows; 







KNF model (sequential): 
 Subunits in a multimeric protein can exist in either a low affinity or high affinity state, 
and switch between the two upon ligand binding. 
 Ligand binding to one subunit induces a change from the inactive to active state. 
 The switch of one subunit causes the neighbouring subunit to change to the high affinity 
state by making it more thermodynamically favourable to change its conformation. This 
happens in a sequential manner. 
Further rules added by the researchers Koshland and Hamadi state: 
 Subunits in the oligomeric enzyme are identical to each other 
 The conformational change is an intramolecular, tertiary structure rearrangement 
within the oligomer (Koshland & Hamadani, 2002). 
MWC model (symmetry): 
 Enzyme oligomers with identical subunits exist in a thermal equilibrium between T and 
R states, independent of ligand binding. 
 The T and R states differ in affinity for the substrate – R generally having higher affinity. 
The equilibrium between the two states when no ligand is bound is called the 
isomerisation constant (L).  
L = [T]/[R]. Were T = inactive state, R = active state.  
 Ligand can bind to either the T or the R state, with varying or identical affinities. The 
ratio of T and R state dissociation constants is expressed as constant c. 
 c = KdR/KdT. If c = 1 both R and T states have the same affinity for the ligand. The smaller 
c, the more equilibrium shifts to the R state.  
 All subunits of the oligomer change state at the same time, known as ‘concerted 
transition’. 










Monod-Wyman-Changeux (MWC) ‘symmetry’ 
model 
Koshland-Nemethy-Filmer (KNF) / sequential 
model 
Conformational change is in the whole protein 
(quaternary structure) between R and T states. 
Conformational change between R and T states is at 
tertiary structure level. 
Only used to describe positive cooperativity. Describes both positive and negative cooperativity. 
Takes into account thermodynamics of change in 
state. 
Does not take into account thermodynamics of 
conformational switch. 
Gives sigmoidal binding curve. Gives sigmoidal binding curve. 
Subunits change from T to R states independent of 
ligand binding 
Subunits only change conformation when ligand 
binding occurs. 
Figure 1.15: Two models for substrate cooperativity. 
A) Cooperative binding schemes for MWC and KNF models. 






1.4.7 AMP activation of T. brucei PFK-1 
The allosteric effector site for TbPFK is located ~38Å from the active site. TbPFK is allosterically 
activated solely by AMP but, unlike its bacterial ancestors it isn’t affected by the activator ADP. 
Substitution of 2 amino acids compared to the E. coli PFK structure (Arg154 and Arg25 in E.coli, 
Tyr256 and Leu121 in T. brucei) explain this specificity for AMP; the unique residues in the T. 
brucei  enzyme were originally thought to sterically hinder ADP binding (McNae & Martinez-
Oyanedel, 2009). An unpublished structure of TbPFK with AMP bound by Montserrat Valdivieso 
and Iain McNae at the University of Edinburgh revealed the binding mechanism of AMP (pers. 
comm. I McNae). Figure 1.16 shows the position of the AMP binding site and the residues 
involved in AMP binding. Residues interacting with AMP are donated from two subunits in the 
dimer interface (figure 1.16B). This structure however revealed that the additional phosphate 
in ADP could theoretically be accommodated, as the orientation of AMP binding was different 
to previously modelled (per. comm. Iain McNae, UoE) (Figure 1.16B).  
The C-terminal reaching arms that become ordered following ATP binding hold the tetramer 
together and span across adjacent subunits. The putative AMP binding site is located under the 
base of each reaching arm helix. It is possible that AMP binding is communicated across the 






                          
Figure 1.16: AMP binding may be communicated via the C-terminal reaching arms. 
A) AMP-TbPFK structure (3F5M) in surface representation, subunits of the homotetramer have 
been coloured. Subunits A and B of a dimer have been labelled. The AMP binding site is located 
under the base of C-terminal reaching arm helices (boxed). White arrows indicate direction of 
‘reaching arm’ helices proposed as communicating AMP binding across the tetramer. B) Binding 
orientation of AMP in AMP-TbPFK structure. MgATP-TbPFK structure overlaid (gold). Space for 
the additional phosphate in ADP can be seen between Arg155 and Arg312. A movement in the 
helix making up the reaching arms can be seen comparing the ATP-bound (gold) and AMP-bound 
(blue – subunit A) can be seen and is labelled with red arrow. C) Schematic of AMP binding to 
TbPFK. A subunit residues shown in green, B subunit residues in blue. Hydrogen bonds shown in 









1.4.8 Target specificity – unique structural features of T. brucei PFK. 
All three human PFK isoforms have <26% identity with Tb, Tc and LiPFK and share 69-73% 
identity with each other (figure 1.10, section 1.4.3). The residues involved in the catalytic activity 
of eukaryotic ATP- PFKs are well conserved, as assessed in section 3.2.1, chapter 3. Compared 
to the mammalian isoforms, TbPFK has two unique residues in its active site – S341 and N343 - 
contributed by the ‘inserted loop’ feature.  
A unique pocket was found via crystal structures identified by a screen for drug-like inhibitor 
compounds against TbPFK (Brimacombe et al., 2014). This so-called ‘CTCB binding pocket’ also 
has low identity (<35 %) with both the rabbit muscle and human isoforms of PFK but is conserved 
between T. cruzi, L. infantum and T. brucei PFKs and poses as an excellent target for structural 
design of specific inhibitor compounds with proximity to the enzyme’s active site. Comparison 
of the apo- and ATP-bound crystal structures of TbPFK show that the ‘CTCB binding pocket’ 
accommodates a leucine residue (Leu232) attached to the Asp229 loop in the apo-enzyme form 
(figure 1.17). Following ATP binding and conformational change of the Asp229 loop, this leucine 
is removed from the pocket. Interruption of this functionally important loop movement by a 
drug molecule sitting in the pocket therefore makes this a promising target for anti-TbPFK drugs.  
The ‘Asp229’ and ‘inserted’ loops also present a unique opportunity for interactions between 






















Figure 1.17: The CTCB inhibitor pocket normally accommodates a leucine residue.  
A) TbPFK monomer (3F5M) with electrostatic charge potential surface representation. The CTCB 
binding pocket lies to the left of the ATP binding pocket. B) The CTCB pocket is a negatively 
charged cleft, surrounded by areas of positively charged residues. ATP shown in stick form. C) 
Apo (purple) and ATP-bound (pink) crystal structures of TbPFK monomers.  Residues involved in 
the ‘CTCB binding’ pocket have been shown in surface form (grey). ATP shown as sticks, Mg2+ 
atom as green sphere. As can be seen, in the apoenzyme form a leucine (L232)(sticks) attached 














A distinct advantage of the CTCB binding pocket in designing anti-HAT drugs is that it is specific 
to the target organism; Figure 1.18 below shows a sequence alignment of the residues making 
up the CTCB binding pocket, ATP binding site and F6P binding site between the three 
trypanosomatid PFKs, rabbit muscle PFK (RbPFKM) and human muscle PFK (HsPFKM). While the 
F6P and ATP binding sites are relatively well conserved between all species, the CTCB binding 
pocket has less than 33% identity between the trypanosomatid PFK and mammalian PFKs. 
TbPFK residue TcPFK LiPFK RbPFKM HsPFKM 
G107* G G G G 
R173 (Arg173 loop) R R R R 
G174* G G C C 
P175 (Arg173 loop) P P K K 
G198 G G G G 
G200* G G G G 
T201 T T V V 
K226 K K  Q Q 
S341 (Inserted loop) S S K K 
N343 (Inserted loop) N N - - 
     
R173 R R R R 
E325 E E E E 
K374 K K R R 
Y380 Y Y H H 
R383 R R R R 
     
Q202 Q Q L L 
P225 P P V V 
K226 K K G G 
T227 T T S S 
D231 D D D D 
L232 L L F F 
I414 I I V V 
A430 A A C C 
T431 T T V V 
 
Figure 1.18: Sequence alignment of ATP, F6P and CTCB compound binding pockets between trypanosomatid 
and mammalian PFKs. 
Residue numbers relate to TbPFKs sequence. Red = unrelated or absent residue. Yellow = residue with 
related properties. Green = identical residue. Tb = T. brucei, Tc = T. cruzi, Li = L. infantum, Rs = rabbit muscle, 












1.4.9 Target specificity – regulatory properties of trypanosomatid PFKs. 
There are no known physiological inhibitors of trypanosomatid PFKs and only one allosteric 
activator, AMP (Claustre et al., 2002).  PFK in trypanosomatids is contained within the 
membrane-bounded organelles, the ‘glycosomes’. Compartmentalisation provides a unique 
environment that affects the regulatory properties of the PFK enzyme; 
I) PFK is insensitive to known effectors of other eukaryotic PFKs. The glycosomal 
membrane is not entirely impermeable to metabolites, but known effectors of 
other eukaryotic PFKs (Table 1.3) such as citrate and F-2,6-BP have not been 
reported as regulators of trypanosomatid PFKs. Phosphoenolpyruvate (PEP) 
enters T. cruzi and Leishmania spp. glycosomes for succinate production, but 
this pathway is not present in BSF T. brucei glycosomes (see fig 1.5). ADP is 
present in the glycosome but while theoretically able to bind to the AMP 
effector site in TbPFK structures, it demonstrated only very weak inhibition of 
the enzyme (IC50ADP = 7.3 mM) (described later in section 4.5.6).  
II) The glycosomes have a specific ATP: ADP ratio. The ATP:ADP ratio is kept 
balanced, and net ATP production occurs outside the glycosome. In silico 
analysis has shown that the ATP:ADP ratio inside the glycosome is different to 
that in the cytosol, and both vary according to the external glucose 
concentration (Barbara M Bakker et al., 2000). As comparisons of the apo- and 
ATP-bound structures of TbPFK have shown, ATP binding induces an active 
conformational state. High ATP will cause a conformational switch from a low 
affinity T-state to a higher affinity R-state form of PFK. The glycolytic membrane 
is impermeable to nucleotides, and so the ATP:ADP ratio is maintained by the 
enzymes phosphoglycerate kinase (PGK), glycerol kinase (GK) and pyruvate 
phosphate dikinase (PPDK) (Deramchia et al., 2014). 
III) In other eukaryotes product feedback inhibition is an important regulatory 
property for the glycolytic enzymes hexokinase and PFK, to prevent the build-
up of intermediates (G6P, F6P and F16BP) in cells that may result from 
autocatalytic activation of the pathway by its net ATP production (‘turbo-effect’) 
(Teusink, Walsh, Van Dam, & Westerhoff, 1998). T. brucei, T. cruzi and L. 
infantum PFKs are not regulated by their products or by F26BP which is an 
important feedback regulator of mammalian glycolysis and glycogenesis. 




cytosol, not the glycosomes; There is no net production of ATP within 
glycosomes, and so hexokinase and PFK do not subject to product activation 
(turbo-effect). As such they do not need to be regulated as they are in organisms 
where these enzymes are not compartmentalised (Haanstra et al., 2008) See 
table 1.3 for a comparison of PFK regulators across species. 
1.5. Developing novel drugs against HAT. 
Treating stage II HAT remains a challenge in developing new drugs against HAT – the parasites 
enter the CNS and the drug compound therefore must have features that allow it to cross the 
blood brain barrier. Uptake or diffusion through the trypanosomes cell membrane and 
glycosomal membrane adds further complications in delivering an inhibitor to a glycosomal 
target at an effective concentration.  Emerging evidence of drug resistance in trypanosomatid 
strains due to the loss of membrane transporters is well documented (Alsford et al., 2012b). 
While this adds an additional challenge to drug development, it also stresses the need for a 
diverse pipeline of novel treatments against infectious trypanosomatids. 
1.5.1 Finding novel inhibitors of TbPFK. 
The initial development of inhibitors against TbPFK was carried out by Claustre et. al in 2002. 
Analogs of 2,5 anhydro-D mannitols, similar in scaffold to F6P and F26BP, were designed and 
tested against recombinant TbPFK. Figure 1.19A shows the chemical scaffold of these 
compounds and the chemical progression in potency. The compounds had relatively weak 
inhibitory activity, and had reversible binding with respect to saturating concentrations of ATP 
and F6P (Claustre et al., 2002). The best compound (‘compound 8’) had an IC50 of 0.45 mM 
against TbPFK at saturating F6P and ATP concentrations (figure 1.19A). 
In 2008 Nowicki et al. at the University of Edinburgh designed, synthesised and tested a range 
of furanose-based analogs against recombinant TbPFK and Leishmania mexicana pyruvate 
kinase (LmPYK). Initial compounds were based on the  same F6P/F26BP analogs developed by 
Claustre et al. Advancement in potency against TbPFK came firstly from the addition of various 
halobenzene combinations, resulting in a 3,4-dichlorobenzyl group which gave the best potency 
of the chemical series –IC50 = 0.41 mM against TbPFK (‘compound 2m’ figure 1.19B). Additional 
increases in potency were achieved from testing the dihalogen benzene groups on a sugar amine 
based scaffold (figure 1.19B), the best compound achieving an IC50 of 23 µM (‘compound 8e’). 
In models of ‘compound 8e’ binding to TbPFK, the furanose ring of the sugar amide structure 




In 2014, a collaboration between the University of Edinburgh and the Chemical Genomics Center 
of the National Institutes of Health (NIH) carried out a screen of 330, 683 compounds against 
recombinant T. brucei and T. cruzi PFK enzyme activity (Brimacombe et al., 2014). More than 
1000 hits were confirmed, and the 3,4-dichlorobenze group identified by Nowicki et al. in 2008 
was a commonality in many of the most potent hits (Brimacombe et al., 2014). The group 
identified a novel para-amido sulphonamide scaffold (figure 1.19C). Increases in potency were 
achieved through addition of halo-benzyl combinations to this initial scaffold – see compounds 
13, 14 and 18 in figure 1.19C. Halogens on the 3 and 4 positions of the benzyl group proved to 
be most potent, as previously confirmed by Nowicki et al. The next advancement in potency was 
achieved by testing dihalo combinations on the 3,4-position of the benzyl ring, with different 
groups on the sulphonamide scaffold (figure 1.19C). This yielded three of the most potent 
compounds – compounds ‘30’, ‘39’ and ‘42’ with IC50 values of 0.37, 0.079 and 0.015 µM against 
TbPFK respectively (figure 1.19C). The most potent compound ‘42’ however showed a degree of 
competition with ATP when tested against TbPFK, but showed no inhibition of rabbit muscle 
PFK. Unfortunately, compound 42 showed no toxicity against cultured BSF T. b. brucei 427 strain 
parasites.  The resulting chemical series were good drug candidates; Compound ‘30’ showed a 
promising EC50 of 16.3 µM against the T. b. brucei 427 parasites, and was selected as the 
compound of choice for further development, known as ‘ML251’ (Brimacombe et al., 2014). 
None of the compounds tested in the study showed significant human toxicity (EC50 > 46µM 
against human MRC-5 lung cell line). ML251 showed good aqueous solubility and plasma 
stability and was selected later as one of the initial chemical scaffolds in the Wellcome Trust 
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Figure 1.19: Lead compound progression in initial studies of TbPFK inhibitors. 
Compound naming is based on numbering system in each publication as stated. A) (Claustre et 






1.5.2 Novel inhibitors of TbPFK – Wellcome Trust Seeding Drug Discovery project. 
An initial screening project of 340, 000 small molecules against T. brucei PFK enzyme activity was 
carried out in collaboration with the Walkinshaw lab at the University of Edinburgh and the 
Chemical Genomics Center of the National Institutes of Health (NIH) (Brimacombe et al., 2014). 
This study identified >1,000 small molecule inhibitors of T. brucei PFK. From here, the 
Walkinshaw lab in collaboration with the medicinal chemistry company Selcia Ltd. undertook a 
structure-based design approach to developing compounds (‘CTCB’ compounds) from these 
chemical series as part of the Wellcome Trust-funded SDD project. Existing crystal structures of 
apo- and ATP-bound T. brucei PFK solved by Iain McNae allowed the identification of the unique 
pocket into which the initial inhibitors bound. This pocket will be referred to as the ‘CTCB 
compound binding site’. Figure 1.17 (section 1.4.8) shows the position of the CTCB pocket.  
1.5.3 Recent drug development against HAT. 
The 5-nitroimidazole compound ‘Fexinidazole’ and its 2 metabolite compounds sulfoxide and 
sulphone have trypanocidal activity against cultured T. brucei strains. The drug shows cures in 
chronic and acute HAT disease models in mice, is orally effective and has no reported side effects 
in rat studies (Kaiser et al., 2011). Fexinidazole is the most advanced novel HAT drug; it entered 
clinical development in 2009 and phase III trials started in 2016. A recent update has shown that 
it led to a 99% cure in patients with stage I HAT. Furthermore, it cured 91% of people with severe 
onset HAT. While this cure rate is lower than with NCET combination therapy (98% treatment 
rate), it has the significant advantage of being an orally prescribed pill, over the 16-injection 
intravenous infusion and oral administration of NCET combination therapy (Maxmen, 2017). 
A new lead compound from Scynexis – ‘SCYX-7158’ is a benzoxaborole compound developed 
against T. brucei from optimisation of a benzoaborole-6-carboxamide series with good parasite 
killing but poor brain penetration.  The compound clears T. brucei parasites from stage II HAT 
mice models after oral dosing (Barrett & Croft, 2012; Jacobs et al., 2011). SCYX-7158 entered 
phase I clinical trials in 2012.  
Inhibitors of the N-myristoyltranferase enzyme involved in membrane targeting and activity of 
many biological proteins have been characterised as a drug target against T. brucei, and 
inhibitors have been successfully developed against it (Frearson et al., 2010). These inhibitors 
had good results against stage I HAT models but poor brain penetration prevented a stage II cure 
from the drugs. Recently, the inhibitor scaffold has been revisited and developed to a new series 




Both Fexinidazole and SCYX-7158 have excellent HAT curing properties in mice models of stage 
I and II HAT and have shown low toxicity levels in human and mammalian cell lines (Barrett & 
Croft, 2012), however their mode of action is not currently known.  
A series of brain-penetrant Indoline-2-carboxamide inhibitors of T. brucei, obtained by a 
phenotypic screen at the University of Dundee have also been reported (Cleghorn et al., 2015). 
These compounds allowed full cures in stage I mice and partial cures in stage II models, but had 
low dose tolerability (Cleghorn et al., 2015). 
A broad spectrum inhibitor of the kinetoplastid proteasome named ‘GNF6702’ has recently been 
developed by a joint collaboration (Khare et al., 2016). The drug cleared infection in disease 
models of HAT (T. brucei), Chagas disease (T. cruzi) and Leishmaniasis (Leishmania spp.) in mice. 
It is a non-competitive inhibitor of the kinetoplastid proteasome, does not inhibit mammalian 





1.6. Thesis aims and outline. 
1.6.1 Thesis aims. 
The overall aim of this project was to test and characterise the molecular regulation of TbPFK, 
alongside similar PFKs from T. cruzi and Leishmania infantum parasites. This included two main 
goals; I) The main focus of the work involved testing and characterising the inhibition of the 
enzyme by small molecule inhibitor compounds, alongside the Wellcome Trust funded ‘Seeding 
Drug Discovery’ (SDD) project carried out by the Walkinshaw group. T. brucei 
phosphofructokinase is a well-researched and validated target for trypanocidal drug 
development, as it is essential for survival of the bloodstream infective form of the parasite. The 
availability of crystal structures (2HIG, 3F5M) of the enzyme and the identification of the unique 
‘CTCB binding’ pocket presents a unique opportunity for a structure-based drug design 
approach. An established expression construct and optimised purification protocol for 
recombinant T. brucei PFK, coupled with expert knowledge and equipment at the Edinburgh 
Protein Production Facility (EPPF) and Centre for Translational and Chemical Biology (CTCB) 
facilities at the University of Edinburgh allowed for excellent practical resources for carrying out 
the SDD project. 
II) The secondary focus of this work was to advance current knowledge of the enzymatic activity 
and regulation of the PFK enzyme in the disease-causing T. brucei, T. cruzi and Leishmania spp. 
parasites. Specifically, to describe a mechanism of regulation of the trypanosomatid PFK 
enzymes. 
To achieve these goals, the work outlined in this thesis has 4 specific aims; 
1) Identification and optimisation of assays for high through-put testing of novel TbPFK 
inhibitors. This included optimisation of orthogonal primary assays to carry out ranking 
of compounds against the PFK enzyme, alongside high throughput ranking through 
surface plasmon resonance (SPR) assays. This was carried out in parallel with assays 
ranking the potency of compounds against cultured parasites, to feed back information 
to aid with the ongoing design and development of inhibitors as part of the SDD project. 
2) Characterisation of the binding properties of PFK inhibitors. This was achieved through 
biophysical assays to characterise the affinity, stoichiometry and thermodynamic 
parameters of compound binding with the TbPFK target. Again, this fed back valuable 





3) Characterisation of the molecular regulation of trypanosomatid PFK activity by inhibitor 
compounds. This was carried out through enzymatic and biophysical assays as well as 
structural analysis, to characterise the effect on enzymatic activity by the drug 
candidates. The goal of this work was to establish the mode of action (MOA) of the CTCB 
compounds against parasitic PFKs. 
4) Describe the molecular regulation of trypanosomatid PFKs by physiological effectors. To 
advance the current knowledge of PFK enzymatic activity and regulation, provide a 
model for AMP activation of the enzyme and investigate the reversibility of the enzyme-
catalysed reaction under physiologically relevant conditions. This was achieved through 
several enzymatic activity assays and biophysical techniques. 
1.6.2 Outline of thesis. 
Chapter 2 acts as a reference for the protocols, materials and methods used to obtain the 
information described in this thesis.  
Chapter 3 describes the cloning, expression and purification of recombinant PFKs from T. brucei, 
T. cruzi, T. vivax, T. congolense and L. infantum Trypanosomatidae species. It also describes the 
biophysical characterisation, validation and quality assurance of the PFK enzymes to be used in 
the subsequent assays involved in the SDD project. 
Chapter 4 describes and compares the kinetic activity and molecular regulation of the PFK 
enzyme from T. brucei, T. cruzi and L. infantum. 
Chapter 5 shows the investigation and unprecedented description of the reverse reaction of 
trypanosomatid PFK under physiologically relevant conditions. 
Chapter 6 describes the testing, development and characterisation of small molecule inhibitors 
of TbPFK, as part of the Wellcome Trust-funded Seeding Drug Discovery (SDD) programme 
carried out by the Walkinshaw Group and the medicinal chemistry company Selcia Ltd. 
Chapter 7 outlines a proposed mechanism of regulation of trypanosomatid PFKs through: 
1. Cooperativity in F6P binding and regulation by AMP. 
2. Inhibition by CTCB inhibitor compounds. 






Chapter 2: Materials and Methods 
This chapter is intended as a reference for the experimental procedures used to measure the 
data described in chapters 3 – 6.  
2.1. Introduction. 
The Wellcome Trust funded Seeding Drug Discovery project involved designing and testing small 
molecule inhibitors specifically against T. brucei PFK. As such, this was the main PFK protein 
being expressed and purified on a regular basis. However in order to carry out comparisons with 
PFK from other trypanosomatid species, Trypanosoma brucei, Trypanosoma congolense, 
Trypanosoma vivax and Leishmania infantum PFK constructs were cloned, expressed and 
purified (T. vivax and T. congolense PFKs were not successfully expressed at the time of writing).  
 
2.2 Expression and purification of trypanosomatid PFKs. 
 
2.2.1 Expression of trypanosomatid PFKs 
T. brucei, T. cruzi and L. infantum PFK constructs in their expression plasmids were provided 
from previous studies by the Walkinshaw group at the University of Edinburgh. Typically, 1 – 2 
µL of 100 – 150 ng/µL DNA was used to transform 50 µL chemically competent cells (according 
to protein construct – see table 2.2 below). These were plated and grown at 37 oC overnight on 
LB agar plates with their corresponding antibiotic. A single colony was used to inoculate 50 ml 
of overnight starter culture media containing the corresponding antibiotic (table 2.2). 
 Competent cell line Grow-up media Antibiotic used for 
selection 
T. brucei PFK C41(DE3) 2xTY Kanamycin (50 µg/ml) 
T. cruzi PFK BL21 (DE3) 2xTY Kanamycin (50 µg/ml) 
T. congolense PFK BL21(DE3) LB or 2xTY Kanamycin (50 µg/ml) 
T. vivax PFK ND ND ND 
L. infantum PFK C41(DE3) 2xTY Carbenicillin (100 
µg/ml) 
 
Table 2.2: summary of conditions for growth and expression of parasitic PFKs.  





All PFK constructs were grown in 500 ml of media using the overnight starter culture to an OD 
of 0.8-0.9 in a shaking incubator at 250 RPM, 37 oC. Cells were cold shocked at 4 oC for 30 mins 
and induced at 18oC for 16 hrs at 100 RPM using 1 mM IPTG. Cells were pelleted at 5000 rpm 
using a Beckmam Coulter Avanti J-26 centrifuge with a JLA-8.1000 rotor at 10oC for 30 minutes. 
2.2.2 Preparation of cell lysates for parasitic PFK purification 
1 litre cell pellets were re-suspended in 30ml TEA buffer (50 mM TEA, 5 mM MgCl2, 50 mM KCl, 
10% glycerol, pH 7.4) supplemented with Roche cOmplete™ EDTA-free Protease Inhibitor 
Cocktail and ~5 mg of deoxyribonuclease (sigma DV25). Cells were lysed at 25 Kpsi using a 
Constant Cell Disruption Systems cell disruptor at 6 oC. The resulting lysate was centrifuged at 
50,000 X g for 45 minutes using a Beckman Coulter Avanti® J-26 centrifuge with JA-25.50 rotor. 
The supernatant was then filtered using a 0.22 µm syringe filter on ice. 
 
2.2.3 Purification of parasitic PFKs 
All purifications were carried out at 6 oC in an ÄKTApurifier system (GE Healthcare). Filtered cell 
lysate was passed over a HiTrap IMAC FF column (GE Healthcare) charged with cobalt at 1 
ml/min using a p960 sample pump module. Unbound sample was washed with 10 column 
volumes (CV) of wash buffer (as described in 2.2.2).  Two additional wash steps carried out at 
1ml/min with a further 10 CV of wash buffer mixed with 8% then 20% elution buffer (50 mM 
TEA, 300 mM NaCl, 500 mM imidazole, 10 glycerol, pH 8.0). PFK was then eluted from the 
column with 15 CV of 100% elution buffer. 1 ml fractions were eluted in a 96-well block (Greiner 
BioOne 780270). 
2.2.3.1 Size exclusion chromatography (SEC) – T. brucei and T. cruzi PFK purification. 
Fractions containing PFK were collected, pooled and concentrated to a volume of 5 ml using a 
Vivaspin 6 column of molecular weight cut off (MWCO) 100 kDa (Sartorius). This sample was 
loaded manually into a 5 ml holding loop before being passed over a HiPrep Sephacryl™ S-200 
16/60 column (GE Healthcare), pre-equilibrated with gel filtration buffer (20 mM TEA, 5 mM 
MgCl2, 50 mM KCl, 10 % glycerol, pH 7.4). An example chromatogram for the Sephacryl S-200 
16/60 column in given in figure 2.1. Sample and buffer flow rate was held at 0.5 ml/min over 
the duration. PFK was eluted off the column with 1.5 column volumes of gel filtration buffer and 
2ml fractions corresponding to PFK were collected, pooled and concentrated to ~0.5 mg/ml 






Figure 2.1: Chromatogram profile for Sephacryl S-200 16/60 SEC column. 
Example chromatogram trace for IgG (160 kDa), BSA (67 kDa), B-lactoglobulin (35 kDa), 
cytochrome C (12.4 kDa) and cytidine (0.24 kDa). Adapted from General Electric Company 
Sephacryl S200 manual 2005-2009.  
2.2.3.2 Desalting step – L. infantum PFK purification. 
Pooled IMAC elutions of L. infantum PFK precipitated on Sephacryl and Sepharose-based size 
exclusion chromatography columns (data not shown) and so this step could not be used for Li 
PFK.  The second stage for LiPFK therefore involved a simple desalt size exclusion 
chromatography step; 5ml of the pooled IMAC fractions were filtered using a 0.22 nm syringe 
filter and were loaded onto a ‘HiPrep 26/10 Desalting’ column (GE Healthcare) equilibrated with 
SEC buffer (20 mM TEA, 5mM MgCl2, 50 mM KCl, pH 7.4) at 7 oC. The PFK was eluted with 1.5 
column volumes of the same buffer. 2 ml fractions were eluted into a 96-well block (Greiner 
BioOne 780270). Fractions containing LiPFK were concentrated using a Vivaspin 6 100 kDa 
MWCO spin concentrator (Sartorius).  
2.2.3.3 Measurement of protein concentration. 
Protein concentration was measured using a ‘NanoDrop Lite’ spectrophotometer. Absorbance 
was measured at 280 nm and converted to concentration using the Beer-Lambert law; A = *c*l 
where A = absorbance,  = extinction coefficient of protein, c = concentration and l = path 
length. A table of extinction coefficients for each parasitic PFK is given in table 2.3. Only T. brucei, 
T. cruzi and L. infantum PFKs were successfully expressed and purified at the time of writing.  
Species Length (a.a) MW (kDa) pI Extinction coeff. (M-1cm-1) 
T. brucei 507 55.76 9.50 37860 
T. congolense 507 55.59 9.15 37860 




T. vivax 504 55.41 9.36 41870 
L. infantum 510 57.07 8.99 56435 
Table 2.3: Extinction coefficients for parasitic PFKs 
 
2.2.4 MALDI-TOF Mass Spectometry confirmation. 
Purified TcPFK and LiPFKs were confirmed using MALDI-TOF mass spectrometry. An in-gel 
Trypsin digest was carried out; 5 µg of each protein sample was run on a 12% acrylamide SDS-
PAGE gel and stained with InstantBlue stain (Expedion). Bands of interest were excised using a 
clean scalpel. SDS was removed from the gel using methanol and the protein was reduced using 
20 mM DTT at 30 oC. Cysteines were alkylated using 50 mM iodoacetimide and the gel pieces 
dehydrated using 50% (v/v) acetonitrile and air dried. The trypsin digest was carried out in 50 
mM ammonium bicarbonate buffer (pH 7.8) with 13.3 µg/ml trypsin (Sigma) for 16 hours at 30 
oC.  
The peptide samples were spotted onto a MS plate with a a-cyano-4-hydroxycinnamic acid 
(CHCA) matrix (Sigma) containing 0.3% trifluroacetic acid (TFA). MALDI-TOF mass spectrometry 
was carried out on a Bruker Ultraflex MALDI TOF TOF mass spectrometer at the School of 
Chemistry, UoE. 
 
2.2. Phosphofructokinase kinetics and inhibition assays. 
 
2.3.1 PYK/LDH linked enzyme assay. 
This assay measures PFK’s phosphotransferase activity by linking ADP-production to 
downstream pyruvate kinase (PYK) and lactate dehydrogenase (LDH) enzyme reactions, as 
shown in figure 2.2 below. The oxidation of NADH to NAD+ by LDH can be measured by reading 






Figure 2.2: PYK/LDH linked enzyme assay reaction scheme  
 
All PYK/LDH linked enzyme assays were performed at 25oC in a 96-well plate format using a 
Molecular Devices Spectramax® M5 Multimode Plate Reader. In all assays, each well had a final 
volume of 100 µL, plated in non-binding, clear 96-well F-bottom plates (Greiner BioOne 655901). 
Unless stated otherwise, all auxiliary enzymes and reagents used were purchased from Sigma-
Aldrich. Human M1 pyruvate kinase (M1PYK) enzyme was recombinantly expressed and purified 
from E. coli at the University of Edinburgh. The expression plasmid containing DNA for M1 PYK 
was kindly provided by Dr Meng Yuan.  Raw NADH absorbance readings were converted to 
concentration using the Beer-lambert law (A = Ɛcl) knowing ɛ340 NADH = 6220 M-1 cm-1. The 
gradient of the linear section of each absorbance over time curve was used to calculate the initial 
rate (µM-1 min-1).  
 
2.3.1.1 PYK/LDH linked enzyme assay for measuring PFK activity 
A 2.5x ‘assay mix’ was made containing 4.8 mM PEP, 1.2 mM NADH , 20 U/ml PYK, 33 U/ml LDH 
and 2.5mM ATP in assay buffer (50 mM TEA, 10 mM MgCl2, 100 mM KCl, , 10% glycerol, 0.005% 
TWEEN20, , pH 7.4). For measuring activity 40 µl of assay mix was plated in a clear, non-binding 




mg/ml stock) to be tested and 40 – 46 µl of assay buffer. This was to allow for variable protein 
stock concentrations to be tested. The reaction was started upon addition of 10 µl of 100mM 
F6P (10 mM final). Where required, TbPFK was used as a positive control by adding 4 µl of a 0.1 
mg/ml stock to 40 µl assay mix and 46 µl assay buffer. Absorbance at 340 nm was read with 20 
second intervals for 10 minutes at 25 oC in ‘kinetic mode’ on the Spectramax© M5 Multicode 
plate reader.  
 
2.3.1.2 PYK/LDH linked enzyme assay for measuring PFK inhibition 
A 2.5X assay mix was made up in assay buffer (as in 2.3.1.1) but with 12.5 mM ATP (5 mM final). 
A 2-fold serial dilution of 100X inhibitor compound stocks in 100% DMSO was carried out in a 
PCR plate. Inhibitor titrations were chosen according to known solubility or previous IC50 data, 
typically in the range of 100 – 0.78 µM, 20 – 0.16 µM or 5 – 0.04 µM (final concentration at 1% 
DMSO).  40 µL of assay mix, followed by 45 µL assay buffer, 4 µL of 0.1 mg/ml PFK and 1 µL of 
100X serial diluted inhibitors were added to a non-binding, clear 96-well plate (Greiner Bio-One 
655901) and incubated at room temperature for 10 minutes. The reaction was started by 
addition of 10 µL of 6 mM F6P. A known TbPFK inhibitor (‘CTCB-001’ and later ‘CTCB-405’) was 
used as a positive control to a final concentration of 5 µM (>2x known IC50). DMSO was used in 
place of inhibitor for negative controls. Where possible a multichannel pipette using non-binding 
tips (Tip-One cat. no. S1180) was used to reduce error. The A340 was measured using a 
Spectramax© M-5 multi-mode plate reader (Molecular Devices) in kinetic mode. Readings were 
taken over 10 minutes, 25 seconds apart at 25 oC. All compounds were tested in duplicate in the 
plate.  
PFK inhibitors were checked for non-specific downstream inhibition of the auxiliary enzymes 
(PYK and LDH) by adding compounds to assay mix without ATP and starting the reaction with 0.4 
mM (final) ADP (see figure 2.2). 
2.3.1.3 Data analysis of PYK/LDH assay for measuring inhibition. 
The gradient of the linear section of raw plots of NADH absorbance over time was converted to 
concentration over time using the Beer-lambert law (A = Ɛcl) knowing ɛ340 NADH = 6220 M-1 
cm-1, for each concentration of CTCB inhibitor. The resulting enzyme velocity values were then 
plotted as a function of compound concentration using Kaleidagraph 4.0 software. The data was 
analysed using non-linear regression and a sigmoidal curve was fitted (figure 2.3) to determine 




Kaleidagraph 4.0 uses the Levenberg-Marquardt algorithm in an iterative procedure to fit non-
linear curves. The equation for the sigmoidal curve given in figure 2.3 was fitted by using the 
positive control (100% inhibition of PFK – 5 µM CTCB 001 or ‘405) as the minimum velocity 
constraint (m1) and the negative control (no inhibition of PFK - 1% DMSO) as the maximum 






𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 =  
𝑚1 + (𝑚2 − 𝑚1)





Where m1 = Minimum velocity, m2 = maximum 




Figure 2.3: Sigmoidal plot equation for inhibition assays (PYK/LDH assay). 
Equation used to plot dose-response curves and measure the IC50 of CTCB compounds against 
PFK. M1 = minimum velocity control (5 µM CTCB 001/405). M2 = max velocity control (DMSO). 
 
2.3.1.4 PYK/LDH linked enzyme assay for enzyme kinetics and competition assays. 
A  50 µl reaction mixture containing a 2-fold dilution series of either F6P or ATP was diluted in 
2X assay mix (5mM PEP, 1.2 mM NADH, >20U/ml PYK, 33 U/ml LDH). To this 50 µl of  2X ‘protein 
mix’ was added containing 8 µg/ml PFK and a saturating concentration of F6P (10mM) or ATP 
(5mM) depending on the kinetic variable being measured. All stocks were buffered to pH 7.4 
before use. When used AMP was added to the 2X ‘assay mix’ to a concentration of 1 mM (final 
concentration 0.5 mM) for F6P titrations. When tested against ATP titrations, AMP was added 
to the ‘protein mix’ (final concentration 0.5 mM). The AMP-assay or AMP-protein mix was 














allowed to reach room temperature before addition to the plate. 96 well non-binding 
translucent plates (Greiner BioOne 655904) were used. Titration assays were carried out in 
triplicate.  Upon addition of 50 µl of assay mix the A340 was measured in kinetic mode over 5 
minutes with readings every 14 seconds at 25 oC. 
When compound competition kinetics were investigated 100X, 100% DMSO stocks were added 
to either the 2X ‘protein mix’ or ‘assay mix’ and incubated at room temperature for 15 minutes 
before testing. Final concentrations of inhibitors were 0.5X, 1X and 2X their respective IC50 (as 
determined in enzyme-linked assay). DMSO was kept at 1% (v/v) (final) in all inhibition assays. 
The PFK concentration used was 4 µg/ml (final).  
2.3.2 Aldolase/G3PDH/TIM linked enzyme assay 
This assay measures PFK activity by linking the product fructose-1,6-biphosphate to the 
downstream enzymes aldolase, triose isomerase (TIM) and glycerol-3-phosphate 
dehydrogenase (G3PDH), as shown in figure 2.4 below. All auxiliary enzymes and reagents were 
sourced from Sigma-Aldrich. Reaction volumes per well were 100 µL. 
 







2.3.2.1 Aldolase/G3PDH/TIM linked enzyme assay for measuring PFK activity. 
A 2.5X ‘assay mix’ was made containing 5U/ml G3PD, 2.5 U/ml aldolase (A2714), 25 U/ml TIM, 
1.25 mM NADH and 2.5 mM ATP using assay buffer (50 mM TEA, 100 mM KCl, 10 mM MgCl2, 
10% glycerol, pH 7.4). 40 µl of assay mix was plated in a clear, non-binding 96 well plate (Greiner 
Bio-One cat. no. 655901) with 4-10 µl of the PFK sample to be tested and 40 – 46 µl of assay 
buffer. This was to allow for variable protein stock concentrations to be tested. The reaction was 
started upon addition of 10 µl of 6mM F6P (0.6 mM final). Where required, TbPFK was used as 
a positive control by adding 4 µl of a 0.1 mg/ml stock to 40 µl assay mix and 46 µl assay buffer. 
Absorbance at 340 nm was read with 20 second intervals for 10 minutes in ‘kinetic mode’ at 25 
oC on a Spectramax© M5 Multicode plate reader.  
 
2.3.2.2 Aldolase/G3PDH/TIM linked enzyme assay for measuring PFK inhibition 
A 2.5X assay mix was used as described above, with assay buffer (as in 2.3.2.1) but with 12.5 
mM ATP (5 mM final). A 2-fold serial dilution of 100X inhibitor compound  stocks in 100% DMSO 
was carried out in a PCR plate. Inhibitor titrations were chosen according to known solubility or 
previous IC50 data, typically in the range of 100 – 0.78 µM, 20 – 0.16 µM or 5 – 0.04 µM (final 
concentration at 1% DMSO).  40 µL of assay mix, followed by 45 µL assay buffer, 4 µL of 0.1 
mg/ml PFK and 1 µL of 100X serially diluted inhibitors were added to a non-binding, clear 96-
well plate (Greiner Bio-One 655901) and incubated at room temperature for 10 minutes. The 
reaction was started by addition of 10 µL of 6 mM F6P. A known TbPFK inhibitor (‘CTCB-001’ and 
later ‘CTCB-405’) was used as a positive control to a final concentration of 5 µM (>2x known 
IC50). DMSO was used in place of inhibitor for a negative control. Where possible a multichannel 
pipette using non-binding tips (Tip-One cat. no. S1180) was used to reduce error. The A340 was 
measured in using a Spectramax© M-5 multi-mode plate reader (Molecular Devices) in kinetic 
mode. Readings were taken over 10 minutes, 25 seconds apart at 25 oC. All compounds were 
tested in duplicate. Data analysis was carried out as described in section 2.3.1.3. 
When tested, human muscle PFK (PFK-M) was used as above at a concentration of 4 µg/ml. ATP 
was added to the 2.5X assay mix at a concentration of 2.5 mM (1mM final). PFK-M was 
expressed, purified and kindly donated by Dr P. Fernandes, UoE. 






2.3.3 Data analysis for kinetic assays. 
Kinetic data for PFK activity measured in the PYK/LDH, Aldolase/TIM and PGI/G6PDH (reverse) 
activity assays was analysed using GraphPad Prism ver. 6 software. PFK velocity was plotted as 
a function of substrate concentration and analysed by non-linear regression. Curves were fitted 
using Michaelis-Menten (figure 2.5) and/or allosteric sigmoidal (Figure 2.6) models. The 
concentration of substrate that provided the half maximal enzyme activity (Vmax/2) was recorded 
as the Km (Micaelis-Menten plots) and Khalf (allosteric sigmoidal plots) values. 
 
 











𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 =  
𝑉𝑚𝑎𝑥 ∗ [𝑆𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒]





Figure 2.6: Allosteric sigmoidal plot equation.  
 
 
2.3.4 ADP-Glo™ assay 
This is an end-point assay manufactured by Promega (cat. No. V9102) that measures ADP 
produced in a kinase reaction. Following the kinase reaction, the addition of a reagent results in 
any unused background ATP being removed and the sequestering of the kinase reaction. A 
second reagent is then added to convert the remaining ADP to ATP which is coupled to the 




non-binding 96-well plates (Greiner Bio-One 655904). ‘Ultrapure’ stocks of ATP and ADP 
provided by Promega were used to reduce background noise. All reagents additional to those 
provided in the Promega ADP-Glo™ kit where purchased from Sigma-Aldrich. Measured 
luminescence units can be converted to ADP concentrations through a standard ADP/ATP 
titration curve (figure 2.8). All ADP-Glo™ assays were carried out with a 25 µL kinase reaction 
volume at 25 oC. 
 
Figure 2.7 ADP-Glo™ assay reaction scheme 
Assay is carried out in 3 steps: 1) Kinase reaction is run at 25 oC. 2) Incubation step 1: ADP-Glo 
reagent is added and background ATP is sequestered. 3) Incubation step 2: kinase detection 
reagent added. ADP is converted back into ATP and used in the luciferase/luciferin reaction and 
light is produced. 
 
2.3.4.1 ADP-Glo™ assay for measuring PFK inhibition 
A TEA-based assay buffer was used (50 mM TEA, 10 mM MgCl2, 5 mM KCl, 0.1% w/v bovine 
serum albumin (BSA), 0.005% Tween20, 1% DMSO, pH 7.4).. A 3-fold serial dilution of 250X 
inhibitor stocks carried out in 100% DMSO. 2 µL of these dilutions was added to 198 µL assay 







carried out to check for solubility at 1% DMSO. Concentration ranges of inhibitor compounds 
were chosen according to known solubility and/or IC50 data. Typical concentrations of 
compounds were 40 – 0.018 µM, and 14 – 0.006 µM (final concentration, 1% DMSO). The PFK 
reaction in the presence of inhibitor is carried out initially; 10 µL of 1 µg/ml PFK (final 
concentration 0.4 µg/ml) was added to 10 µl of the 1% DMSO inhibitor compound serial dilutions 
in a white, non-binding 96-well plate (Greiner BioOne 655904). CTCB-001 or CTCB-405 
compounds were used as a positive control at a final concentration of 5 µM. Assay buffer 
containing 1% DMSO was added instead of inhibitor compound for the negative control. The 
protein/inhibitor mixture was incubated for 10 minutes at room temperature. The kinase 
reaction was started upon addition of a 5X ATP/F6P stock in assay buffer (final concentrations 
0.5 mM F6P and 0.1 mM ATP). Plates were then sealed, centrifuged at 1000X RPM for 30 seconds 
and incubated at RT for 30 minutes. 25 µL of ‘ADP-Glo™ Reagent’ was then added to each well, 
mixed using a multichannel pipette and incubated at room temperature for 40 minutes. 50 µL 
of ‘Kinase Detection Reagent’ was added and incubated for 50 minutes at room temperature.  
The luminescence was recorded using a Spectramax© M5 Multi-mode Plate Reader (Molecular 
Devices) in end-point mode, with 750 msec integration time. 
2.3.4.2 Data analysis of ADP-Glo assay for measuring inhibition. 
The raw luminescence values were converted to ADP concentration using a calibration curve for 
ADP standards (figure 2.8). 
Figure 2.8: Calibration curve for ADP standards in ADP-Glo™ assay. 
Carried out in ADP-Glo buffer (50 mM TEA, 10 mM MgCl2, 5 mM KCl, 0.1% w/v (BSA), 0.005% 





The resulting ADP concentrations were plotted as a function of inhibitor compound 
concentration using Kaleidagraph 4.0 software. The data was analysed using non-linear 
regression and a sigmoidal curve was fitted (figure 2.9) to determine the IC50 – the concentration 
of inhibitor that leads to 50% inhibition of maximal enzyme activity. Kaleidagraph 4.0 uses the 
Levenberg-Marquardt algorithm in an iterative process to fit non-linear curves. The equation for 
the sigmoidal curve given in figure 2.9 was fitted by using the positive control (100% inhibition 
of PFK – 5 µM CTCB 001 or ‘405) as the minimum constraint (m1) and the negative control (no 
inhibition of PFK - 1% DMSO) as the maximum constraint (m2) of the curve. The slope of the 




𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 =  
𝑚1 + (𝑚2 − 𝑚1)





Where m1 = Minimum velocity, m2 = maximum 
velocity and m4 = slope of curve at midpoint. 
 
 
Figure 2.9: Sigmoidal plot equation for inhibition assays (ADP-Glo assay). 
Equation used to plot dose-response curves and measure the IC50 of CTCB compounds against 
PFK. M1 = minimum ADP produced control (5 µM CTCB 001/405). M2 = max. ADP produced 
control (DMSO). 
 
2.3.5 Kinase-Glo® assay 
This is an end-point assay manufactured by Promega (cat. No. V6713) that measures ATP-
consumption by a kinase reaction by linking any remaining ATP to the luciferase/luciferin 
reaction to produce light. Measured luminescence units were converted to ATP concentrations 
through a standard ATP titration curve (data not shown). All assays were carried out in white, 
non-binding flat-bottomed 96-well plates (Greiner BioOne 655904) with a final reaction volume 
















2.3.5.1 Kinase-Glo® assay to measure PFK inhibition. 
A TEA-based assay buffer was used (50 mM TEA, 10 mM MgCl2, 5 mM KCl, 0.1% w/v BSA, 0.005% 
Tween20, 1% DMSO, pH 7.4). A 3-fold serial dilution of 250X inhibitor stocks carried out in 100% 
DMSO. 2 µL of these dilutions was added to 198 µL assay buffer and mixed well using a 
multichannel pipette. A visual inspection of these dilutions was carried out to check for solubility 
at 1% DMSO. Concentration ranges of inhibitor compounds were chosen according to known 
solubility and/or IC50 data. Typical concentration ranges of compounds were 40 – 0.018 µM, and 
14 – 0.006 µM (final concentration, 1% DMSO). The PFK reaction in the presence of inhibitor is 
carried out initially; 10 µL of 1 µg/ml PFK (final concentration 0.4 µg/ml) was added to 10 µl of 
the 1% DMSO inhibitor compound serial dilutions in a white, non-binding 96-well plate (Greiner 
BioOne 655904). CTCB-001 or CTCB-405 compounds were used as a positive control at a final 
concentration of 5 µM. Assay buffer containing 1% DMSO was added instead of inhibitor 
compound for the negative control. The protein/inhibitor mixture was incubated for 10 minutes 
at room temperature. The kinase reaction was started upon addition of a 5X ATP/F6P stock in 
assay buffer (final concentrations 0.5 mM F6P and 0.1 mM ATP). Plates were then sealed, 
centrifuged at 1000X RPM for 30 seconds and incubated at RT for 30 minutes. 25 µL of ‘Kinase-
Glo® Reagent’ was then added to each well and incubated at RT for 30 minutes.  
The luminescence was recorded using a Spectramax© M5 Multi-mode Plate Reader (Molecular 
Devices) in end-point mode, with 750 msec. integration time. Data was analysed as described in 
section 2.3.4.2. 
2.3.5.2 Kinase Glo assay for measuring reverse PFK activity. 
The reverse PFK assays were carried out in standard assay buffer (50 mM TEA, 10 mM MgCl2, 5 
mM KCl, 0.1% w/v BSA, 0.005% Tween20, 1% DMSO, pH 7.4). 40 µL of a PFK solution (final 
concentration 2 µg/ml) with ADP (final concentration 5mM) was incubated at room temperature 
for 10 minutes. The kinase reaction was started upon addition of 10 µL of a 5X F16BP stock (final 
concentration 5 mM) in assay buffer. All substrates were buffered to pH 7.4 before use. Plates 
were then sealed, centrifuged at 1000X RPM for 30 seconds and incubated at RT for 30 minutes. 
25 µL of ‘Kinase-Glo® Reagent’ was then added to each well and incubated at RT for 30 minutes. 




2.3. Phosphofructokinase reverse reaction assays. 
2.4.1 PGI/G6PDH linked enzyme assay - reverse PFK activity. 
This assay measures the formation fructose-6-phosphate (F6P) from F16BP as a product of 
reverse PFK activity by linking its production to the downstream enzymes phosphoglucose 
isomerase (PGI) and glucose-6-phosphate dehydrogenase (G6PDH) as shown in figure 2.10 
below. The reduction of NAD+ to NADH by the latter enzyme can be measured by recording 
absorbance at 340 nm. Glycerol kinase (GK) was used as an auxiliary kinase to prevent ATP 
accumulation. All reagents and auxiliary enzymes were purchased from Sigma Aldrich. 
 
Figure 2.10: PGI/G6PDH linked enzyme assay reaction scheme. 
 
2.4.1.1 PGI/G6PDH linked enzyme assay for measuring reverse PFK kinetics. 
A 2.5X ‘assay mix’ containing 0.75 mM NAD+ (Sigma NAD100-RO), 10 U/ml G6PDH (Sigma/Roche 
G8529), 2.2 U/ml PGI (Sigma P9544) and 12.5 U/ml GK (Sigma G0774) was made up in assay 




of assay mix was plated in a clear, non-binding 96 well plate (Greiner Bio-One cat. no. 655901) 
with 10 µL 20 µg/ml PFK and 10 µL 20mM ADP (or ADP titration). When used, AMP was added 
to a final concentration of 0.5 mM prior to the addition of ADP and the mixture was incubated 
for 10 minutes at room temperature. The reaction was started by addition of 20 µL of 50 mM 
F16BP (or 5X F16BP titration).  Absorbance at 340 nm was read with 25 second intervals for 15 
minutes at 25 oC in ‘kinetic mode’ on the Spectramax© M5 Multicode plate reader.  
Data was analysed similar to that of the PYK/LDH and aldolase/TIM assays – see section 2.3.3. 
 
2.4.1.2 PGI/G6PDH linked enzyme assay for measuring reverse PFK inhibition. 
A 2-fold serial dilution of 100X inhibitor ‘working’ stocks in 100% DMSO was carried out in a PCR 
plate. Inhibitor titrations were chosen according to known solubility or previous IC50 data, 
typically in the range of 100 – 0.78 µM, 20 – 0.16 µM or 5 – 0.04 µM (final concentration at 1% 
DMSO). A 1.6X ‘assay mix’ (2 U/ml PGI, 0.5mM NAD+) was made up in assay buffer (10 mM 
MgCl2, 50 mM TEA, 100 mM KCl, 10 glycerol, 0.005 % TWEEN20, 1% DMSO, pH 7.4). 60 µl of assay 
mix was plated in a clear, non-binding 96 well plate (Greiner Bio-One cat. no. 655901) with 4 µL 
0.1 U/µL G6PDH (Sigma no. G8529), 10 µL 20 µg/ml PFK, 1 µL of 100X inhibitor dilutions and 10 
µL 20mM ADP. Plates were incubated for 10 minutes at room temperature. The reaction was 
started by addition of 20 µL of 10 mM F16BP.  Absorbance at 340 nm was read with 25 second 
intervals for 15 minutes at 25 oC in ‘kinetic mode’ on the Spectramax© M5 Multicode plate 
reader.  
Data was analysed with the same protocol as the inhibition assays in the PYK/LDH assay – see 
section 2.3.1.3. 
 
2.4.2 Kinase-Glo® assay for measuring reverse reaction. 
The same Promega Kinase-Glo® assay kit as described in section 2.3.5.2 was also used to 









2.4. Biophysical analysis. 
2.5.1 Dynamic light scattering of trypanosomatid PFKs. 
Dynamic Light Scattering (DLS) involves focusing infra-red (IR) light on a sample of protein held 
in solution in a vertical capillary. The particles in solution move according to Brownian motion. 
The movement of particles scatters the infrared light and the diffraction pattern is measured on 
a detector behind the capillary (figure 2.11).  
 
Figure 2.11: Schematic of dynamic light scattering steps. 
A) Infra-red light is focused onto capillary containing protein molecules in solution. Scattering of 
light by diffusion of molecules is measured on a detector. 
B) The correlation factor of the scatter (C) is plotted against time. The diffusion coefficient of the 
molecules is calculated from this plot. Smaller molecules have a faster exponential decay of the 
correlation factor than large particles.  
C) Using the Stokes-Einstein equation, the radius of the particles can be calculated, and the 










The rate at which spherical particles diffuse in solution is related to the size of the particles, and 
the two are linked by the Stokes-Einstein equation: 
𝑑 =    Stokes-Einstein equation 
Where 𝑑 = hydrodynamic diameter, KB = Boltzmann constant, T = absolute temperature (Kelvin), 
D = diffusion coefficient and 𝜂  = viscosity of solution. Using this equation and the diffusion 
coefficient calculated from the plot of correlation factor against time (figure 2.11B), the 
hydrodynamic diameter can be calculated. Assuming the protein particles to be roughly 
spherical in shape, this allows a calculation of the size of the protein molecules. The primary goal 
of DLS however is to assess the population of protein molecules. By plotting the populations of 
particles of various sizes (figure 2.11C), we can use DLS to show if a protein sample is 
monodisperse (a population of protein where the particles are all the same size) or if there are 
aggregates or contaminants in the sample (shown by a range of particles with differing 
hydrodynamic diameters).  
All DLS experiments were carried out using a Zetasizer APS instrument (Malvern). 50 µL of 
sample was added per well in a 384-well plate . T. brucei, T. cruzi and L. infantum PFKs were 
tested at concentrations of 0.6, 0.7 and 0.5 mg/ml respectively. All samples were centrifuged at 
4000 rpm for 10 minutes at 10 oC. All protein samples were tested in triplicate in a TEA – based 
buffer containing 20mM TEA, 10 mM MgCl2, 50 mM KCl, pH 7.4. This buffer gave a viscosity of 
1.14 cP – as calculated by the dedicated Zetasizer software. All analysis and graph plotting was 
carried out using this software.  
 
2.5.2 Thermal Denaturation Assay (TDA). 
Thermal Denaturation Assays (TDA) can be used to assess the thermal stability of proteins by 
measuring the transition melting temperature (Tm). The protein sample is subjected to an 
incremental temperature range in the presence of a environment-sensitive fluorescent dye such 
as SYPRO orange. Upon protein denaturation the protein unfolds and the surrounding dye is 
exposed the exposed hydrophobic residues, causing a rapid increase in fluorescence. A BioRad 
‘IQ5 ICycler’ RT-PCR machine was used to carry out all TDA experiments. Sypro Orange (Life 
Technologies, S6650) fluorescent dye was used (ex/em 485/575 nm). Experiments were carried 
out in 96-well PCR plates (BioRad, 2239441) sealed with dedicated PCR seals (BioRad, MSB1001) 




2.5.2.1 TDA for measuring natural ligand binding. 
The effect on thermal stability of T. brucei, T. cruzi and L. infantum PFKs in presence and absence 
of AMP, ADP, F6P and F16BP was carried out. The reaction buffer contained 50 mM TEA, 10 mM 
MgCl2, 5 mM KCl, 10% glycerol and 0.005% Tween20 at pH 7.4. A reaction volume of 50 µL was 
used, containing: 10 µL analyte (final concentration 1mM), 5 µL 50X Sypro orange dye (5X final) 
and 35 µL PFK (1.9 µM final). Each condition as tested in triplicate. A negative control containing 
buffer in place of an analyte, a background control (containing buffer and dye only) and an 
analyte control (containing only analyte and dye) were also carried out in triplicate. Plates were 
sealed, centrifuged at 1000 rpm for 30 seconds and subjected to a temperature range of 20 – 
80 oC in 0.5 oC increments, with 30 second intervals between temperature increases. Plots of 
RFU v temperature and –d(RFU)/dt were exported from the BioRad software and plotted in 
Graphpad Prism to calculate the Tm. The average Tm and standard deviation was reported. 
 
2.5.2.2: TDA for measuring ADP/AlF3/F16BP complex. 
Various combinations of 1.25 mM solutions of ADP, AlF3 and F16BP were made up in TEA buffer 
(50 mM TEA , 10 mM MgCl2, 5 mM KCl, 10% glycerol, 0.005% TWEEN20, pH 7.4). 40 µL of these 
solutions was added to the 96-well PCR plates with 5 µL of 50X Sypro orange. 5 µl of 20 µM 
TbPFK was then added to each condition and allowed to incubate at room temperature for 15 
minutes before the TDA protocol outlined in section 2.5.2.1 was carried out.  
 
2.5.2.3: TDA for determining Kd of TbPFK for AMP. 
A 1.5X 2-fold serial dilution series of AMP was made up in TEA buffer (50 mM TEA, 10 mM MgCl2, 
5 mM KCl, 10% glycerol, 0.005% TWEEN20, pH 7.4). 35 µl of this AMP titration was added to each 
well in the 96 well PCR plate. 5 µL of 50X Sypro orange was added. 10 µL of trypanosomatid PFK 
was then added (2µM final). When used, ATP was added to the PFK stock to a concentration of 
3.75 mM (0.75 mM final) and allowed to incubate with the protein for 10 minutes at room 
temperature. All stocks were buffered to pH 7.4 before use. Thermal melt temperatures were 
plotted against concentration of AMP and a curve was fitted using the Langmuir isotherm 









2.5.3 Surface Plasmon Resonance (SPR). 
SPR assays measure the change in the angle of a wave of excited electrons known as a surface 
plasmon resonance (SPR) as polarised light is focused and refracted off a gold surface onto which 
a population of protein has been immobilised (figure 2.12). The SPR wave is sensitive to the 
amount of material on the gold surface – the refractive index. The binding of an analyte to this 
protein surface causes a change in the refractive index due to the build-up of material, and this 
changes the angle of the plasmon resonance. This change in angle is recorded in real time as 
resonance units (RU) (Wear, Blackburn, & Nowicki, 2009). As binding response is measured in 
real time, steady state kinetics, on and off rates can be determined. All SPR experiments were 
carried out on a GE Healthcare Biacore™ T200 instrument 
 
 
Figure 2.12: Surface plasmon resonance (SPR) schematic. 
As material binds to immobilised protein on a gold surface, the change in the refractive index of 
the material leads to the change in angle of refracted light close to the protein surface (from I to 
II). This change is recorded and plotted as a response over time in a sensorgram. Image adapted 
from (Cooper, 2002). 
 
2.5.3.1 Trypanosomatid PFK immobilisation for SPR assays. 
Active N-terminally His6-tagged T. brucei, T. cruzi and L. infantum PFK surfaces were generated 
by using a capture/stabilisation method optimised at the Centre for Translational and Chemical 
Biology (CTCB) at the University of Edinburgh(Wear & Walkinshaw, 2006)(Martin A. Wear, 




13, 000 resonance units (RU) were immobilised on Ni2+-nitrilotriacetic acid (NTA) sensor chips 
(GE Healthcare).  
The surface was first primed with 500 µM NiSO4. The dextran matrix on the chip was then 
activated using 0.2M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 50 mM N-
hydroxysuccinimide (NHS) to give reactive succinimide esters. EDC and NHS were injected at a 
rate of 5 µL.min-1 for 500 seconds. 20 - 50 nM PFK in HBS buffer (10 mM HEPES, 150 mM NaCl, 
0.05% P20, pH 7.4) was washed over the surface at 30 ml/min until saturation in response was 
achieved. The PFK tetramers were captured via the N-terminal His6 tags co-ordinating with the 
charged Ni2+ NTA groups (figure 2.13). 350 mM EDTA was washed over to strip any divalent ions 
off the surface, followed by ethaloamine (a primary amine) to quench any remaining active 
succinimide esters. Figure 2.13 below summarises the surface preparation.  
 
Figure 2.13:  PFK is immobilised to the SPR chip via His-tag orientation and covalent binding with 
succinimide esters. 
  
All SPR data analysis was carried out using the dedicated Biacore T200 evaluation software ver. 
1.0 (GE healthcare). Steady state and kinetic parameters were calculated by fitting a 1:1 binding 
model to the sensorgram traces.  Analyte binding responses reference subtracted and corrected 
for molecular weight. 
2.5.3.2 SPR for measuring binding of PFK substrates and metabolites. 
20 nM of T. brucei, T. cruzi and L. infantum PFK was used to create surfaces with ~3000 RU 




up and buffered in HBS buffer (10mM HEPES, 150 mM NaCl, 10 mM MgCl2, 0.05 % TWEEN20, pH 
7.4). Analytes were made up in 2.5-fold serial dilutions with concentration ranges: AMPǂ, ADP, 
ATPǂ, GTP, GDP, F6P, F16BP, F26BP – 10 mM – 7.8 µM. Citrate, PPi, Phosphoenolpyruvate (PEP) 
– 20 mM – 156 µM. ǂ1 mM when tested alongside another analyte. Analytes were tested against 
low density TbPFK, TcPFK and LiPFK surfaces of 1,500 – 300 RU. Analytes were washed over the 
surfaces at a rate of 30 µL.min-1 with 30 second contact times and washed off with HBS running 
buffer (as above) for 30 seconds. When analytes were tested in the presence of AMP or ATP, 
these analytes were added to a concentration of 1 mM to the HBS running buffer and all analyte 
dilution series were made up in this buffer. 
2.5.3.3 SPR for measuring binding of inhibitor compounds to PFK. 
CTCB inhibitor compounds were screened against active T. brucei and T. cruzi PFK surfaces. 50 
nM of PFK protein was used to create surfaces initially of 11,000 – 13, 000 RU. Later less crowded 
TbPFK surfaces of ~1,500 RU were used. Compounds were first screened at 50 µM in HBS running 
buffer (10 mM HEPES; 150 mM NaCl, pH 7.4; 50 µM EDTA; 0.05 % P20; 1 % DMSO) and ranked 
compared to a normalised standard (CTCB-001 and CTCB-405). Run parameters were 30 μl.min-
1, 15-second contact and 60-second dissociation times. Responses were corrected for molecular 
weight and bulk shift. Inhibitors which showed clean binding responses relative to the standard 
were further tested in a 2-fold dilution series ranging from 25 – 0.19 µM or 50 – 0.38 µM 
(solubility permitting) in HBS running buffer (as above). Steady state and kinetic parameters for 
a 1:1 binding model with mass transport correction were obtained using the dedicated Biacore 
T200 evaluation software. 
2.5.3.4 SPR for measuring compound binding to human serum albumin (HSA). 
Active His6-TbPFK surfaces were generated by using a capture/stabilization method (Wear & 
Walkinshaw, 2006). Surfaces of ~ 12,000 RU were immobilized on an NTA sensor chip. 
Additionally, monomeric human serum albumin (HSA) (Sigma A3782), fatty acid and globulin 
free, and purified to homogeneity in 10 mM HEPES; 150 mM NaCl, pH 7.4; 50 µM EDTA; 0.05 % 
P20, using a Superdex200 10/300 GL column) was immobilized to 12,600 RU using standard 
amine coupling chemistries . Single point screens at 50 µM were performed, with solvent 
correction, running simultaneously over both TbPFK and HSA surfaces, with flow cell 1 (Fc1) as 
the bulk-shift reference surface, and responses corrected for molecular weight. Following visual 
assessment of each compound and ranking of response using CTCB 001 as the normalized 
standard selected compounds were run with a 2-fold dilution series (in the range from 50 µM – 




Run parameters were 30 µl.min-1, 15 second contact and dissociation times (increased 
stabilization times were introduced between runs for compounds exhibiting slow multiphasic 
binding; see below). Kinetic and steady-state affinity values were fitted to 1:1 binding model 
with solvent correction. A two-state model was used to try and account for multiphasic binding 
behaviour against the HAS surface. Analytical-standard Warfarin (Sigma A2250) was used as a 
positive binding control against the HSA surface. 
2.5.3.5 SPR for measuring compound binding thermodynamics against PFK. 
To measure the thermodynamic properties of CTCB compound binding to PFK a low density 
(~1,500RU) and medium density (~6000 RU) surface of active T. brucei PFK were immobilised in 
pairs (Fc1 and Fc3 were left as reference cells for bulk-shift correction).  Run parameters were 
30 μl.min-1, 15-second contact and 60-second dissociation times. A 2-fold dilution series ranging 
50 – 0.062 µM of CTCB compounds was carried out in HBS buffer (10 mM HEPES; 150 mM NaCl, 
pH 7.4; 50 µM EDTA; 0.05 % P20; 1 % DMSO). Each dilution series was run at 5 – 41 oC with 3oC 
increments.  Steady state and kinetic parameters were measured by fitting a 1:1 binding model 
to sensorgrams using the dedicated Biacore T200 evaluation software. Thermodynamic 
parameters were calculated using van’t Hoff plots of (InKd against 1/T) and thermodynamic 




∆ °)     van’t Hoff equation 
Where Kd = equilibrium  dissociation constant, R = universal gas constant, T = absolute 
temperature (K) ΔHo = enthalpy change and ΔSo = entropy change. Taking the change in heat 
capacity of the system into account, the equation used was: 




Where ΔCpo = change in heat capacity and To is the reference temperature (298K) (Martin A. 
Wear et al., 2017). Van’t Hoff plots were plotted using Kaleidagraph 4.0 software. 
2.5.4 Isothermal titration calorimetry (ITC). 
ITC measures the change of heat upon the binding of analyte to ligand in a thermally isolated 
(adiabatic) cell. The apparatus includes two cells: a sample cell containing the 
macromolecule(PFK) and a reference cell. The ligand (CTCB compound) is held in a syringe and 
titrated into the sample cell. A constant power is applied to the reference cell and acts as a 
feedback circuit to the sample cell. This maintains the two cells at the same temperature (ΔT=0). 




between the cells is detected by a calorimeter and the power applied to the sample cell is 
adjusted accordingly. The power used to maintain ΔT = 0 between the cells is the baseline. The 
change in reference power upon ligand and analyte interaction is measured as peaks (in 
endothermic reactions) or troughs (exothermic) showing the change in ‘reference power’ over 
time (µcal/sec). The heat evolved or absorbed during binding is quantified by integration of 
these peaks (figure 2.14)(Holdgate, 2001). ITC offers the ability to directly measure the enthalpy 
change from binding. As well as this ITC can be used to simultaneously measure the molar ratio 




Figure 2.14: schematic of ITC for measuring CTCB compound binding. 
CTCB compound is titrated into a cell containing PFK. The change in temperature ΔT is accurately 
measured by measuring the power (µcal/sec) required to heat or cool the sample cell so that 
ΔT=0 compared to the reference cell. Image adapted from Freyer & Lewis, 2008. 
 
All ITC experiments were performed on a MicroCal auto-iTC200 with liquid handling robot (GE 
Healthcare). Both CTCB compounds and PFK protein were made up in HBS buffer (10 mM HEPES, 







used for injections. Concentrations were adjusted according to compound stability and 
predicted Kd values. A Wiseman ‘C-value’ parameter of 10<C<100 was aimed for. To adjust for 
heat of dilution and check for buffer mismatch, controls where buffer was injected into protein 
and compound injected into buffer were carried out. 16 injections with 750 RPM stirring were 
carried out with 180 second delays between injections. Prior to syringe and cell filling, buffer, 
protein and compounds were stored at 15 oC, with injections carried out at 25 oC.  
2.5.4.1: ITC data analysis. 
Data was analysed using the dedicated MicroCal Origin® ITC analysis software. All raw injection 
peaks were adjusted for heat of dilution using the last 2 injections in each run. The raw injection 
peaks (figure 2.15) were baseline corrected and integrated to calculate the area underneath 
each peak (µcal). This data was plotted in Kcal per mole of injectant (y-axis, figure 2.15) against 
molar ligand : protein ratio (x-axis, figure 2.15). Curve fitting was carried out using the ‘One set 
of sites’ model. Curves were fitted by non-linear regression in an iterative process until the sum 
of squares (Chi2) value was as low as possible. When ITC data was normalised (section 6.4.6, 
chapter 6), the stoichiometry (‘N’) parameter was fixed to 1.0 during curve fitting. 
 





2.5. X-ray Crystallography 
2.6.1 Robot screening 
Automated robot crystal screens were conducted using an Art Robbins Instruments Gryphon 
LCP liquid handling robot. T. brucei PFK was used at a concentration of 3-4 mg/ml, mixed with 
1mM ADP, F16BP and AlF3 (sigma) in TEA buffer (20 mM TEA, 5 mM MgCl2, 100 mM KCl, 10% 
glycerol, 0.005 % Tween20, pH 7.4). 200 nL drops containing 100 nL of screening buffer and 100 
nL of protein were plated in a 96-well microplate, sealed and crystals left to grow at 16 oC. 
Molecular Dimensions’ ‘JCSG-plus’ screening kit was used.  
 
2.6.2 AlF3 co-crystallisation 
Equimolar (1mM) concentrations of Aluminium fluoride trihydrate (AlF3) (Sigma 23609), ADP 
and F16BP (> 99% purity, Sigma) were made and mixed in TEA buffer (as in 2.6.1). Crystals were 
plated using the hanging drop method with a 1:1 and 1:2 protein: well conditions ratio in 1 µL 
drops. Varying pH and precipitant concentrations were used in each well conditions using MES-
hydrate (2-(N-morpholino)ethanesulphonic acid) buffer (Sigma M2933), Imidazole (Fisher 288-
32-4) and Poly (ethylene glycol) Mn 4000 (Sigma 81240) in a 24-well Linbro plate (Molecular 
Dimensions). Table 2.5 shows an example plate layout. Crystal wells were sealed and left to grow 
at 16 oC. Smaller or ‘needle-like’ crystals were vortexed with glass beads and used as micro seeds 














 pH 6.1 pH 6.3 pH 6.5 pH 6.7 pH 6.9 pH 7.1 
12% 
PEG 
240 µL 50% 
PEG4K 
72.0 µL 1M 
MES 
28.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
260 µL H2O 
240 µL 50% 
PEG4K 
67.0 µL 1M 
MES 
33.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
260 µL H2O 
240 µL 50% 
PEG4K 
61.2 µL 1M 
MES 
38.8 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
260 µL H2O 
240 µL 50% 
PEG4K 
55.0 µL 1M 
MES 
45.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
260 µL H2O 
240 µL 50% 
PEG4K 
50.0 µL 1M 
MES 
50.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
260 µL H2O 
240 µL 50% 
PEG4K 
45.0 µL 1M 
MES 
55.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
260 µL H2O 
14% 
PEG 
280 µL 50% 
PEG4K 
72.0 µL 1M 
MES 
28.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
220 µL H2O 
280 µL 50% 
PEG4K 
67.0 µL 1M 
MES 
33.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
220 µL H2O 
280 µL 50% 
PEG4K 
61.2 µL 1M 
MES 
38.8 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
220 µL H2O 
280 µL 50% 
PEG4K 
55.0 µL 1M 
MES 
45.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
220 µL H2O 
280 µL 50% 
PEG4K 
50.0 µL 1M 
MES 
50.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
220 µL H2O 
280 µL 50% 
PEG4K 
45.0 µL 1M 
MES 
55.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
220 µL H2O 
16% 
PEG 
320 µL 50% 
PEG4K 
72.0 µL 1M 
MES 
28.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
180 µL H2O 
320 µL 50% 
PEG4K 
67.0 µL 1M 
MES 
33.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
180 µL H2O 
320 µL 50% 
PEG4K 
61.2 µL 1M 
MES 
38.8 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
180 µL H2O 
320 µL 50% 
PEG4K 
55.0 µL 1M 
MES 
45.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
180 µL H2O 
320 µL 50% 
PEG4K 
50.0 µL 1M 
MES 
50.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
180 µL H2O 
320 µL 50% 
PEG4K 
45.0 µL 1M 
MES 
55.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
180 µL H2O 
18% 
PEG 
360 µL 50% 
PEG4K 
72.0 µL 1M 
MES 
28.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
140 µL H2O 
360 µL 50% 
PEG4K 
67.0 µL 1M 
MES 
33.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
140 µL H2O 
360 µL 50% 
PEG4K 
61.2 µL 1M 
MES 
38.8 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
140 µL H2O 
360 µL 50% 
PEG4K 
55.0 µL 1M 
MES 
45.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
140 µL H2O 
360 µL 50% 
PEG4K 
50.0 µL 1M 
MES 
50.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
140 µL H2O 
360 µL 50% 
PEG4K 
45.0 µL 1M 
MES 
55.0 µL 1M 
IMIDAZOLE 
400 µL 50% 
GOL 
140 µL H2O 
 
Table 2.5: Example crystallography plating scheme for TbPFK. 
GOL = glycerol, MES = 2-(N-morpholino)ethanesulphonic acid). PEG4K = polyethylene glycol Mn 
4000.  
 
2.6.3 X-ray crystallography data collection. 
Crystals were sent to the Diamond Light Source synchrotron in Oxfordshire for remote data 













Chapter 3 : Expression, purification and characterisation 
of trypanosomatid PFKs. 
 
3.1. Introduction. 
The work in this chapter describes the expression, purification and enzyme activity of T. brucei, 
T. cruzi, L. infantum, T. congolense and T. vivax PFK enzymes. The basis of the purification of the 
PFK enzymes mentioned above was pioneered by the work of Cronin and Tipton in 1985 who 
purified the enzyme from populations of bloodstream-form T. brucei parasites in rats (Cronin & 
Tipton, 1985). These researchers later described the dependence of Mg2+ ions for the enzymatic 
activity of T. brucei PFK, the lack of inhibition at ATP concentrations exceeding 2 mM, the co-
operative relationship to F6P binding, and the steady state enzyme kinetics of the protein 
(Cronin & Tipton, 1987).  Later work in purifying PFK was facilitated from the identification of 
the TbPFK gene from genomic libraries (Michels et al, 1997) and the recombinant expression 
and purification in E. coli (Keillor et al., 2003).  
3.2. Trypanosomatid PFK sequences. 
The target for the Seeding Drug Discovery (SDD) programme was specifically T. brucei PFK due 
to its role in Human African Trypanosomiasis (HAT). Traditionally T. b. brucei strains have been 
studied for this purpose. This strain differs from the disease-causing T. b. rhodesiense and T. b. 
gambiense subspecies by the loss of a single gene that normally prevents lysis of the parasite in 
human blood, facilitating its use in the laboratory with greater ease. The T. b. brucei PFK enzyme 
is representative of the enzyme found in the human infective subspecies that cause HAT.  Other 
trypanosomatid PFKs from T. cruzi (Chagas disease), L. infantum (Leishmaniasis), T. congolense 
and T. vivax (animal trypanosomiasis) were also expressed, purified and tested, as described 
throughout this thesis. Unfortunately, successful expression of T. vivax and T. congolense PFKs 
was not achieved before this thesis could be completed. 
3.2.1 Sequence analysis of trypanosomatid PFKs. 
Full length amino acid FASTA files were obtained from the Uniprot protein database 
(http://www.uniprot.org/) for T. brucei, T. cruzi, T. congolense, T. vivax and L. infantum PFKs. 
Sequence identity was analysed alongside other eukaryotic and prokaryotic PFKs (table 3.1a) 
and sequences were aligned to each other using the ‘Clustal Omega’ multiple alignment 




relatively high identity of ~70 – 88% with each other, compared to ~23 – 26% identity with the 
mammalian and yeast PFKs. The active site is extremely well conserved across all the species 
outlined in table 3.1A (data not shown, see full alignment in supplementary material). A 
sequence alignment for the trypanosomatid PFKs is given in figure 3.1. A fact file of the 5 
trypanosomatid PFK sequences is given in table 3.1B.  
A 
 L. inf. T. bruc. T. cong T. vivax T. cruzi E. coli S. cere. Rb (M) Hs 
(M) 
L. inf. - 70.3 69.5 70.0 71.8 23.0 22.8 25.3 24.7 
T. bruc. 70.3 - 87.7 79.8 76.9 24.8 25.5 24.4 23.6 
T. cong. 69.5 87.7 - 81.6 77.3 25.1 24.6 23.6 22.7 
T. vivax 70.0 79.8 81.6 - 78.7 26.4 24.5 24.7 24.2 
T. cruzi 71.8 76.9 77.3 78.7 - 25.7 24.0 25.0 24.2 
E. coli 23.0 24.8 25.1 26.4 25.7 - 34.4 40.2 40.8 
S. cere. 22.8 25.5 24.6 24.5 24.0 34.4 - 42.9 42.7 
Rb (M) 25.3 24.4 23.6 24.7 25.0 40.2 42.9 - 96.3 
Hs (M) 24.7 23.6 22.7 24.2 24.2 40.8 42.7 96.3 - 
L. inf. = Leishmania infantum. T. bruc. = Trypanasoma brucei brucei/ T. cong. = T. congolense 
(IL300 strain), S. cere. = Saccharomyces cerevisiae. Rb (M) = Rabbit muscle (Oryctolagus 
cuniculus). Hs (M) = Homo sapiens muscle.  
B 




T. brucei brucei (strain 427) O15648 AF008186 487 
T. cruzi ( strain CL Brener) Q4E657 AAHK01000001 485 
T. congolense (strain IL3000) F9W8G2 CAEQ01001170 487 
T. vivax (strain Y486) G0TSZ6 HE573019 484 
L. infantum (strain JPCM5) A4I4W5 FR796461 486 
 
Table 3.1: Sequence Identity matrix for selected eukaryotic and prokaryotic PFKs. 
A) Identity matrix of amino acid sequences between PFKs in Trypanosomatid (bold), bacterial 
(E.coli), yeast (S. cerevisiae) and mammalian (O. cuniculus, H. sapiens) species. B) Details of 




















Figure 3.1: Sequence alignment of trypanosomatid PFKs. 
Amino acid sequence alignment of select trypanosomatid PFK monomers. Identical residues are 
boxed. Active site features of TbPFK including inserted loop 329-348 (purple), Arg173 loop 170-
178 (blue) and Asp229 loop 225-235 (green) are underlined. Residues involved in ATP binding (*) 
and F6P binding (Δ) as described by McNae et. al are annotated beneath the sequence (McNae 
& Martinez-Oyanedel, 2009).  
  
* * 





Sequence alignments of the trypanosomatid PFKs tested in this thesis are shown in figure 3.1. 
There is 100% identity in residues involved in ATP and F6P binding (as described by McNae et. 
al) across all 5 species (McNae & Martinez-Oyanedel, 2009). The residues making up dynamic 
active site loops ‘Arg173 loop’ and ‘Asp229 loop’ have high identity across all species, as does 
the ‘inserted loop’ unique to trypanosomatid PFKs. 
3.2.2 Sequence analysis against mammalian PFKs. 
As the T. b. rhodesiense/gambiense parasites have infective life cycle stages in mammals, it is 
advantageous that the targeted pocket in trypanosomatid PFKs structure is either not present 
or sufficiently different in the mammalian equivalent, to prevent inhibition of the host enzyme. 
A sequence comparison of the residues involved in F6P and ATP binding, as well as the residues 
making up the ‘CTCB binding pocket’ in T. brucei PFK is given in section 1.4.8, chapter 1.  
3.2.3 Recombinant trypanosomatid PFK enzyme sequence overview. 
All recombinant trypanosomatid PFKs were cloned and purified with N-terminal His6-tags ; T. 
brucei, T. congolense, T. cruzi and T. vivax PFKs all had the same thrombin-cleavable tag with 
a.a. sequence ‘MGSSHHHHHHSSGLVPRGSH’. L. infantum PFK had the TEV-cleavable site 
‘MSYYHHHHHHDYDIPTTENLYFQG’. Characteristics of each sequence are given in table 3.2. 
Species Strain Length (a.a) MW 
(monomer) 
(kDa) 
pI Extinction coeff. (M-
1cm-1) 
T. b. brucei 427 507 55.76 9.50 37860 
T. congolense IL3000 507 55.59 9.15 37860 
T. cruzi CL Brener 505 55.81 9.23 40380 
T. vivax Y486 504 55.41 9.36 41870 
L. infantum JPCM5 510 57.07 8.99 56435 
 
Table 3.2: Computed parameters for trypanosomatid PFK sequences. 
All parameters computed using amino acid FASTA sequences and Expasy ‘ProtParam’ 
bioinformatics tool (http://web.expasy.org/protparam/). All sequence data include the His6 






3.3. Cloning of trypanosomatid PFKs. 
3.3.1 Cloning of T. congolense and T. vivax PFKs. 
DNA sequences of T. congolense (1515 bp) and T. vivax (1512 bp) PFK with N-terminal His6 tags 
were codon optimised for E. coli expression and synthesised into pMC vectors with Kanamycin 
resistance by Life Technologies ‘GeneArt’ services. Primers were designed for PCR amplification 
of the PFK insert from the pMC vector. The resulting DNA product was ligated into a pGEM®-T 
vector with coding for the beta-galactosidase enzyme and carbenicillin resistance. The vector 
was then transformed into DH5α cells and grown on LB agar plates with X-Gal and IPTG to allow 
for blue/white colony picking. White colonies containing the PFK DNA insert were grown up and 
the plasmid was extracted using a miniprep kit. PCR validation using the same primers for T. 
congolense and T. vivax PFK amplification confirmed the presence of the insert. The PCR 
validation of 8 colonies containing the T. congolense PFK insert is given in figure 3.2. A full 
description of T. congolense and T. vivax cloning is given in section 2.1.1. 
 
 
Figure 3.2: Agarose gel electrophoresis of T. congolense PFK T-vector PCR product. 
1% w/v agarose gel stained with ‘safeview’ DNA stain. M = Hyperladder 1Kb MW marker. 1-4 = 
individual colonies from 3:1 insert:plasmid ligation reaction. 5-8 = individual colonies from 5:1 
ligation reaction. T. congolense PFK DNA sequence = 1515 bp. 
 
10,037 bp - 
1,500 bp - 
1,000 bp - 
800 bp - 
600 bp - 
400 bp - 
200 bp - 
M 1 2 3 4 5 6 7 8
3000 bp - 




An overnight culture of a single colony of pGEM®-T. congolense/T. vivax PFK was pelleted and 
plasmid DNA was digested with HindIII and XbaI restriction enzymes. The destination vector 
(pET28a) was digested with the same restriction enzymes. Figure 3.3 shows the resulting 
digest products for T. congolense PFK.  
 
 
Figure 3.3: Agarose gel electrophoresis of T. congolense PFK T-gEM colony and pET28a vector. 
1% w/v agarose gel stained with ‘safeview’ DNA stain. Digest of T-gEM/T.congolense PFK vector 
and pET28a vector by HindIII and XbaI restriction enzymes. pET28a vector (cut) = 5,207 bp. 
T.congolense PFK insert = 1,515 bp. M= Hyperladder 1Kb MW marker. 1-2 = pET28a digest. 3-4 
= T-gEM/T.congolense PFK digest. ‘X’ = empty lane.  
 
Digested pET28a and T. congolense/T. vivax PFK DNA was gel extracted and purified to an 
A260/A280 ratio of 1.8 – 2.0. Ligation ratios of 2:1, 3:1 and 5:1 were used, in both 100 and 50 
ng ligation reactions in 10 µl volumes using T4 ligase. Transformation into DH5α cells and growth 
on LB agar with 34 µM kanamycin was unsuccessful. C41, BL21 and ‘E.cloni’ (Lucigen) competent 
cells were also used in transformations but none yielded colonies on the LB agar/kanamycin 
plates. A full protocol for ligation and transformation attempts is given in section 2.1.1.  
  

















3.4. Expression of trypanosomatid PFKs. 
Expression constructs of T. brucei, T. cruzi and L. infantum were previously designed and 
cloned by H. Morgan of the Walkinshaw group at the University of Edinburgh. Table 3.3 
summarises all 5 trypanosomatid PFK expression systems used.  








T. brucei MGSSHHHHHHSSGLVPRGSH 
(Thrombin protease) 
pET28a Kanamycin C41 (DE3) 
T. congolense MGSSHHHHHHSSGLVPRGSH 
(Thrombin protease) 
pET28a Kanamycin NA 
T. cruzi MGSSHHHHHHSSGLVPRGSH 
(Thrombin protease) 
pET28a Kanamycin BL21 (DE3) 
T. vivax MGSSHHHHHHSSGLVPRGSH 
(Thrombin protease) 
pET28a Kanamycin NA 
L. infantum  MSYYHHHHHHDYDIPTTENLYF
QG (TEV protease) 
pDEST17 Carbenecillin C41 (DE3) 
Table 3.3: Trypanosomatid PFK expression systems. 
 
All three trypanosomatid PFKs were transformed into chemically competent C41 (DE3) (T. 
brucei, L. infantum) or BL21 (DE3) cells (T. cruzi) and grown up on lysogeny broth (LB) agar plates 
with kanamycin. Single colonies were picked and use to inoculate overnight 50 ml cultures in 
2xTY media containing 34 µM kanamycin at 37 oC. These overnight cultures were used for larger 
volume (0.5 – 1 L) grow-ups of cultures to an OD of 0.8-0.9. Expression of PFK was induced using 
100 mM IPTG at 18 oC overnight. Cells were then pelleted and flash frozen in liquid nitrogen for 
use in purification later. A full protocol for trypanosomatid PFK transformation, grow-up an 





3.5. Purification of trypanosomatid PFKs. 
 
3.5.1 Affinity chromatography 
All three trypanosomatid PFKs were purified using a two-step protocol – an affinity 
chromatography step followed by a size exclusion chromatography or desalting step. Each 
trypanosomatid PFK was initially purified using a HiTrap IMAC sepharose column with cobalt, 
binding to the N-terminal His6-tag of the protein. Cell suspensions were lysed in wash buffer 
(50mM TEA, 300 mM NaCl, 20 mM imidazole, 10% glycerol, protease inhibitors, pH 8.0) using a 
high pressure homogeniser and the resulting lysate was loaded onto the IMAC columns. 
Additional washes of 10 or 20% of a buffer containing 500 mM Imidazole (‘Buffer B’ - 50mM TEA, 
300 mM NaCl, 500 mM imidazole, 10% glycerol, pH 8.0) were carried out to strip weakly bound 
molecules from the IMAC column. PFK was eluted with 100% buffer B (500 mM imidazole), 
stripping the His6-tagged PFK molecules from the Co2+ with the higher imidazole concentration. 






















































Figure 3.4: IMAC Co2+ affinity chromatography of trypanosomatid His6-PFKs. 
Affinity chromatography of T. brucei (A), T. cruzi (B) and L. infantum (C) PFKs. Cell lysates with 
N-terminal His6-PFK washed over Sepharose IMAC column charged with Co2+ in wash buffer (50 
mM TEA, 300 mM NaCl, 20 mM imidazole, 10% glycerol, pH 8.0). Eluted with 100% ‘buffer B’ (50 
mM TEA, 300 mM NaCl, 500 mM imidazole, 10 glycerol, pH 8.0). Red underline represents pooled 
fractions. Fraction at highest point of elution peak is labelled in red. All proteins purified from 
lysate of 1 litre cell pellets. X-axis shows millilitres (mL) of lysate/buffers run over column from 
the start of the affinity chromatography step.  
 
3.5.2 Size exclusion purification – T. brucei and T. cruzi PFKs. 
A second purification step was carried out for T. brucei and T. cruzi PFKs through size exclusion 
chromatography (SEC) using a GE Healthcare SephacrylTM S-200 16/60 size exclusion column. 
5ml of the concentrated pooled fractions from the affinity chromatography step was filtered 
using a 0.22 nm filter syringe and loaded onto the column, pre-equilibrated in SEC buffer (20 
mM TEA, 5mM MgCl2, 50 mM KCl, pH 7.4). The PFK was eluted by washing with 1.5 column 
volumes of the above buffer. Figure 3.5 shows the size exclusion profiles for both T. brucei and 
T. cruzi PFKs. Confirmation and quality control of each purification step (IMAC and SEC) was 







Figure 3.5: Size exclusion chromatography of T. brucei and T. cruzi PFKs. 
Size exclusion chromatography profile of T. brucei (A) and T. cruzi (B) pooled fractions from IMAC 
CO2+affinity chromatography. GE Healthcare Sephacryl S-200 16/60 SEC column used, pre-










Figure 3.6: SDS-PAGE gel electrophoresis of T. brucei and T. cruzi purification steps. 
M= Marker (BioRad Precision Plus Protein™ standards), WC = whole cell lysate, FT = flow through 
from IMAC column, X = empty well. Fractions for affinity (black) and size exclusion (blue) 
chromatography are labelled.   
M WC FT Tb C5 C6 C7 C8 C9 D9 D12 E6 E8 E9 
Affinity chromatography Size exclusion chromatography 
Size exclusion chromatography Affinity chromatography 





























3.5.3 Second stage purification of L. infantum PFK. 
Pooled IMAC elutions of L. infantum PFK precipitated on Sephacryl and Sepharose-based size 
exclusion chromatography columns (data  not shown) and so this step could not be used for L. 
infantum PFK.  As seen in figure 3.7B the IMAC fractions for L. infantum PFK are reasonably clean 
– with relatively little contaminating bands. The second stage for L. infantum PFK therefore 
involved a simple desalt size exclusion chromatography step; 5ml of the pooled IMAC fractions 
were added to a ‘HiPrep 26/10 Deslating’ column (GE Healthcare) equilibrated with SEC buffer 
(20 mM TEA, 5mM MgCl2, 50 mM KCl, pH 7.4). The PFK was eluted with 1.5 column volumes of 
the same buffer. Figure 3.7A shows the desalt profile for L. infantum PFK. Figure 3.7B shows the 
SDS-PAGE electrophoresis of all purification steps for LiPFK (both IMAC and desalt). 
3.5.4 Trypanosomatid PFK protein yields. 
On average, 1 litre cultures of E. coli expressing T. brucei, T. cruzi and L. infantum PFKs yielded 
16, 11 and 3 mg of active, purified protein. For the T. brucei and T. cruzi purifications, ~20% of 
protein was lost between the IMAC and SEC steps. It was assumed that this was due to 
aggregation on the Sephacryl column – a greater amount of protein was lost if this column was 














































Figure 3.7: Desalt and SDS-PAGE electrophoresis of L. infantum PFK. 
M= Marker (BioRad Precision Plus Protein™ standards), WC = whole cell lysate, FT = flow through 
from IMAC column, X = empty well. Fractions for affinity (black) and desalt column (blue) 
chromatography are labelled. 
M WC FT C3 C4 C5 C6 C7 C9 A5 A6 A7 A8 X X 


















3.6. Biophysical characterisation of trypanosomatid PFKs. 
3.6.1 Mass spectrometry confirmation of trypanosomatid PFKs. 
Purified TcPFK and LmPFK were confirmed using MALDI-TOF mass spectrometry. TbPFK was not 
tested as the protein from the same expression construct was previously confirmed by mass 
spectrometry by M. Valdivieso at the UoE (data not shown).  
TcPFK and LmPFK gel bands were subjected to a Trypsin digest and spotted onto the MS plate 
with a CHCA matrix solution containing 0.3% trifluroacetic acid (TFA) to produce positively 
charged peptide fragments. MS data was collected using a Bruker ‘Ultraflex’ MALDI-TOF 
spectrometer at the School of Chemistry, UoE. The MS peptide spectra for T. cruzi PFK and L. 
infantum PFK and reuslts of a MASCOT peptide fingerprint search 
(http://www.matrixscience.com) are shown in figures 3.8 and 3.9 respectively. 
 
 
Figure 3.8: T. cruzi PFK MALDI-TOF mass spectrometry confirmation. 
MS peptide fingerprint and MASCOT score histogram shown for LiPFK. MASCOT search results: 
Score at 173: Mass = 53,988. 6-phospho-1-fructokinase [Trypanosoma cruzi strain CL Brener] 
Score at 157 : Mass = 53,951 6-phospho-1-fructokinase, putative [Trypanosoma cruzi 
marinkellei]. T. c. marinkellei and the CL Brener strain have 98.6 % identity – differing by 2 amino 






























Figure 3.9: L. infantum PFK MALDI-TOF mass spectrometry confirmation. 
MS peptide fingerprint and MASCOT score histogram shown for LiPFK. MASCOT search results: 
Score at 190:  Mass = 54,014 Da : ATP-dependent phosphofructokinase [Leishmania infantum 



























3.6.2 Purified trypanosomatids were monodisperse when measured using DLS. 
Purified stocks of the T. brucei, T. cruzi and L. infantum PFKs were analysed using dynamic light 
scattering (DLS) to assess the size distribution of protein particles in solution – checking for 
aggregation and giving an estimate of the size of the molecules in the solution. A full description 
of the protocol for DLS is given in section 2.5.1. 
The 3 trypanosomatid PFKs tested in DLS were suspended in TEA buffer (20mM TEA, 10 mM 
MgCl2, 50 mM KCl, pH 7.4). These concentrations were taken into account when preforming DLS, 
giving the buffer a viscosity of 1.14 cP (table 3.4A). DLS experiments were carried out at 25 oC 
using a Zetasizer APS (Malvern Instruments). Results were analysed using the dedicated Malvern 
software. 
Published crystal structures of T. brucei  PFK show it to be a homotetramer (PDB: 2HIG, 3F5M) 
(Martinez-Oyanedel et al., 2007; McNae & Martinez-Oyanedel, 2009). Assuming all three 
trypanosomatid PFKs form similar homotetramers, the theoretical masses and radii of gyration 
are given in table 3.4B. The radius of gyration was calculated using Pymol 2.0.  
A 
Material RI Material absorbance Buffer RI Viscosity (cP) 
1.45 0.001 1.34 1.14 
 
B 
 T. brucei PFK T. cruzi PFK L. infantum PFK 
Theoretical tetramer 
mass (kDa) 
223 223 228 
Theoretical radius of 
gyration (nm) 
5.6 ND 
(no crystal structure) 
ND 
(no crystal structure) 
 
Table 3.4: General parameters for DLS of trypanosomatid PFK samples. 
A) Experimental parameters for DLS using TEA buffer (20mM TEA, 10 mM MgCl2, 50 mM KCl, 






Both T. brucei and T. cruzi  PFKs gave singular peaks by volume and by intensity – suggesting a 
singular, monodisperse population of protein (figures 3.10 and 3.11). The calculated particle 
diameters by volume were 12 and 11 nm for T. brucei and T. cruzi respectively, close to the 
estimated diameter of T. brucei PFK of 11.2 nm (table 3.4B). The L. infantum PFK sample had a 
very small contaminating amount of large aggregates (>100 nm in size) – observed by the size 
distribution profile by intensity (figure 3.12). These larger particles however only accounted for 
~3% of the population. The size distribution by volume shows the majority of the L. infantum 















Peak 2 Peak 3 
By Intensity 293 11.3 100% 
12.2 ± 1.9 
nm 
N/A N/A 




Figure 3.10: DLS results for T. brucei PFK. 
Particle size distribution calculated by intensity and volume. Calculated and measured particle 
sizes given in table. T. brucei PFK sample appears to be monodisperse and made up of particles 
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Peak 2 Peak 3 
By Intensity 298 11.2 100% 
11.2 ± 1.6 
nm 
N/A N/A 




Figure 3.11: DLS results for T. cruzi PFK.  
Particle size distribution calculated by intensity and volume. Calculated and measured particle 
sizes given in table. T. cruzi PFK sample appears to be monodisperse and made up of particles 
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By Intensity 303 45.3 70% 
15.3 ± 5 nm 
27 % 
50 ± 9 nm 
3% 
225 ± 71 
nm 
By Volume 303 13.6 99% 




190 ± 65.4 nm 
N/A 
 
Figure 3.12: DLS results for L. infantum PFK. 
Particle size distribution calculated by intensity and volume. Calculated and measured particle 
sizes given in table. L. infantum PFK sample has low (3%) population of large particles (>100 
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3.6.3 Thermal denaturation measurements of trypanosomatid PFK. 
Thermal denaturation assays (TDA) were carried out to assess the thermal stability of the 
trypanosomatid PFKs both with and without a range of substrates. TDA determines the 
transition melting temperature (Tm) or ‘denaturation point’ – the temperature at which the 
tertiary structure of the protein breaks down, exposing hydrophobic regions to a fluorescent 
dye. A real- time PCR instrument was used (BioRad iQ™5 ICycler) to heat the PFK samples from 
20 – 80 oC in the presence of a fluorescent dye – ‘SYPRO Orange’ (Sigma). Upon denaturation of 
the protein, the SYPRO Orange dye binds the newly exposed hydrophobic regions, and the 
increase in fluorescent signal (ex/em = 485/575 nm) is measured in relative fluorescence units 
(RFU).  
3.6.3.1 Trypanosomatid PFKs have good thermal stability. 
The transition melting temperatures of T. brucei, T. cruzi and L. infantum PFKs were calculated 
in the same TEA-based buffer (10 mM MgCl2, 100 mM KCl, 50 mM TEA, 10% glycerol, 0.005% 
TWEEN, pH 7.4). 50 µL reactions containing 1.9 µM PFK were heated with 0.5 oC increments 
from 4 – 80 oC in the presence of sypro orange. T. brucei, T. cruzi and L. infantum PFKs had 
melting temperatures (Tm) of 59 ± 0.2 , 54 ± 0.2 and 39 ± 0.3 oC respectively. The trypanosomatid 
PFKs preformed well in TDA with good reproducibility - standard deviations (N=3) of transition 
melting temperatures (Tm) were between 0.2-0.3 oC. Figure 3.13 shows the traces for the 3 
trypanosomatid PFKs tested. As seen in figure 3.13 the protein melts in a single unfolding event.  
The enzymes therefore are stable at room temperature (25 oC) – under which the activity, 














Figure 3.13 : Thermal denaturation assays of trypanosomatid PFKs. 
All experiments carried out in triplicate – single experiment trace shown for each PFK. TDA 
carried out in TEA buffer (10 mM MgCl2, 100 mM KCl, 50 mM TEA, 10% glycerol, 0.005% TWEEN, 
pH 7.4) with SYPRO orange dye. 1.9 µM PFK in 50 µL reaction. Temperature gradient 20 – 80 oC 




3.6.3.2 : Stability of trypanosomatid PFKs with substrates.  
A range of analytes were tested alongside the trypanosomatid PFKs in TDA experiments to test 
their effect on the thermal stability of the protein. Figure 3.14 shows the change in melting 
temperature (ΔTm) for T. brucei, T. cruzi and L. infantum PFKs in the presence of the allosteric 
activator AMP, the substrates ATP and F6P and the products ADP and F16BP. AMP, ATP and 
F16BP all increased the thermal stability of the trypanosomatid PFKS with a positive ΔTm. F6P 
did not cause a change in the Tm of any of the trypanosomatid PFKs - suggesting that F6P cannot 
bind in isolation – as previously hypothesised when comparing the apo- and ATP-bound crystal 
structures of TbPFK (McNae & Martinez-Oyanedel, 2009). Interestingly, ADP reduced the 
stability in TbPFK and TcPFK and increased LiPFK stability by 2-3oC - a small but significant 
change. This had a cumulative effect when added together with F16BP, suggesting that both 

































Figure 3.14 : Melting temperature shifts for trypanosomatid PFKs with substrates. 
All experiments carried out in triplicate. 2 µM PFK. Carried out with sypro orange dye, 20 – 80 oC 
temperature range, 0.5 oC increments in TEA buffer (10 mM MgCl2, 100 mM KCl, 50 mM TEA, 
10% glycerol, 0.005% TWEEN, pH 7.4). Standard deviation = 0.1-0.3 oC, error bars not shown. 











































































































































































3.7. Trypanosomatid PFK activity and quality control. 
A full description and comparison of the enzyme activity of the three Trypanosomatd PFKs 
discussed in this thesis is available in Chapter 4 : PFK enzyme kinetics. 
3.7.1 T. brucei PFK was consistent in activity between purification batches. 
The SDD project required the testing of a large number of compounds (>600) tested against the 
T. brucei PFK enzyme. From a 1L pellet of C41 cells, the average PFK yield after purification was 
15.7 mg. The activity of each batch of enzyme was tested for activity under saturating substrate 
conditions (5 mM ATP, 10 mM F6P) using a linked enzyme assay (PYK/LDH assay). This assay 
measures PFK activity by linking the production of ADP by the enzyme to two downstream 
enzymes – pyruvate kinase (PYK) and lactate dehydrogenase (LDH). The activity is measured by 
recording the change in absorbance of NADH at 340 nm as it is oxidised to NAD+ using a 
photospectrometer (figure 3.15). A full protocol for this assay is given in section 2.3.1. 
 
Figure 3.15: Reaction schematic of PYK/LDH assay for measuring PFK activity.  
 
Specific activity was measured firstly by taking the gradient of the raw absorbance trace over 
time at the linear section of the curve. Each absorbance value was converted to concentration 
of NADH using the Beer-Lambert law ( A = εcl ) assuming an extinction coefficient of 6.22 mM.cm-
1. Rate of NADH oxidation was converted to specific activity (µmoles NADH converted per minute 
per milligram of protein). Figure 3.16 Shows the specific activity of the T. brucei PFK batches 






Figure 3.16: T. brucei PFK batches were consistent in activity. 
Specific activity of purified recombinant His6-tagged T. brucei PFK batches over a 2-year period. 
Activity was tested at 25 oC in TEA buffer (10 mM MgCl2, 100 mM KCl, 50 mM TEA, 10% glycerol, 
0.005% TWEEN, pH 7.4) using the PYK/LDH assay. 5mM ATP, 10 mM F6P used. All experiments 
carried out in triplicate, error bars denote standard deviation.  
 
3.7.2 DMSO inhibits T. brucei PFK activity. 
To test the organic inhibitor compounds against trypanosomatid PFK, a solvent is required to 
dissolve and make up the powdered compound stocks, and to attempt to keep the compound 
soluble  when testing in aqueous buffer. The solvent used for this was dimethyl sulphoxide 
(DMSO). The activity of T. brucei PFK in the presence of different concentrations of DMSO was 
analysed using the PYK/LDH linked enzyme assay. The effect of DMSO on the downstream 
auxiliary  enzymes (pyruvate kinase and lactate dehydrogenase) was first assessed by providing 
the assay with 0.5 mM ADP in the absence of PFK – to fuel the downstream reactions (see figure 
3.15). DMSO had relatively no effect on the auxiliary enzymes up to 10 % (v/v) DMSO (figure 
3.17). The solvent was then tested against T. brucei PFK in the assay with 5 mM ATP and 0.6 mM 
F6P provided – the substrate concentrations used in the PYK/LDH assay when testing the 
inhibitor compounds (see section 6.2.1, chapter 6). DMSO inhibited the activity of T. brucei PFK 
as a function of concentration. 1 % DMSO lead to a 16 % decrease in activity, and 10 % (v/v) 
DMSO inhibited the enzyme by almost 70%. It was decided that 1% DMSO would be used as a 
final concentration in assays as a balance between enzyme activity and likelihood of compound 





Figure 3.17: DMSO inhibits T. brucei PFK activity. 
Tested using the PYK/LDH linked enzyme assay. 4 µg/ml PFK, 5 mM ATP and 0.6 mM F6P was 
used when testing against T. brucei PFK (black). 0.5 mM ADP was provided when testing against 
auxiliary enzymes only (red)(data normalised to TbPFK activity data). All experiments carried out 





3.8. Structural characterisation of T. brucei PFK (X-ray 
crystallography). 
Table 3.5 summarises the available crystal structures of a range of eukaryotic PFKs. As can be 
seen in the table, the only eukaryotic PFK to be solved with F6P bound is S. cerevisiae PFK (PDB 
code 3O8O) (Banaszak et. al, 2011). Evans et al. carried out pioneering work on the bacterial PFK 
structural and mechanism by obtaining a crystal structure of a chimeric bacterial PFK – made up 
of the ATP binding region of B. stearothermophilus PFK grafted onto the E. coli PFK enzyme 
(Evans, 1992). Apo- and ATP-bound structures of T. brucei PFK revealed that upon ATP binding, 
a conformational change in 3 loops surrounding the active site opened up space for F6P to be 
accommodated (McNae et. al, 2009). As ATP is required as a precursor to F6P binding, it is 
difficult to produce conditions where either only F6P or ATP and F6P would be bound, without 
the enzyme turning the substrates over. Protocols for all crystallography experiments can be 
found in section 2.6, chapter 2. 
 
Author Organism Ligand PBD code Protein 
stoichiometry 
Martinez-oyandel 
et. al. 2007 
T. brucei Apo 2HIG Homo 4-mer (A4) 
McNae et. al. 2009 T. brucei MgATP 3F5M Homo 4-mer (A4) 
Banaszak et. al. 
2011 
S. cerevisiae F6P, F26BP 3O8O Hetero 4-mr A2B2 
Benjamin, 2007 S. pombe F6P/ATP NA Homo-octamer 
Banaszak et. al. 
2011 
Rabbit - muscle ADP/ADP,ATP 308N/308L Monomer 
Strater et. al. 2010 P. pastoris ATP, SO42- 3OPY Hetero 12-mer 
(A4B4C4) 
Kloos et. al 2015 H. sapiens – 
platelet 
Apo/ADP 4RH3/4U1R Homo 4-mer (A4) 
Webb et. al. 2015 H. sapiens – 
platelet 
ATP/ADP 4XYJ/4XYK Home 4-mer (A4) 
 
Table 3.5: Summary of published eukaryotic PFK crystal structures. 
 
3.8.1 Two strategies for obtaining a fructose-bound structure of TbPFK.  
To obtain a T. brucei PFK structure with the F6P substrate bound, two strategies were adopted 




F6P bound structure, or trapping the enzyme in an intermediate form – using aluminium 
trifluoride to obtain an ADP-AlF3-F6P bound structure in a mimicked transition state. 
3.8.2 Crystallography using non-hydrolysable ATP with TbPFK. 
 A non-hydrolysable ATP analog (Adenosine 5′-(β,γ-imido)triphosphate) was added to an 
equimolar concentration of F6P (0.5mM) with 4.0 mg/ml TbPFK. This mixture was made up in 
standard enzyme assay buffer (10 mM MgCl2, 100 mM KCl, 50 mM TEA, 10% glycerol, 0.005% 
TWEEN, 1% DMSO, pH 7.4) and incubated at 25 oC for 20 minutes before being used in 
automated crystallography screens using an Art Robbins ‘Gryphon’ nano-litre pipetting robot. A 
JCSG-Plus (Molecular Dimensions) 96 condition plate was used to screen for crystal conditions. 
Rod-like crystals similar to those shown in figure 3.18A were found under 2 buffer conditions: 
(0.1M Tris, 0.2 M MgCl2, 10 % Peg 8K, pH 7.0) and (0.2M Magnesium formate, 20% Peg 3.35K, 
pH 7.0). Crystals from these conditions were vortexed to produce microseeding material which 
was used to streak additional Limbro plates with the same conditions but with a pH range from 
6.1 -7.1. No crystals large enough to be picked were obtained. Additionally, some larger 
diamond-like crystals were identified from the screen (0.1 M Bicine, 10 % PEG 6K, pH 9.0)(figure 
3.18B). These crystals were large enough to pick but diffracted poorly, with the best resolution 





Figure 3.18: Non-hydrolysable ATP with TbPFK produces rod-like and diamond-like crystals. 
Plated using Art Robbins ‘Gryphon’ nano-litre pipetting robot (1µl drop). A) TbPFK with 0.5 mM  
ATPNH, 0.5 mM F6P.1M Tris, 0.2 M MgCl2, 10 % Peg 8K, pH 7.0 grown at 16 oC over 3 days. B) 0.1 










3.8.3 Attempting the ADP-AlF3-F6P transition state. 
To capture the TbPFK enzyme in a ‘transition state-like’ crystal conformation, aluminium 
trifluoride was used (AlF3). The transition state of the phosphotransfer of the γ-phosphate on 
ATP to F6P is represented in figure 3.19A.  The free phosphate [PO4]3- when bound transiently 
by both ATP and F6P forms a trigonal bipyramid structure. Aluminium trifluoride is also able to 
form a trigonal bipyramid structure in solution by forming aluminium tetrafluoride – a square 
planar structure but when transiently coordinated to two additional oxygens forms a trigonal 
biplanar structure closely mimicking a phospho-transfer transition state (Wittinghofer, 
1997)(figure 3.19B). 
 



























Figure 3.19: Aluminium trifluoride mimics the transition state phosphate in a kinase reaction. 
A) Schematic representation of phosphotransfer from ATP to F6P. In its transition state, the 
phosphate [PO4]3- adopts a trigonal biplanar structure. 
B) Phosphotransfer intermediate can be mimicked by either aluminium tetrafluoride (1) or 
aluminium trifluoride (2) in solution. NDP = nucleotide diphosphate. R = nucleophile. Adapted 







3.8.4 AlF3 in the presence of ADP and F6P increases TbPFK thermal stability. 
As a source of aluminium trifluoride was immediately available, it was decided to dissolve a 
solution in standard enzyme buffer (10 mM MgCl2, 100 mM KCl, 50 mM TEA, 10% glycerol, 
0.005% TWEEN, 1% DMSO, pH 7.4) and to pre-incubate the solution with different combinations 
with TbPFK. TDA was then carried out to observe any effect of the thermal stability of the protein 
in the presence of the F6P/ADP/AlF3 mixture. A full protocol can be seen in section 2.5.2.2. Table 
3.6 shows the change in transition melting temperature (ΔTm) for TbPFK tested against the 
various components of the transition state. The F6P/ADP/AlF3 complex increased the stability of 
TbPFK by 12 oC, with no signs of aggregation by the complex (figure 3.20). Alone, AFP, F6P and 
AlF3 produced little or no increases in the thermal stability of TbPFK. 
 
Component ADP AlF3 F6P F6P/ADP F16BP ADP/AlF3 F6P/ADP/AlF3 
ΔTm -2 0 0 +1 +2 +1 +12 
 
Table 3.6: The F6P/ADP/AlF3 complex significantly increases the thermal stability of TbPFK. 
Thermal Denaturation Assay (TDA) results for TbPFK tested against a range of analytes (1mM) 





































Figure 3.20: The F6P/ADP/AlF3 complex significantly increases the thermal stability of TbPFK. 
A) Raw fluorescence trace for TbPFK with and without the F6P/ADP/AlF3 mixture (1mM). 2 µM 
PFK, 0.5 oC increments from 20 – 81 oC using Spyro Orange fluorescence dye. Each condition 
carried out in triplicate. B) Plot showing change in fluorescence over time (d(RFU)/dT).  
 
It was clear from TDA measurements that when all three elements of the F6P/ADP/AlF3 complex 
were mixed together in the presence of TbPFK, some form of stabilising complex is present. This 
experiment was repeated to ensure no aggregated AlF3 was being formed and similar results 
were produced – suggesting the ADP-AlF3-F6P intermediate complex was being formed with 
TbPFK. Controls containing the F6P/ADP /AlF3 alone without protein showed no significant 
fluorescent response (data not shown).  








3.8.5 Obtaining crystals of TbPFK with the F6P/ADP/AlF3 complex. 
To recreate the conditions used when the F6P/ADP/AlF3 complex was tested against TbPFK in 
TDA, an equimolar (1mM) solution of F6P, ADP and AlF3 was made up in the standard enzyme 
buffer (50 mM TEA, 10 mM MgCl2, 100 mM KCl, 10% glycerol, 0.005% TWEEN20, pH 7.4), in the 
presence of 3 – 4 mg/ml His6-TbPFK. The mixture was pre-incubated with the protein for 15 
minutes at room temperature before being used. The mixture was plated out using the hanging 
drop method with 2 drops on each cover slide for each well condition – a 2 µl drop (1:1 protein 
: well solution) and 3 µl drop (2:1 protein : well solution). Well solutions were buffered from pH 
6.1 – 7.1 across the plate using 2-(N-morpholino) ethanesulfonic acid (MES) and imidazole as 
buffering agents. Polyethelene glycol (PEG) 4K was used at 12 – 18% down the plate. A full 
protocol can be seen in section 2.6.2. 
After an average of 4 days small rod-like crystals similar to those found in the robot screen with 






16% PEG 4K, pH 7.1 
 
18% PEG 4K, pH 6.9. 
Figure 3.21: Rod-like crystals of TbPFK in complex with F6P/ADP/AlF3. 
 
Different PEG types, micro seeding using existing crystals, streak plating and repeats of previous 
conditions were all used in an attempt to improve the crystal yield. None produced any 
significant advances in the size of the rod-like crystals. After a week of rod-like crystal growth it 







Figure 3.22: Larger diamond-like crystals of TbPFK in complex with F6P/ADP/AlF3 grow after 1 
week. 
3.5 mg/ml TbPFK + 1mM F6P/ADP/AlF3. 16% PEG 4K, pH 6.9. 
Despite obtaining larger crystals no usable diffraction data below ~8 Å was able to be collected, 
despite the crystals diffracting as protein. No further attempts at the F6P/ADP/AlF3 transition 











Chapter 4: Enzyme kinetics and regulatory properties of 
phosphofructokinase. 
 
4.1. Introduction to phosphofructokinase-1. 
Phosphofructokinase-1 catalyses the conversion of fructose 6-phosphate to fructose 1,6-
bisphosphate by using either ATP (‘ATP-kinase’) or PPi (‘PPi-kinase) as a phospho donor. The 
enzyme exists in a wide range of organisms and cells, can be compartmentalised, and can 
operate as different isozymes and under different metabolic cell stress conditions. As such, the 
enzymatic activity and regulation of phosphofructokinase is remarkably diverse. Gene 
duplication and fusion events from a bacterial-like ancestral PFK have resulted in diversity in the 
structure and regulation of PFK-1 across species (Chapter 1, section 1.4.1). Despite this variation 
in structure, function and regulation, the active site of ATP-kinases is strikingly conserved 
amongst organisms (figure 3.1, section 3.2.1). Compartmentalisation of trypanosomatid PFKs as 
well as unique structural features and a reversion from PPi to ATP-dependency is likely to be key 
to their unique enzymatic profile. T. brucei PFK has been found to be more evolutionarily 
comparable to PPi-dependant PFK rather than ATP-PFK, and has been described as a ‘chimera’ 
of ATP and PPi-PFKs (Michels et al., 1997). What consequences does this PPi-kinase lineage have 
on the enzymatic activity of trypanosomatid PFK, and does this separate it from other eukaryotic 
PFKs? The majorly regulated enzyme in the glycolytic pathway of trypanosomes is the cytosolic 
enzyme pyruvate kinase (PYK) (Claustre et al., 2002). The only known effector of T. brucei PFK is 
the allosteric activator AMP (Nwagwu & Opperdoes, 1982).  
The aim of this chapter is to characterise the kinetic and regulatory properties of three 
recombinantly expressed ATP-PFKs from T. brucei, T, cruzi and L. infantum parasites, and to 
compare and contrast and gain a greater insight into the function of these enzymes in different 
trypanosomatids. This may further our understanding of their role in glycolysis, and as potential 
therapeutic targets. To achieve this a plate based assay was modified to test the kinetics of each 
enzyme under different concentrations of substrates, pH conditions, known and unknown 
metabolic intermediates and effectors. Additionally, substrate affinity measurements were also 
made using surface plasmon resonance (SPR) and thermal denaturation assays (TDA), to 





4.2. Substrate kinetics of PFK measured through a linked 
enzyme assay. 
To test the substrate kinetics of the trypanosomatid PFKs, the PYK/LDH enzyme assay was 
optimised for use as a 96-well plate based kinetic assay. This enzyme-linked assay measures 
PFK activity by linking ADP production to two downstream enzymes – pyruvate kinase (PYK) 
and lactate dehydrogenase (LDH). Activity is measured by reading the change in absorbance at 
340 nm as NADH is oxidised to NAD+ using a spectrophotometer. Figure 4.1 outlines the 
reaction scheme for the assay, and a full protocol can be found in section 2.3.1.  
 
Figure 4.1: PYK/LDH enzyme linked assay used for measuring PFK substrate kinetics. 
 
To measure substrate kinetics against PFK, serial dilutions of ATP and F6P were titrated against 
a set concentration of PFK and a saturating concentration of F6P or ATP respectively. 
Absorbance at 340 nm was recorded in 10 second intervals over 10 minutes and converted to 
concentration using the Beer-lambert law (A = εcl). Initial rates were calculated by taking the 
slope of absorbance over time then converted to specific activity (µmoles of NADH converted 
per minute, per milligram of protein). In all experiments an optimised final concentration of 4 
µg/ml of PFK enzyme was used. All assays were plated into clear 96-well plates, with a final 
reaction volume in each well of 100 µl in a TEA-based buffer (10 mM MgCl2, 100 mM KCl, 50 




4.2.1 Substrate kinetics of trypanosomatid PFKs. 
F6P and ATP titrations were carried out against T. brucei, T. cruzi and L. infantum PFKs using the 
PYK/LDH enzyme assay and data was plotted using Graphpad prism. Hyperbolic Michaelis-
Menten and ‘allosteric sigmoidal’ curves were fitted to each dataset and the best fit was 
assessed by the R2 value. Details of the Michaelis-Menten and Allosteric Sigmoidal fit models can 
be found in section 2.3.1.3. Km, Khalf, kcat, Vmax and Hill coefficient values were taken from these 
plots using Graphpad Prism ver. 6. Figure 4.2 shows an example plot for the titration of ATP 
against T. brucei PFK.  
 
Figure 4.2: Michaelis-Menten plot of ATP titration against T. brucei PFK (PYK/LDH assay). 
2-fold serial dilution of 5 mM – 2.4 µM ATP against 4µg/ml PFK and 10 mM F6P. Data points for 
the highest two concentrations have been omitted for clarity of fit for lower concentrations. 
Michaelis-Menten fit has been applied. All experiments were carried out at 25 oC in triplicate, 
error bars denote standard deviation. 
 
All three enzymes showed hyperbolic responses with respect to ATP, and fitted Michaelis-
Menten curve models well (R2 ≥ 0.99). F6P titrations however revealed sigmoidal binding 
responses at lower concentrations (data shown in section 4.2.3), and were fitted with the 
‘allosteric sigmoidal’ curve model. Table 4.1 shows the calculated kinetic parameters for all 
three enzymes. Kinetic constants are given as Michaelis constants (Km) for ATP titrations, and 
half maximal constants (Khalf) for F6P titrations. Both represent affinity for the substrate and 



















TbPFK 803 ± 48 2.1 ± 0.2 83 ± 5 1.2 ± 0.2 60 ± 1 54 ± 1 
TcPFK 469 ± 26 1.9 ± 0.2 79 ± 6 1.1 ± 0.1 59 ± 1 53 ± 1 
LiPFK 2391 ± 
99 
2.2 ± 0.1 24 ± 0.4 1.1 ± 0.3 26 ± 1 23 ± 1 
 
Table 4.1: T. brucei and T. cruzi PFKs show comparable substrate kinetics. 
Data measured using the PYK/LDH linked enzyme assay. ATP titrations: 12 dilutions 5 mM – 2.4 
µM. F6P titrations: 12 dilutions 20 mM – 9.8 µM. All experiments were carried out at 25 oC in 
triplicate, standard deviations for each parameter are given.  
 
T. brucei and T. cruzi PFK had comparable enzyme activities and affinities for F6P and ATP. 
Interestingly, L. infantum PFK, while having the strongest affinity for ATP (KmATP 24 µM), had a 
relatively low affinity for F6P (KhalfF6P >2 mM) and slower maximum activity compared to the 
other trypanosomatid PFKs at saturating concentrations of (F6P Vmax = 26 µmol-1.min-1.mg-1). 
 
4.2.2 Trypanosomatid PFKs show a hyperbolic response to ATP. 
ATP titrations against T. brucei, T. cruzi and L. infantum PFKS are shown in figure 4.3. Hill plots 
of the ATP titrations (data not shown) showed no evidence of binding cooperativity with regards 
to ATP for any of the enzymes tested (Hill coefficient ‘h’ = ~1). The trypanosomatid enzymes 
were not inhibited by ATP at concentrations up to 5mM, unlike mammalian PFKs which are 
inhibited at ATP concentrations above 2 mM (per. comm. P Fernandes). ATP binds to PFK by 
forming a complex with Mg2+ ions. A sufficient ratio of Mg2+ and ATP is therefore required for 
maximum activity. Only when ATP exceeds Mg2+ concentration, is ATP inhibitory against TbPFK 
(Nwagwu & Opperdoes, 1982). ATP and Mg2+ must therefore bind as a pair (MgATP) – when ATP 
exceeds the Mg2+ concentration a high population of individual ATP molecules bind without Mg2+ 







Figure 4.3: ATP titrations against Tc, Tb and LiPFKs. 
2-fold serial dilution of 5 mM – 2.4 µM ATP against 4µg/ml PFK and 10 mM F6P. Highest two 
dilutions have been omitted for clarity of fit. Experiments carried out at 25 oC in triplicate, error 




4.2.3 Trypanosomatid PFKs show cooperativity in F6P binding. 
F6P titrations against all three trypanosomatid PFK enzymes gave Hill coefficient (h) values of 
>1, as shown in table 4.1. Furthermore, the plots fitted non-hyperbolic, sigmoidal curve better 
than a traditional Michaelis-Menten curve fit, and a noticeable sigmoidal tail can be observed at 
the lower concentrations of F6P for all three enzymes (figure 4.4) This sigmoidal binding 
response and Hill coefficient values of h >1 suggest co-operative binding; That the binding of 
one F6P molecule to one subunit within the PFK tetramer induces a change in a neighbouring 








Figure 4.4: F6P titrations against Tc, Tb and LiPFKs. 
2-fold serial dilution of 20 mM – 9.8 µM F6P against 4µg/ml PFK and 1.5 mM ATP. Highest two 
dilutions have been omitted for clarity of fit for T. brucei and T. cruzi plots. Experiments carried 
out in triplicate at 25oC, error bars denote standard deviation. ‘AM’ = allosteric sigmoidal fit. 




4.2.4 Reaction order matters when measuring PFK kinetics. 
 
A series of F6P and ATP titrations were carried out against PFK in the PYK/LDH assay with 
different  reaction orders; 
 ‘PFK/ATP + F6P’: ATP is incubated with the PFK protein for 15 minutes (RT). Reaction is 
started by adding F6P. 
 ‘PFK + F6P/ATP’ : A premade mixture of F6P and ATP is added to the PFK to start the 
reaction (no PFK pre-incubation). 
 ‘PFK/F6P + ATP’ : F6P is incubated with the PFK protein for 15 minutes. Reaction is 
started by adding ATP. 
The dose-response plots for F6P titrations against T. brucei PFK using these different reaction 
order combinations is shown in figure 4.5.  
 
 P/ATP + F6Ptit P + F6Ptit/ATP P/F6Ptit + ATP 
Vmax (µmol-1.min-1.mg-1) 48 ± 0.8 50 ± 0.9 50 ± 1.3 
KhalfF6P (µM) 596 ± 19 736 ± 37 1220 ± 97 
Hill coefficient (h) 1.7 ± 0.1 1.4 ± 0.1 1.2 ± 0.1 
 
Figure 4.5: Reaction order effects the measured kinetics of T. brucei PFK with regards to F6P. 
Allosteric sigmoidal plots of F6P titrations. All experiments carried out at 25oC in triplicate, error 
bars denote standard deviation. F6P concentrations ranged from 15 mM to 117 µM. ‘tit’ = 
titration. Assay buffer contained Mg2+ (10 mM MgCl2, 100 mM KCl, 50 mM TEA, 10% glycerol, 
0.005% TWEEN, pH 7.4). 
TbPFK F6P titration - reaction order effect





























From the plots in figure 4.5 it is evident that when incubated with F6P only, the TbPFK has a 
lower overall measured affinity for F6P (KhalfF6P = 1.2 mM). The strongest affinity for F6P is 
observed when the enzyme is pre-incubated with ATP (KhalfF6P = 0.6 mM). The overall velocity of 
the enzyme is unaffected by the reaction order, remaining at ~50 µmol-1.min-1.mg-1 for each 
condition.  
The effect shown may therefore be observed due to the proportion of the PFK population that 
is in an ATP bound state when the reaction is started; Comparison of apo enzyme and ATP-bound 
crystal structures of T. brucei PFK reveal that upon ATP binding, a conformational change opens 
up the active site to more readily accommodate F6P (McNae & Martinez-Oyanedel, 
2009)(Section 1.4.4, figure 1.14). Pre-incubation with ATP is likely to force the enzyme 
population into an active state that has greater affinity for F6P. Conversely, incubation with F6P 
may allow weak binding of F6P initially, perhaps forcing the enzyme into a conformation with 
lower affinity for the substrate. However, reaction order had little effect on ATP affinities (data 
not shown), suggesting either; 
 F6P cannot bind without ATP  
 F6P binds weakly to PFK in the absence of ATP. Weak binding is then overcome by high 
concentrations and greater affinity for ATP when added. 
Cooperativity in F6P binding, measured through the Hill Coefficient (h) for each plot was 
strongest also when ATP was pre-incubated with PFK. The conformational state of TbPFK with 




4.3. Alternative substrates used by trypanosomatid PFKs. 
Phosphofructokinases can be grouped into one of two families; PPi-dependant PFKs and ATP-
dependant PFKs. The three trypanosomatid PFKs described in this chapter are ATP-dependant 
PFKs, but have a PPi-dependant ancestral lineage. To examine if alternative phospho donors 
could be used, guanosine triphosphate (GTP) and pyrophosphate (PPi) were titrated against PFK 
with a set concentration of F6P (10 mM final). Again, all PFK enzymes were tested at 
concentrations of 4 µg/ml.  
4.3.1 Trypanosomatid PFKs can no longer use PPi as a phospho donor. 
PPi titrations against T. brucei, T. cruzi and L. infantum PFKs with a set concentration of F6P 
tested in the Aldolase/TIM linked enzyme assay (described in section 2.3.2) yielded no 
observable activity (data not shown). PPi titrations against PFK could not be tested in the 
orthogonal PYK/LDH assay as this assay relies on the creation of ADP for the downstream 
enzymes to work (see section 2.3.1, chapter 2). No PPi binding was observed against any of the 
enzyme surfaces tested in SPR, up to a final concentration of 10 mM.  
4.3.2 GTP is an alternative phospho donor for trypanosomatid PFKs. 
GTP titrations against PFK and a set concentration of F6P showed hyperbolic responses (h  = 1.2 
± 0.1) in the PYK/LDH assay, suggesting GTP could be bound and turned over by the PFK enzyme 
in place of ATP. Furthermore, it was found that AMP had the same activating effect on the 
enzyme in relation to GTP as it does when used in ATP titrations - reducing the Vmax but 
significantly increasing the affinity of PFK for the nucleotide phospho donor (discussed in section 













TbPFK GTP titration - AMP effect.
















TbPFK + 0.5 mM AMP
Vmax = 44.5  1 M-1 min-1 mg-1
Vmax (+AMP) = 27   1M-1 min-1 mg-1
KmGTP = 176  23 M
KmGTP (+AMP) = 95  14 M
h = 1.3  0.1







Figure 4.6: AMP increases GTP affinity in T. brucei PFK. 
A) GTP titration against T. brucei PFK with and without 0.5 mM AMP. All experiments carried out 
at 25oC in triplicate, error bars denote standard deviation. TbPFK tested at 4 µg/ml final 
concentration. B) Structures of ATP and GTP. 
 
 ATP and GTP differ only by an amino group on the C6 position of ATP being replaced by a 
carbonyl group in GTP (figure 4.6B). Clearly this does not perturb important interactions with 
the molecule completely, but moderately reduces affinities for GTP when compared to ATP; 
Kinetic parameters for ATP and GTP binding for the trypanosomatid PFKs are compared in table 
4.2. 
  


















T. brucei (ATP) 44.5 ± 1.4 50.4 ± 1.8 41 ± 1 0.81 1.3 ± 0.1 
T. brucei (GTP) 38.8 ± 0.8 176 ± 23 36 ± 1 0.20 1.4 ± 0.1 
T. cruzi (ATP) 68.4 ± 1.0 94.6 ± 4.9 64 ± 1 0.68 1.2 ± 0.1 
T. cruzi (GTP) 62.9 ± 1.8 194.8 ± 14.2 59 ± 2 0.30 1.4 ± 0.1 
L. infantum (ATP) 7.9 ± 0.1 93.2 ± 5.7 8 ± 1 0.09 1.3 ± 0.1 
L. infantum (GTP) 9.9 ± 0.8 331 ± 47.5 10 ± 1 0.03 1.3 ± 0.1 
 
Table 4.2: GTP can be used by trypanosomatid PFKs, but is bound with a lesser affinity than ATP. 
All experiments carried out at 25oC in triplicate, standard deviation is given. All PFKs tested at a 
final concentration of 4 µg/ml. 
As seen by the kcat/km values, each trypanosomatid enzyme has greater efficiency (higher kcat/km) 
when using ATP over GTP, showing that it is the preferred phospho donor. Despite the increased 
affinity for ATP, Michaels constants (km) for ATP and GTP are comparable. This suggests that the 







4.4. Substrate affinity measurements using SPR. 
 SPR assays measure the change in the angle of a wave of excited electrons known as a surface 
plasmon resonance (SPR) as polarised light is focused and refracted off a gold surface onto which 
a population of protein has been immobilised. The SPR wave is sensitive to the amount of 
material on the gold surface – the refractive index. The binding of an analyte to this protein 
surface causes a change in the refractive index due to the build-up of material, and this changes 
the angle of the plasmon resonance. This change in angle is recorded in real time as resonance 
units (RU) on a ‘sensorgram’ (Wear, Blackburn, & Nowicki, 2009). Figure 4.7 shows an example 
sensorgram. As binding response is measured in real time, steady state kinetics, on and off rates 
can be determined. Association (kon) and dissociation (koff) rate constants can be measured from 
these sensorgram traces in real time, as well as steady state equilibrium constants (Kd). Please 
see section 2.5.3 for a detailed explanation of SPR, and the experimental procedures for the 
results shown in this section. All SPR experiments were carried out on a GE Healthcare Biacore™ 
T200 instrument. 
 
Figure 4.7: example SPR sensorgram. 
1) Association phase: analyte is washed over the immobilised ligand surface. Rate of 
association for the ligand-analyte complex is measured (kon) as mass binds to the surface. 
2) Steady state phase: analyte is still washed over surface but the formation of 
[Ligand][Analyte] complex is now at equilibrium; rates of complex formation and 
complex dissociation are balanced and Equilibrium dissociation constants can be 
calculated (Kd). 
Steady state response 





3) Dissociation phase: buffer without analyte is washed over surface. Analyte is removed 
from the system and the association phase of the reaction is essentially eliminated. 
Dissociation rate constants (koff) can now be measured. 
 
4.4.1 SPR surface preparation for testing trypanosomatid PFK substrate binding 
A detailed protocol for surface preparation is given in section 2.5.3.1. 20 nM stocks of N-
terminally His6-tagged T. brucei, T. cruzi and L. infantum PFKs were used to create low density 
surfaces of ~3000 RU using a modified amine capture method (Wear & Walkinshaw, 2006 and 
Wear et al., 2017). A Ni2+-nitrilotriacetic acid (NTA) chip consisting of 4 flow cells was used – flow 
cell 1 (‘Fc1’) which contained no bound ligand and acted as a reference, ‘Fc2’ had a His6-TcPFK 
surface, ‘Fc3’ His6-TbPFK and ‘Fc4’ His6-LiPFK. Surface activity was tested using a 1 mM ATP 




∗ 𝑅𝑈 𝑜𝑓 𝑖𝑚𝑚𝑜𝑏𝑖𝑙𝑖𝑠𝑒𝑑 𝑙𝑖𝑔𝑎𝑛𝑑 ∗ 𝑛 
Where n = stoichiometry of interaction. 
Assuming the interaction to have a stoichiometry of 1 and using the 1mM ATP control, the T. 
brucei and T. cruzi PFK surfaces both had similar maximum responses (RUmax) of ~28 RU. Ligand 
interactions giving a response above the RUmax of the surface suggest multivalent binding. The 
L. infantum surface had a lower RUmax of ~8 RU. The use of the Ni2+ NTA chip allowed orientation 
of the PFK enzymes away from the sensor surface, via the N-terminal His6 tags (Wear et al., 
2017).  
4.4.2 Substrates and other analytes tested against trypanosomatid PFKs in SPR. 
A range of substrates, known and unknown PFK effectors and other metabolites were tested for 
binding responses against all three trypanosomatid PFK surfaces. 2.5-fold serial dilutions of 
analytes were made up in running buffer (10mM HEPES, 150 mM NaCl, 10 mM MgCl2, 0.05 % 
P20, pH 7.4). All analytes to be tested were made up in this buffer and stocks were buffered to 
pH 7.4 before use. Each concentration of analyte was run over each of the flow cells in parallel 
at a constant rate of 30 µl.min-1. Analytes had 30 seconds contact time with the surface before 
being washed off with running buffer for 30 seconds. Steady state affinities (Kd) were calculated 
by plotting the equilibrium response value (RU) at the equilibrium phase of each sensorgram 
trace against concentration of analyte. This is measured as the average response over a 4 second 




dissociation rates of each analyte a ‘1:1 binding’ model was fitted to each sensorgram trace 
using the dedicated Biacore T200 evaluation software. Analyte binding responses are 
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       
Specific 
binding? 
       
   Metabolites /  other    
 GTP GDP Citrate Citrate 
+ ATP 
PPi PEP F26BP 
Binding 
response? 
       
Specific 
binding? 
       
 
Table 4.3: SPR binding responses of analytes tested against T. brucei, T. cruzi and L. infantum PFKs. 
Analytes are designated according to whether they firstly showed a binding response on the 
protein surface then if that response could be read and plotted as being specific binding* to the 
PFK enzyme. Analyte concentration ranges tested were : AMPǂ, ADP, ATPǂ, GTP, GDP, F6P, F16BP, 
F26BP – 10 mM – 7.8 µM. Citrate, PPi, Phosphoenolpyruvate (PEP) – 20 mM – 156 µM. ǂ1 mM 
when tested alongside another analyte. 
* ‘Specific binding’ was considered to be a response approaching saturation close to the 
theoretical maximum response (RUmax) of the PFK surface (RUmax TbPFK and TcPFK = ~28 RU, 





4.4.3 Trypanosomatid PFKs bind ATP with strong affinity. 
MgATP bound specifically to all three trypanosomatid PFK surfaces, and with comparable 
affinities for the three enzymes. Figure 4.8 shows the sensorgram and steady state kinetic plots 
for ATP titrations against the three PFKs. Table 4.4 below shows the calculated kinetic 
parameters from steady state measurements and from the 1:1 fit kinetic model applied to the 
sensorgrams shown in figure 4.8.  
    ATP     
  Steady state   Kinetic   




Chi2  kon (1/Ms) koff (1/s) Kd (µM) Chi2 
T. brucei 15.8 ± 
2.3 







T. cruzi 35.4 ± 
5.6 



















Table 4.4: ATP binds with high affinity and with comparable levels between PFKs in SPR. 
All values calculated from plots shown in figure 4.7. Chi2 values are for goodness of fit of curve 
(in steady state plots) and fit of 1:1 model (in sensorgrams). Chi2 < 2.0 is considered a good fit. 
Standard errors are given for each parameter. 
 
Measured steady state affinities for ATP were strong for all three trypanosomatid PFKs, and 
values were within the same order of magnitude to the KmATP measurements for all three PFKs 
(table 4.1, section 4.2.1). Affinities measured from the kinetic plots (Kd = kon/koff) were mostly in 
agreement with steady state measurements for T. brucei and T. cruzi PFK, but not for L. infantum 
PFK;  large injection spikes were removed from the start and end of LiPFKs sensorgram traces 
(data not shown). These spikes masked the true association phase response for LiPFK and meant 
the 1:1 binding model fitted poorly. As can be seen in figure 4.8, the kon rates fitted by the 1:1 
model are inaccurate and much too fast – resulting in a high Kd value for ATP against LiPFK. These 
injection spikes may have resulted from slight buffer mismatch between the running buffer and 
ATP titrations. The same batch of buffer was used as running buffer and to make up the ATP 






Dissociation rate (koff) values gained from the 1:1 binding fit on the sensorgrams however are 
more reliable when looking at the fit of the 1:1 binding model with the recorded sensorgram 
traces and give a good indication of the time of dissociation for ATP for each of the surfaces – 
ranging from 0.31 s-1 for T. brucei PFK to 1.78 s-1 for T. cruzi PFK. The measured affinities for ATP 
calculated by steady state measurements are marginally lower, but comparable with those 
values found using the PYK/LDH enzyme linked assay (section 4.2.1, table 4.1). Considering the 
homology in ATP binding residues between the three enzymes, the steady state measurements 
are more feasible – it is expected that each enzymes affinity for ATP would be in the same order 
of magnitude. 























Figure 4.8: SPR sensorgrams show tight, specific binding of ATP against trypanosomatid PFKs. 





















   
 
 
Figure 4.8: SPR sensorgrams show tight, specific binding of ATP against trypanosomatid PFKs. 




4.4.4 F6P cannot bind to PFK in isolation in SPR. 
No binding response was observed against any of the trypanosomatid PFK surfaces with regards 
to F6P, up to a top concentration of 10 mM (data not shown). From crystal structures of T. brucei 
PFK it is known that ATP binding induces a conformation change to open up the active site and 
accommodate F6P more readily. To test for F6P binding in the presence of MgATP, ATP was 
added to the running buffer (10mM HEPES, 150 mM NaCl, 10 mM MgCl2, 0.05 % P20, pH 7.4) at 
a concentration of 1mM. F6P series dilutions were made in the same 1mM ATP running buffer 
and tested against all three PFK surfaces. Under these conditions a F6P binding response was 
observed for all 3 enzymes, however it did not reach saturation at the highest concentrations 
(up to 10 mM) (figure 4.9). 
 
Figure 4.9: In F6P shows weak binding in the presence of ATP, but does not reach saturation. 
F6P titration against TbPFK surface (3,000 RU) using SPR at 25oC. RUmax of TbPFK surface with 
ATP control = 26 RU. RUmax F6P = 19.5 RU. 
As can be seen in figure 4.9, at concentrations of F6P approaching 10mM, the response does 
not appear to reach saturation, and the Rmax (5.8 RU) remains ~4X lower than the maximum 
binding response for the T. brucei surface (~19.5 RU). F6P is therefore binding very weakly or 
promiscuously to the protein even in the presence of ATP. It is also possible that the enzyme is 
turning over F6P in the presence of ATP. Tethering of PFK to a surface may also be interfering 
with the dynamic changes that are required for F6P to be accommodated in the active site. The 
presence of ATP however must have induced a change in the enzyme to allow at least weak 




no response was observed. This SPR data adds evidence to the hypothesis that ATP must be 





4.5. Molecular regulation of trypanosomatid PFKs. 
Table 4.5 shows the range of known effectors of bacterial, trypanosomatid, mammalian and 
other eukaryotic PFKs. The aim of this section of work was to measure and describe the kinetics 
of known effectors of trypanosomatid and mammalian PFKs, to further understand the reaction 
mechanism and regulation of the trypanosomatid PFK enzymes in vitro. 
 Bacteria Yeasts Trypanosomatids Mammals Protists Plants 

























































Table 4.5 : Known effectors of bacterial and eukaryotic PFKs. 
Known effectors of various bacterial and eukaryotic PFK enzymes. Information summarised 





4.5.1 AMP is the only known effector of trypanosomatid PFK. 
The putative AMP binding site in the T. brucei PFK structure is located in a pocket under the base 
of the C-terminal reaching arms, as seen in figure 4.10 below.  
 
Figure 4.10: The putative Amp binding site in T. brucei PFK is located under the C-terminal ‘reaching 
arms’. 
Figure made using ATP-bound TbPFK structure (PDB code 3F5M) (McNae & Martinez-Oyanedel, 
2009). 
  
AMP is a known allosteric effector of trypanosomatid PFK: from the ATP-bound structure solved 
by McNae et al (figure 4.10), it has been shown that upon ATP binding, order is brought to the 
C-terminal reaching arms, and a pocket with a lid forms the putative AMP binding site (McNae 
& Martinez-Oyanedel, 2009). An unpublished structure of T. brucei PFK with AMP bound 
(Montserrat Valdiviesso, UoE) shows the C-terminal reaching arms forming a lid over the AMP 
binding site with AMP bound. It is suggested that these C-terminal reaching arms communicate 
AMP binding across the PFK tetramer, as they form intra-dimer links between adjacent subunits. 





4.5.2 AMP stimulates trypanosomatid PFK activity. 
The effect of AMP on the substrate kinetics for the three trypanosomatid PFKs was tested using 
the PYK/LDH linked enzyme assay (see section 2.3.1.4 for full details). AMP was incubated with 
each PFK enzyme in the presence of either a set concentration or series dilution of ATP for 10 
minutes at room temperature. The reaction was started by adding either a series dilution or set 
concentration of F6P. AMP was used at a final concentration of 0.5 mM. This AMP concentration 
had no significant effect on the activity of the downstream enzymes (PYK and LDH) in the assay 








Figure 4.11: AMP strongly increases affinity for both ATP and F6P in T. brucei PFK. 
Experiments carried out at 25oC in triplicate, error bars denote standard deviation. Measured 
using PYK/LDH linked assay. ATP titrations have Michaelis-Menten curve fit, F6P plots have 
allosteric sigmoidal curve fitted using GraphPad Prism ver. 6. All PFKs tested at 4 µg/ml final 
concentration. ATP titration = 5 mM – 2.5 µM, top 2 concentrations omitted for clarity. F6P 







Kinetic parameters in the presence and absence of AMP for each of the trypanosomatid enzymes 
are given in table 4.6. 
AMP significantly increases the affinity of the trypanosomatid PFKs for both ATP and F6P. AMP 
also removes the observed cooperativity in F6P binding – reducing the Hill coefficient from h = 
2.1 to h = 1.1 for T. brucei PFK. This observed effect on cooperativity must result from one of 
two possibilities; 
a) AMP induces a change in the enzyme structure such that previous cooperativity in F6P 
binding is now not possible. For example from a re-ordering of the C-terminal reaching 
arms that may communicate change between adjacent subunits. 
b) Co-operative binding in the presence of AMP is beyond the resolution of the PYK/LDH 
assay. As the Khalf for F6P becomes significantly lower in the presence of AMP, the dose-
response curve becomes tighter. As cooperativity is most visible at the lower 
concentrations of substrate, the plots generated from the data may not have the 
resolution show any co-operative behaviour. 
 
A structure with both ATP and AMP bound may help answer this question. No significant 
structural changes to the C-terminal helices are observed in the unpublished AMP-TbPFK 
structure by M. Valdiviesso, UoE. 
0.5 mM AMP also results in a lowering of the Vmax by ~20 % with both ATP and F6P titrations. 
Despite this, the efficiency of the enzyme is increased in the presence of AMP due to increased 
affinity for substrate; In T. brucei for example the Kcat/Km increases from 0.07 to 0.21 µM-1.s-1 


























TbPFK 803 ± 48 2.1 ± 0.2 90.7 ± 6 1.2 ± 0.2 0.07 0.60 
+ AMP 182 ± 20 1.1 ± 0.1 9.7 ± 1 0.8 ± 0.1 0.21 3.90 
TcPFK 469 ± 26 1.9 ± 0.2 79 ± 6 1.1 ± 0.1 0.11 0.67 
+ AMP 58 ± 14 0.9 ± 0.1 12 ± 2 0.9 ± 0.2 0.68 3.30 
LiPFK 2391 ± 99 2.2 ± 0.1 99 ± 2 1.1 ± 0.3 0.01 0.24 
+ AMP 134 ± 48 0.9 ± 0.1 74 ± 3 0.7 ± 0.2 0.15 0.28 
 
Table 4.6: AMP improves the catalytic efficiency of the three trypanosomatid PFKs. 
Data measured using PYK/LDH linked enzyme assay. All experiments carried out in triplicate, 
standard deviation of each kinetic parameter is given.  
 
For each of the T. brucei, T. cruzi and L. infantum enzymes, AMP increases the affinity for 
substrates (KmATP or KhalfF6P) while also decreasing the maximum velocity of the enzyme 
(Vmax). For all three enzymes this results in an increase in catalytic efficiency ( Kcat/Km) and 
we can say that AMP is an activator of the PFK enzyme. This is divergent from the traditional 
description of allosteric activation where the affinity for substrates is increased, without an 
effect on the Vmax of the enzyme.  
It may be possible that AMP induces an enzyme state where the overall velocity of substrate 
turnover is lower, but increased interactions allow for much greater affinity for substrate 
binding, allowing rapid binding of relatively low concentrations of substrate. A further possibility 
is that AMP is competing with ATP in the active site, and this is resulting in a slower overall 
velocity of the enzyme. Indeed, previous studies on T. brucei PFK have shown that 0.25 – 0.75 
mM AMP demonstrates uncompetitive inhibition with ATP (Claustre et al., 2002)  
L. infantum had the greatest response to AMP activation – with a 15-fold increase in the catalytic 
efficiency for F6P in the presence of AMP. Interestingly, this activating effect from AMP places 




4.5.3 Reaction order dictates if AMPs activating effect on TbPFK is observed. 
As described in section 4.2.4, the order that components are added has an effect on the 
observed kinetics for PFK when tested in the PYK/LDH assay. Combinations of reaction 
incubations were carried out again, to test the effect this had on AMP eliciting its activating 
effect on the enzyme; 
 PFK/AMP + ATP + F6P : PFK incubated with AMP for 15 minutes. ATP added. Reaction 
started with F6P. 
 PFK/ATP + AMP + F6P : PFK incubated with ATP  for 15 minutes. AMP added. Reaction 
started with F6P. 
 PFK/F6P + AMP + ATP: PFK incubated with F6P  for 15 minutes. AMP added. Reaction 
started with ATP. 
Figure 4.12 shows the effect of differing reaction orders on AMP-induced activation of TbPFK 






Hill coefficient  
(h) 
P/AMP + ATP + F6P 394 ± 19 29.1 ± 0.5  2.2 ± 0.2 
P/ATP + AMP + F6P 178 ± 17 27.1 ± 0.7 1.1 ± 0.1 
P/F6P + AMP + ATP 369 ± 19 29.2 ± 0.6 2.5 ± 0.3 
Figure 4.12: TbPFK activation by AMP is only observed when pre-incubated with ATP. 
F6P titration (5 mM – 78 µM) against His6-TbPFK in LDH/PYK assay. P = PFK protein. ‘/’ represents 
incubation at room temperature for 15 minutes. AMP was used at a final concentration of 0.5 





The effects of AMP on stimulating activity was seen only when PFK was pre-incubated with ATP, 
suggesting again that ATP must be bound first for AMP to bind or elicit its effect on the enzyme. 
Again, we see that when AMP does elicit an effect on the PFK enzyme, it removes any observed 





4.5.4 AMP binds with varying affinity to Trypanosomatid PFKs 
Titrations of AMP were carried out against all three trypanosomatid PFK surfaces in SPR assays, 
and against TbPFK and TcPFK in thermal denaturation assays (TDA). The steady state affinity 
plots from SPR measurements (ss Kd) for AMP titrations against the three trypanosomatid 





















Kd = 1.04  0.3mM
Rmax = 31  1.4
Kd (+ATP) = 1.69  0.1 mM
Rmax = 29  0.6
TcPFK
TcPFK + 1mM ATP
 
 
Figure 4.13: AMP affinity measurements against TbPFK, TcPFK and LiPFK at steady state – SPR. 




AMP titration = 10 mM – 0.4 µM. All experiments carried out at 25 oC in running buffer (10mM 
HEPES, 150 mM NaCl, 10 mM MgCl2, 0.05 % P20, pH 7.4). Tested against low density (~1,400 – 
3,200 RU) surfaces. Rmax TbPFK and TcPFK = ~28 RU, LiPFK = 8 RU.  
AMP bound to T. brucei PFK with a relatively tight affinity (KdAMP = 470 µM) measured by steady 
state kinetics in SPR. T. cruzi and L. infantum PFK however had weaker measured steady state 
affinities of > 1 mM (figure 4.13). In the presence of ATP, affinities for AMP were weaker for 
TbPFK and LiPFK with ss KdAMP values of 1.9 and 12 mM respectively in the presence of 1 mM 
ATP. Interestingly, TcPFK was only moderately effected by ATP, its SS KdAMP increasing from 1 to 
1.7 mM in the presence of ATP. 
AMP titrations were also carried out against TbPFK and TcPFK using TDA. AMP was titrated 
against PFK samples with and without a saturating (0.75 mM) concentration of ATP –  protocol 
can be seen in section 2.5.2.3. Melting curves for an AMP titration against TcPFK with and 
without ATP are shown in figure 4.14. To determine the KdAMP, thermal melt temperatures were 
plotted against concentration of AMP and a curve was fitted using the Langmuir isotherm 





Where c = Tm of PFK sample alone.  
 
Figure 4.15: AMP titration against T. cruzi PFK carried out using TDA. 
TcPFK conc = 2 µM. Temperature range 25 -79 ᵒC. Experiments carried out in triplicate, error bars 




Table 4.9 summarises the calculated Kd values for AMP binding with T. brucei and T. cruzi PFKs 
in the presence and absence of ATP, as measured in SPR and TDA. L. infantum PFK was not tested 
in TDA. 
 
 TbPFK TbPFK  
+ ATP* 
TcPFK TcPFK  
+ ATP* 




























Table 4.9: AMP affinity for T. brucei and T. cruzi PFKs. 
* 1 mM ATP in SPR, 0.5 mM AMP in TDA.   
Equilibrium constants for AMP (KdAMP) are comparable when measured using SPR or TDA. In all 




















Figure 4.14: AMP titrated against TcPFK in TDA – thermal melt peaks. 
AMP concentration from left to right: 0 , 0.078, 0.156, 0.312, 0.625, 1.25, 2.5, 5, 10 and 20 mM. 
T. cruzi PFK  
+ 0 – 20mM AMP  
(left to right) 
T. cruzi PFK + 0.5mM ATP  
  + 0 – 20mM AMP  




4.5.5 AMP did not show activation of trypanosomatid PFKs in SPR experiments. 
To test the effect of AMP on analyte binding to immobilised PFK surfaces in SPR, AMP was added 
to the SPR running buffer (10mM HEPES, 150 mM NaCl, 10 mM MgCl2, 0.05 % P20, 1 mM AMP 
pH 7.4). Titrations of analytes were made and conducted in the same 1 mM AMP running buffer. 
AMP did not significantly affect the binding affinity of either ATP or F6P with any of the 
trypanosomatid PFK surfaces in SPR. Any increase or decrease in Kd was within the margin of 
error for the experimental values (average standard error in Kd = ± 0.1 mM) (data not shown). 
Tethering of the enzyme to the SPR chip surface may have hindered either the binding of AMP 
or a conformational change responsible for carrying out the increase in affinity for ATP or F6P in 
the presence of AMP. 
According to the SPR and TDA data shown in table 4.9, there is an interesting range in the binding 
affinities for AMP between the three enzymes (KdAMP = 0.47 – 2.3 mM). The effect of AMP on 
enzyme activity when measured in the PYK/LDH assay (section 4.5.2) was similar between T. 
brucei and T. cruzi at the same concentration of AMP (0.5 mM). This SPR data however suggests 
that a greater concentration of AMP is required to test the effect, if the SPR affinities shown 
here are representative of binding to each enzyme. However, no additional activating effect was 
observed when AMP concentrations >0.5 mM were tested against T. brucei or T. cruzi PFK (data 





4.5.6 ADP weakly inhibits trypanosomatid PFK activity. 
ADP is a known activator of bacterial, mammalian and yeast PFKs (see table 4.5). The effect of 
ADP on the trypanosomatid PFKs was tested. Firstly, ADP affinity measurements were made 
against T. brucei, T. cruzi and L. infantum PFK surfaces using SPR, as described in section 4.4. 
Figure 4.15 shows the steady state measurements for ADP titrations against the three 
trypanosomatid PFK surfaces.  
ADP bound with reasonably tight affinity to the T. brucei and T. cruzi PFK surfaces. Interestingly, 
L. infantum PFK had the strongest affinity for ADP (KdADP = 0.16 mM). When 1 mM AMP was 
added to the running buffer, no significant change in the affinity for ADP was observed (data not 
shown). In the presence of ATP, the affinity (ss Kd) dropped 3-5 – fold for each of the 
trypanosomatid enzymes (data not shown). This is likely due to competition in the active site 
and suggests ADP does not bind in an allosteric site, but instead in the ATP binding site. 
To test the effect of ADP on the enzyme activity, the TIM/Aldolase assay was used. A 2-fold 
dilution series of ADP (40 mM – 0.32 µM) was added to 4 µg/ml TbPFK in the presence of 
saturating ATP (2 mM) and F6P (10 mM). TbPFK was incubated with ATP at room temperature 
prior to the addition of the ADP titration. Reaction was started by addition of F6P. ADP weakly 
inhibited the TbPFK activity with an IC50ADP of 7.3 mM (figure 4.16). ADP did not have an 
inhibitory effect on the downstream enzymes (aldolase, TIM or G3PDH) (data not shown).  
To test if this inhibition was a competitive effect against ATP or F6P binding, or indeed an 
allosteric inhibition through binding of ADP elsewhere, set concentrations of ADP were added 















KD = 0.732  0.1 mM
Rmax = 27  1.6
 
 
Figure 4.15 : ADP affinity measurements against TbPFK, TcPFK and LiPFK at steady state – SPR. 
ADP titration = 3.2 mM – 0.8 µM. All experiments carried out at 25 oC in running buffer (10mM 
HEPES, 150 mM NaCl, 10 mM MgCl2, 0.05 % P20, pH 7.4). Tested against low density (~1,500 RU) 

























Figure 4.16 : ADP is a weak inhibitor of TbPFK activity. 
A) ADP titration (40 mM – 0.32 µM) against TbPFK measured in the aldolase/TIM assay. 4 µg/ml 
PFK, 2 mM ATP and 10 mM F6P provided. Carried out in triplicate at 25 oC, error bars denote 
standard deviation. 
4.5.7 GMP is an alternative activator of trypanosomatid PFK. 
Guanosine monophosphate (GMP) had the same activating effect on substrates as AMP on the 
trypanosomatid PFKs – decreasing the Vmax but increasing the affinity for F6P (KhalfF6P)(figure 
4.17). This results in a significantly increased enzyme efficiency – with kcat/Km values for T. brucei 
PFK increasing from 0.07 to 0.1 µM-1.s-1 in the presence of 0.5 mM GMP. 
 
TbPFK vs ADP titration. 
4 µg/ml PFK, 2 mM ATP, 10 mM F6P 
IC50ADP = 7.33 
mM 
R2 = 0.99 
M1 = 0.1 % 




TbPFK F6P titration - GMP effect
























Vmax = 58  3 M-1 min-1 mg-1
Vmax (+GMP) = 40  1 M-1 min-1 mg-1
KhalfF6P = 802  69 M
KhalfF6P (+GMP) = 353  16 M
h = 2.1  0.3







Figure 4.17: GMP is also an activator of T. brucei PFK. 
All experiments carried out using the PYK/LDH assay at 25oC in triplicate, error bars denote 
standard deviation. 5 mM – 9.8 µM F6P titration, 0.5 mM GMP. PFK pre-incubated with 1.5 mM 
ATP. Tested against 4 µg/ml TbPFK. 
 
Similar to AMP, GMP must be added after the PFK enzyme has been incubated with ATP for the 
activating effect to be observed. These findings reveal that both GMP and AMP must be 
accommodated in the same allosteric AMP binding site in T. brucei PFK. Unfortunately GMP was 
not tested in SPR so no comparison in binding affinity for the analyte can be made.  Table 4.7 
shows the effect of GMP on substrate binding by PFK in the PYK/LHD linked assay. GMP was not 















T. brucei 802 ± 69 58 ± 3 2.1 ± 0.3 0.07 
+ GMP 353 ± 16 40 ± 1 1.4 ± 0.1 0.10 
T. cruzi 498 ± 35 62 ± 2 2.2 ± 0.1 0.09 
+ GMP 163 ± 17 53 ± 2 1.2 ± 0.2 0.12 
 
Table 4.7: GMP is an activator of T. brucei and T. cruzi PFKs. 
Experiments carried out at 25oC in triplicate, standard deviations are given. 
 
4.5.8 Mammalian PFK activators and other metabolites did not affect 
trypanosomatid PFK activity. 
To date, only AMP has been described as an effector of trypanosomatid PFKs. A range of 
mammalian effectors and metabolic intermediates were tested at a single concentration against 
the trypanosomatid PFKs using either the LDH/PYK or TIM/Aldolase assays using the standard 
assay buffer (50 mM TEA, 100 mM KCl, 10 mM MgCl2, 10% glycerol, pH 7.2). To test for an effect 
on the enzyme, the assays were carried out with substrate (F6P and ATP) concentrations 
between the KmATP/KhalfF6P  and saturating concentrations – i.e. concentrations used were ~K0.75. 
For TbPFK and TcPFK this equated to a concentration of 600 µM F6P, 300 µM ATP and for LiPFK 
700 µM F6P, 170 µM ATP (see section 4.2.1, table 4.1 for Km/Khalf values). Data was normalised 
by taking the ratio of enzyme activity with effector against without effector (control) for each 
enzyme. A value of 1.0 therefore represents no change in ‘normal’ activity for each enzyme. This 
work was carried out in collaboration with Dr P. Fernandes (UoE).  None of the tested 
metabolites had a significant effect on T. brucei, T. cruzi and L. infantum PFKs (Figure 4.18). Both 
ADP and G6P showed a slight drop in activity for LiPFK, however this is likely due to competition 







Figure 4.18: Metabolic intermediates had no effect on trypanosomatid PFK activity. 
Data measured using the PYKlLDH and Aldolase/TIM assays. All experiments carried out at 25oC 




4.5.9 AMP reduces potency of CTCB compounds. 
A range of inhibitor compounds were tested against TbPFK with and without 0.5 mM (final) AMP. 
In the presence of AMP the IC50 values were higher for most compounds (a range of compounds 
is shown in table 4.8), suggesting weaker interaction and/or an altered mechanism of inhibition 
between the compound and TbPFK. 
As discussed in section 4.5.1, AMP induces a 2nd enzymatic state following ATP binding, likely a 
conformational change in the active site to increase affinity for F6P. The putative AMP binding 
site is located ~40Å from the active site and CTCB binding pocket so direct competition with the 
compound is unlikely. We also discuss later Chapter 6 how CTCB inhibitor compounds are not 
competitive with either ATP or F6P. The conformational change upon AMP binding must 
therefore alter either interactions with the CTCB compound or the inhibitory mechanism outside 





 TbPFK IC50 (µM) TbPFK IC50 (µM) + 0.5 mM AMP 
 
CTCB 002 
3.11 ± 0.41 4.45 ± 0.98 
 
CTCB 012 
0.98 ± 0.2 1.14 ± 0.30 
 
CTCB 097 
1.97 ± 0.56 3.90 ± 0.70 
 
CTCB 123 
0.08 ± 0.06 0.10 ± 0.02 
 
CTCB 360 
0.11 ± 0.08 0.11 ± 0.02 
 
CTCB 405 
0.17 ± 0.08 0.21 ± 0.05 
 
CTCB 370 
0.63 ± 0.2  3.82 ± 0.3 
 
CTCB 470 
0.30 ± 0.1 1.29 ± 0.2 
 
CTCB 540 
0.32 ± 0.1 1.71 ± 0.2 
Table 4.8 : CTCB compounds are less potent in the presence of AMP. 




























































Trypanosomatid enzyme activity. 
Affinities for ATP and F6P match well with published data for T. brucei and T. cruzi PFKs from 
recombinantly expressed PFK preparations (table 4.9). 
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T. cruzi This study Recombinant. E.coli 
expression. 















7200 25 2800 
Leishmania 
spp. 
This study Recombinant. E.coli 
expression. 









ND ND 3600  
/ 0.157 
 (Berens, R. 
Marr, 1977) (L. 
donovani) 
Parasite. 
Part purified lysate. 
0.29 / 0.43 80 10000  
/ 500 
 (Berens, R. 
Marr, 1977) (L. 
braziliensis) 
Parasite. 
Part purified lysate. 
0.16 / 0.28 60 1400 / 500 
 
Table 4.9 : Comparison of trypanosomatid PFK kinetic parameters with published work. 
* AMP was used at a concentration of 0.5 mM in this study. In all other studies here (+AMP) 





 Cooperativity in F6P binding. 
Sigmoidal binding responses with relation to F6P have been reported for bacterial PFK (Evans, 
1992; Evans, Farrants, Hudson, & Britton, 1981), trypanosomatid PFKs (Cronin & Tipton, 
1987)(Nwagwu & Opperdoes, 1982)(Claustre et al., 2002) and mammalian PFK-1 (Moreno-
Sanchez et al., 2012). Cooperativity confers the metabolic advantage of amplifying the sensitivity 
of a signal (Koshland & Hamadani, 2002). PFK can therefore maintain high efficiency in substrate 
turnover during times of low F6P concentrations. 
We have shown in this chapter that F6P appears to bind with positive cooperativity to the 
trypanosomatid PFKs. F6P titrations produced Hill coefficients of h > 1 and a clear sigmoidal 
behaviour could be observed in dose-response curves. We showed that the reaction order is key 
to this cooperative behaviour – only when ATP was pre-incubated with the trypanosomatid 
enzymes did F6P titrations show positive cooperativity. Furthermore, affinity for F6P was greater 
when PFK was pre-incubated with ATP. This suggests upon ATP binding, the enzyme adopts a 
conformational state with greater affinity for F6P. This is re-enforced by comparing apo enzyme 
and ATP-bound TbPFK structures by McNae et. al, where ATP bound forms show an 
conformational change in 3 active site loops, opening up the active site to more easily 
accommodate F6P (Martinez-Oyanedel et al., 2007; McNae & Martinez-Oyanedel, 2009). We 
also observed that co-operative binding of F6P was negated in the presence of the allosteric 
activator AMP, as previously observed for Leishmania donovani PFK (López et al., 2002). In the 
presence of AMP the sigmoidal responses to F6P titrations changed to more hyperbolic 
responses with h ≤ 1.0.  
The next question was to address is how ATP binding is communicated across the PFK tetramer, 
to lead to cooperativity in F6P binding. Again referring to structures by McNae et. al, ATP-binding 
brings order to C-terminal helices known as ‘reaching arms’. These span across adjacent 
monomers between the dimer of dimers and are likely to the structures responsible for 
allosterically communicating conformational change across the tetramer as a whole. Provided 
ATP is bound first, these structural features may be responsible for communicating the signal of 
F6P binding to the next subunit, promoting a conformational change to a state with higher 
affinity for F6P.  
Two well known models for describing cooperativity in enzymes are the Monod-Wyman-
Changeux (MWC) model and the opposing Koshland-Nemethy-Filmer (KNF) or ‘sequential’ 




As we have no evidence of an R and T state with trypanosomatid PFKs without ligand bound, the 
MWC (symmetry) model cannot be considered. The KNF (sequential) model however fits our 
observations regarding F6P binding better; The binding of F6P to one subunit confers a 
conformational change to an adjacent subunit -perhaps through the ‘reaching arms’ to allow the 
binding of another F6P molecule more readily. This would be assuming that ATP is bound to all 
subunits prior to F6P binding. As we observed, ATP must be bound before F6P can be 
accommodated, and sigmoidal F6P binding responses are only seen when the enzyme is pre-
incubated with ATP. One may argue that the PFK apo enzyme may be the low affinity ‘T’ state in 
the MWC model, with the ATP-bound enzyme being the high affinity ‘R’ state. This does not fit 
however as F6P would have to bind both the low and high affinity states, and we have shown 
that ATP binding is required before F6P can be accommodated.  
F6P binding must induce a second conformational change that is communicated across the 
tetramer, to allow a more rapid binding of the next F6P molecule. A model for co-operativity is 
discussed further in Chapter 7, section 7.2. 
AMP effect and other allosteric effectors. 
We have shown in this chapter that trypanosomatid PFKs are not inhibited by ATP at 
concentrations up to 5mM, and that AMP allosterically activates trypanosomatid PFKs - 
increasing the catalytic efficiency of the enzyme. Of all of the potential effectors tested, only 
AMP showed a significant effect on the trypanosomatid PFKs. ADP showed weak inhibition 
(IC50ADP = >7 mM) of TbPFK activity – likely due to competition with ATP rather than an allosteric 
effect. 
While the increase in affinity for F6P in the presence of AMP correlated well with literature on 
trypanosomatid PFKs (table 4.9), our observed effect of AMP on the PFK enzyme kinetics is 
novel; We found that trypanosomatid enzyme efficiency was increased in the presence of AMP, 
through an increase in affinity for ATP and F6P. This was coupled to a slight (~20%) drop in 
activity (Vmax). Previous literature has only reported an increase in F6P affinity, coupled with an 
increase in Vmax (Claustre et al., 2002). These are more traditional characteristics of an allosteric 
activator. We have shown however that trypanosomatid PFKs response to AMP in vitro is 
dependant on reaction order –  the AMP effect was only observed when PFK was pre-incubated 
with ATP. In some of the published literature, this pre- incubation step was not carried out, or it 
is unclear what the reaction order was. Under no reaction conditions did we observe a significant 




however is in agreement that AMP increases the efficiency of the trypanosomatid PFKs; AMP 
remains the signal for low energy stores in trypanosomatids - its binding to PFK increases the 
enzymes affinity for the substrates ATP and F6P, allowing rapid binding at low concentrations. 
Of each of the trypanosomatid PFKs tested L. infantum PFK showed the greatest sensitivity to 
AMP – with an 18-fold increase in the affinity for F6P. This is in agreement with published data 
for Leishmania spp. PFKs (table 4.9), including a reported 20-fold increase in the affinity for F6P 
when L. donovani PFK is in the presence of AMP (Berens, R. Marr, 1977). This information may 
add to our understanding of the physiological control of the glycolytic enzymes in the 
environment in which Leishmania spp. survive in the human infective stage, as discussed further 
in chapter 7, section 7.2. 
We outlined evidence of a possible reaction scheme; showing that AMP can only activate the 
enzyme if ATP is already bound. AMP changed the sigmoidal binding behaviour of F6P to a more 
hyperbolic response with each of the trypanosomatid PFKs. This effect was also observed in 
previous studies on T. brucei PFK – the addition of AMP caused the enzyme to exhibit hyperbolic 
behaviour for F6P binding (Claustre et al., 2002). Claustre et. al. also found that the binding of 
ATP dramatically increased the affinity of the enzyme for F6P binding. Comparisons of apo and 
ATP-bound TbPFK reveal the AMP binding site is formed upon ATP binding, and the ordering of 
the C-terminal reaching arms forms a lid over the allosteric site (McNae & Martinez-Oyanedel, 
2009). A description of the proposed binding mechanism of F6P cooperativity and AMP 



















Chapter 5: Phosphofructokinase in reverse. 
5.1. Introduction – PFK in reverse. 
Phosphofructokinase-1 is considered an irreversible enzyme. It plays a regulatory role in 
glycolysis because of this feature; committing the cell to glycolysis. The enzyme fructose 1,6-
bisphosphatase converts F16BP to F6P in gluconeogenesis, and so PFK need not run in reverse. 
In trypanosomatids, an additional FBPase enzyme (FBPase-2) facilitates the conversion of F26BP 
back to F6P (see section 1.4.2, chapter 1). PFK-1 therefore is not required to run in the reverse 
reaction in the cell. Phosphofructokinases can be grouped into one of two major families 
according to whether they use ATP (ATP-kinases)(E.C. 2.7.1.11) or pyrophosphate (PPi-
kinases)(E.C. 2.7.1.90). Both are high-energy phosphodonors;  
ΔGo (PPi + F6P → F16BP + Pi) = -2.1 Kcal/mol 
ΔGo (ATP + F6P → F16BP + ADP) = -4.4 Kcal/mol. 
Many PPi-Kinases, such as those found in higher plants, are known to run in reverse (Mertens, 
1991). T. brucei PFK evolved from an ancestral PPi-PFK to an ATP-dependant enzyme and has 
retained a number of structural features from this divergence (Martinez-Oyanedel et al., 2007). 
The ability to run in reverse however, is not considered to be one of these inherited traits (P. a 
Michels et al., 1997). Three of the four ATP-consuming steps in glycolysis are considered to be 
‘irreversible’ – the reactions carried out by hexokinase, phosphofructokinase and pyruvate 
kinase. To run these reactions in reverse a high thermodynamic cost must be paid to drive the 
equilibrium in the reverse direction. It is difficult to imagine therefore how or why one of these 
enzymes would run in reverse. This chapter aims to investigate how efficiently the PFK enzyme 
can run in reverse, what the conditions required are and whether these conditions are 
physiologically relevant.  Orthogonal enzyme assays were used to test conditions where the 
kinetics of the reverse reaction could be measured. A schematic of the reverse PFK reaction is 
shown in figure 5.1 below. 
 




5.2. Substrate kinetics of PFK in reverse. 
5.2.1 Reverse PFK activity observed using the kinase-Glo assay. 
The Promega ‘Kinase-Glo®’ kit is an end point assay that measures ATP production or 
consumption in a kinase reaction by quenching the reaction and measuring the resulting ATP 
concentration - linking it to the luciferin/luciferase reaction. For the forward reaction (where 
ATP is consumed) a decrease in luminescence suggests kinase activity. For the reverse reaction, 
an increase in luminescence (ATP production) suggests reverse kinase activity when ADP is 
provided. This is summarised in figure 5.2 below. 
 
Figure 5.2 – Kinase-glo® scheme used for measuring reverse PFK activity. 





An initial test was carried out using 2 µg/ml T. brucei PFK pre-incubated with 5 mM ADP for 10 
minutes at 25oC. The reaction was then started with 5mM F16BP. The ‘reverse’ kinase reaction 
was allowed to run for 30 minutes at 25oC in reaction buffer (50 mM TEA, 10 mM MgCl2, 5 mM 
KCl, 0.1% w/v bovine serum albumin (BSA), 0.005% Tween20 , pH 7.4). A comprehensive protocol 
for this assay can be found in section 2.3.5.2.   
As figure 5.3 shows below, the luminescence for the wells containing T. brucei PFK with ADP and 
F16BP increased relative to the well containing TbPFK and ADP only (which shows a low level of 
background luminescence signal). This suggests that the PFK present is turning over ADP to 
produce ATP only when F16BP is also present. Additional controls containing PFK and F16BP only 
(no ADP) did not show a significant increase in luminescence relative to buffer only and PFK only 
controls (data not shown). ADP only controls did not result in significant increases in 
luminescence, ruling out the possibility of spontaneous formation of ATP. Promega ‘Ultrapure’ 























Figure 5.3 : Evidence of the T. brucei PFK reverse reaction in Kinase-Glo assay. 
All conditions carried out in triplicate at 25 oC, error bars denote standard deviation. ADP, F16BP 





With evidence of T. brucei PFK producing ATP in the presence of ADP and F16BP, two additional 
trypanosomatid PFK enzymes were tested: T. cruzi and L. infantum PFKs, along with a crude 
preparation of one of the human PFK isoforms – PFK-M (muscle isoform PFK).  
Again, 2 µg/ml of PFK was used and pre-incubated with 5 mM ADP. The reaction was started 
with 5mM F16BP and allowed to run for 30 mins at 25oC. The resulting luminescence values 
were converted to ATP concentrations using an ATP standard calibration curve (see figure 5.4A) 
to give the concentration of ATP produced for each PFK enzyme (figure 5.4B).  
The three trypanosomatid PFKs had comparable activities – each converting ADP to ATP at a rate 
of ~2 – 2.35 µmol.min-1.mg-1. The rates were calculated based on the concentration of ATP 
produced (µM) over the time the kinase reaction was allowed to run (30 mins). The final 
concentration of the crude PFK-M preparation was not able to be determined at the time, but 
this enzyme also showed ATP production from ADP, at a rate of ~8.2 µM.min-1. These crude rates 
are estimations only – the limitation of the Kinase-Glo assay is that it is an end point assay and 
steady state rates cannot be measured. It also only measures ATP production – no F6P 
production resulting from the reverse reaction can be measured. An orthogonal assay was 
therefore required to check if the apparent reverse activity observed was an enzymatic turnover 



































Figure 5.4: ATP produced by reverse PFK reaction using Kinase-Glo™ assay. 
A) Calibration curve showing luminescence (RLU) of a standard ATP concentration range in assay 
buffer. B) ATP produced by PFKs in reverse reaction shown in µM. Luminescence values from 
Kinase-GloTM assay were converted to ATP concentration using above calibration curve. Each 
condition tested in duplicate at 25 oC, error bars show standard error. ADP and F16BP were added 




5.2.2 Optimisation of PGI/G6PDH reverse PFK assay. 
To measure the reverse PFK activity in a kinetic-based assay an established protocol for an 
FBPase activity assay was altered. The reaction scheme for the final assay is shown below in 
figure 5.5. The assay was optimised for measuring reverse PFK activity at 25 oC in reaction buffer 
(10 mM MgCl2, 50 mM TEA, 100 mM KCl, 10 % glycerol, 0.005 % Tween20, pH 7.4). The assay 
links the production of F6P by PFK to the downstream enzyme phosphoglucose isomerase (PGI) 
and glucose-6-phosphate dehydrogenase (G6PDH). The reduction of NAD+ to NADH provided a 
measurement of activity by measuring absorbance at 340 nm using a spectrophotometer. A 
detailed explanation of the assay can be found in section 2.4.1. 
 
 
Figure 5.5: PGI/G6PDH linked enzyme assay reaction scheme for measuring reverse PFK activity. 
F6P production by PFK working in reverse (1) is measured through the linked enzymes 
phosphoglucose isomerase (PGI)(2) and glucose 6-phosphate dehydrogenase (G6PDH)(3) via 
measuring the reduction of NAD+ to NADH which can be measured on a spectrophotometer at 









An ATP-sink was added to the assay to remove the build-up of ATP that could inhibit the PFK 
being tested and/or skew the equilibrium of the reverse reaction (figure 5.5). A 
luciferin/luciferase reaction was initially considered but after checking absorption spectra it was 
observed that the absorption maximum for D-luciferin was 330 nm – preventing an accurate 
reading of NADH at 340 nm. Next, glycerol kinase was considered however the commercially 
available form of the enzyme from Bacillus stearothermophilus (Sigma G0774) Glycerol kinase 
in E.coli is  known to be inhibited by F16BP as a feedback loop (Zwaig & Lin, 1966). Despite this 
an available stock was tested to examine its effect on the assay.  
To optimise the concentration of glycerokinase a titration of the enzyme was carried out under 
super-saturating downstream conditions (all other downstream enzymes and glycerol in excess 
– see section 2.4.1 for protocol). Figure 5.6 shows the effect of this glycerol kinase titration on 
the measured TbPFK activity.  The addition of glycerol kinase to the assay increased the overall 
measured TbPFK rate by ~25%, despite being inhibited by F16BP. ATP is possibly bound to the 
glycerol kinase enzyme without being hydrolysed, and thus the enzyme is still acting as a sink 
for free ATP molecules. With free ATP removed from solution, the equilibrium shifts in favour of 
the reverse reaction.  
A final glycerokinase concentration of 5 U/ml in each 100 µl assay well (0.5 U/well) was used. 1 
Unit of glycerokinase converts 1 µmol. Of ATP at 25oC. At its maximum rate, with glycerokinase 
included, TbPFK converts ADP to ATP at a rate of ~12 µM.min-1 (figure 5.6). The reverse assays 
were run at 25oC for a maximum of 15 minutes. This means that at 15 minutes a maximum of 
0.018 µmol of ATP will be produced in the well (12 µM.min-1 for 15 min. in a 100 µL reaction 
volume = 0.018 µmol ATP produced). Since the concentration of glycerokinase used (0.5 U/well)  














Figure 5.6: Effect of glycerol kinase titration of PGI/G6PDH reverse assay. 
Effect of glycerol kinase on the initial rate of PGI/G6PDH reverse PFK activity assay. Each 
experiment was tested in duplicate at 25oC, error bars show standard error. Sigmoidal curve 
applied using GraphPad Prism 6.0. Glycerol kinase concentration is shown in Log10 scale on the 
X-axis. 
5.2.3 Substrate kinetics for trypanosomatid PFK in reverse. 
The optimised PGI/G6PDH assay allowed for real-time measurements of reverse PFK enzyme 
activity. Titrations of the substrates of the reverse reaction (F16BP and ADP) were carried out to 
calculate the Michaelis constant (Km) for each, when PFK is running in reverse. An optimised 
concentration of 2 µg/ml of PFK was used and all experiments were carried out in triplicate at 
25oC. No significant drop in NADH absorbance at 340 nm was observed in negative controls 
containing no PFK enzyme (data not shown). Rate calculations were made by taking the gradient 
of at least 6 points in the linear section of the raw absorbance trace and converting absorbance 
values to micro molar NADH concentrations using the Beer-Lambert law (A = Ɛcl). Velocity was 
calculated as micromoles NADH converted per minute (µM.min-1) and converted to specific 
activity (µmol.min-1.mg-1). 
Figure 5.7 shows substrate-velocity plots for ADP and F16BP titrations against T. brucei PFK in 
the PGI/G6PDH assay. Contrary to the forward reaction, both ADP and F16BP fitted a hyperbolic 
curve fit for TbPFK. However with regard to TcPFK and LiPFKs, F16BP titrations fitted allosteric 
sigmoidal curves better, suggesting cooperativity in F16BP binding with these species. Hill 







Figure 5.7: Michaelis-Menten plots for ADP and F16BP titrations in the PGI/G6PDH reverse PFK 
assay. 
A) MM plot of ADP titration against TbPFK and a set concentration (3 mM) of F16BP. All reactions 
preformed in triplicate, error bars denote standard deviation.  
B) MM plot of F16BP titration against TbPFK and set concentration (3 mM) ADP. All reactions in 
triplicate, error bars denote standard deviation. 
 
















Reverse      
TbPFK  601 ± 78 1.2 ± 0.3 685 ± 233 4.1 ± 0.3 15 ± 1 
TcPFK 1295 ± 98 2.3 ± 0.4 265 ± 48 4.5 ± 0.4 9 ± 1 
LiPFK 4891 ± 958 1.9 ± 0.2 2636 ± 720 3.8 ± 0.5 7 ± 1 
Forward      
TbPFK 803 ± 48 2.1 ± 0.2 83 ± 5 60 ± 1 54 ± 1 
TcPFK 469 ± 26 1.9 ± 0.2 79 ± 1 59 ± 1 53 ± 1 
LiPFK 2391 ± 99 2.2 ± 0.1 24 ± 0.4 26 ± 1 23 ± 1 
*F16BP or F6P titrations only. 
Table 5.1: kinetic parameters for Trypanosomatid PFKS run in reverse.  
All values taken from plots of initial velocity versus substrate concentration. All plots fitted with 
either a hyperbolic or allosteric sigmoidal curve using GraphPad Prism 6.0. All experiments were 
carried out in triplicate at 25 oC, standard deviation is given. 
 
Both T. brucei and T. cruzi PFK enzymes have similar kinetic parameters with respect to substrate 
affinity and maximum velocity in the reverse reaction. Reverse substrate Michaelis constants 
(Km) are within a similar range as those for the forward substrates (ATP and F6P)(table 5.1). L. 
infantum PFK however, similar to the forward reaction with regards to F6P, had a significantly 
reduced affinity for F16BP and ADP, and a lower overall enzyme activity (demonstrated by the 
kcat) compared to TbPFK and TcPFK in the reverse reaction. All three parasitic PFKs however 
appear to be acting enzymatically in reverse: all have enzyme turnover (kcat) values within a 
sensible range for a working enzyme (~ 10 – 106 s-1) and all could be fitted to substrate dose-
response curves with hyperbolic or allosteric sigmoidal curves.  
5.2.4 L. infantum and T. cruzi PFK show co-operatively in F16BP binding. 
Similar to F6P titrations in the forward reaction, the F16BP titrations against T. cruzi and L. 
infantum PFK did not obey Michaelis-Menten kinetics at concentrations below 10mM. Allosteric 
sigmoidal curves fitted better to F16BP titrations for TcPFK and LiPFK, and significant 




suggested cooperativity in F16BP binding (h = 1.9 – 2.3 ± 0.2) for F16BP alone. Interestingly, no 
cooperative binding response was observed for TbPFK with regards to F16BP. The 
trypanosomatid PFK enzymes were each tested in triplicate on at least three separate occasions. 
While TcPFK and LiPFK were consistent in showing a cooperative response to F16BP titrations, 





5.3. Allosteric regulation of PFK in reverse. 
As described in the study of the forward PFK reaction (Chapter 4, section 4.4), trypanosomatid 
PFKs are allosterically activated by AMP. In the presence of AMP they showed a slight drop in 
Vmax coupled with a significant drop in the Km for both ATP and F6P. As discussed in the 
aforementioned section, AMP is likely to alter the structure of the PFK active site to more readily 
accommodate the F6P and ATP substrates. We also found that reaction order dictates this 
response – AMPs activating effect was only observed when the PFK enzyme was pre-incubated 
with ATP. The logical question is what effect, if any, AMP would have on the reverse reaction. 
Without an AMP/ATP-bound structure it is hard to speculate with confidence, but two 
theoretical models are possible;  
I. AMP inhibits the reverse reaction by forcing the enzyme into a state that favours the 
binding of the forward reaction substrate F6P only. 
II. AMP activates the reverse reaction by forming state that accommodates ADP and F16BP 
in the same manner as it accommodates ATP and F6P with increased affinity. 
Figure 5.8 summarises these two possibilities as a reaction schematic for PFK working in the 
forward and reverse directions.  
Figure 5.8: Theoretical models for AMP-induced conformational states of PFK monomer. 
ATP binds first in the trypanosomatid reaction scheme. AMP and/or F6P cannot bind until ATP is 




5.3.1 AMP allosterically activates trypanosomatid PFK reverse reaction. 
Substrate dose-response curves for the reverse PFK reaction were carried out as stated in 5.2.3, 
in the presence and absence of AMP. AMP was added to a final concentration of 0.5 mM after 
PFK incubation with ADP. The mixture was incubated at 25 oC for 10 minutes and the reaction 
was started with the addition of F16BP at 25 oC in the PGI/G6PDH assay.  
T. cruzi, T. brucei and L. infantum PFKs were all activated by AMP in the reverse reaction with 
regards to F16BP titrations. In contrast to the activation of the forward reaction by AMP, T. 
brucei PFK responded in a more ‘textbook’ manner for allosteric activation; the Khalf for F16BP 
dropped while Vmax remained relatively constant, as shown for the F16BP titrations with and 
without AMP (figure 5.10A). AMP increased the affinity for F16BP with TcPFK and LiPFK, coupled 
with an increase in the Vmax of the enzymes. Similar to the forward reaction with regards to 
F6P, AMP removed the observed cooperativity in F16BP binding in the reverse reaction. This can 
be observed in the loss of the sigmoidal tail in F16BP dose response curves (TcPFK and LiPFK, 
figure 5.10B, 5.10C) and the Hill coefficient values (table 5.2). 
AMP increases the affinity for ADP too in the reverse reaction. With respect to ADP titrations 
against TbPFK and TcPFK, the presence of AMP slightly increased the affinity for ADP (~2-fold 
decrease in KmADP) (table 5.2), and results in a slight reduction (~20-25% reduction) in the Vmax 
(figure 5.9A, 5.9B). 
Again, LiPFK was more affected by AMP with regards to both F16BP and ADP titrations in the 
reverse reaction. The affinity for both substrates was dramatically increased in the presence of 
AMP (8-fold increase for ADP, 4-fold increase for F16BP) as well as the Vmax for the enzyme 
(figure 5.10C, 5.9C). Activation by AMP resulted in a 5-fold and 8-fold increase in catalytic 
efficiency (kcat/Km) for F16BP and ADP respectively. Table 5.2 shows the kinetic parameters for 
each PFK enzyme tested in reverse, with and without AMP. Experimental procedures were as 










Figure 5.9: AMP activation of T. brucei and T. cruzi PFK in reverse. 
Dose-response plots of ADP titrations with (red) and without (black) 0.5 mM AMP for 
trypanosomatid PFKs. Michaelis-Menten curve fitted (GraphPad Prism 6.0) All conditions carried 












Figure 5.10: AMP activation of T. brucei and T. cruzi PFK in reverse. 
Dose-response plots of F16BP titrations with (red) and without (black) 0.5 mM AMP for 
trypanosomatid PFKs. Allosteric sigmoidal curve fitted (GraphPad Prism 6.0) All conditions 




















 601 ± 84 7.2 13 0.022 1.2 ± 0.2 
 + AMP 351 ± 54 8.1 ± 0.3 14 0.039 0.9 ± 0.2 
T. cruzi  
PFK 
 1295 ± 98 3.8 ± 0.2 7 0.005 2.3 ± 0.4 




 4831 ± 958 1.9 ± 0.1 4 0.001 1.9 ± 0.2 
 + AMP 1329 ± 91 3.8 ± 0.2 7 0.005 1.3 ± 0.1 













 685 ± 233 8.2 ± 0.8 15 0.022 0.7 ± 0.1 
 + AMP 235 ± 79 6.0 ± 0.5 11 0.046 0.7 ± 0.1 
T. cruzi  
PFK 
 265 ± 48 4.5 ± 0.4 8 0.030 1.1 ± 0.1 




 2636 ± 720 3.8 ± 0.5 7 0.003 1.3 ± 0.2 
 + AMP 351 ± 37 5.1 ± 0.1 9 0.026 0.8 ± 0.1 
 
Table 5.2: Kinetic parameters for AMP-activation of trypanosomatid PFK reverse activity. 
All experiments were carried out in PGI/G6PDH reverse assay at 25oC. All parameters are 
calculated from substrate-vs-initial rate plots with either Michaelis-Menten plots fitted (TbPFK 






The apparent stimulatory effect of AMP appears to be more complicated in the reverse reaction, 
with multiple responses observed. The Vmax for each enzyme either increased or remained the 
same in the presence of AMP with respect to F16BP titrations. The Vmax of all enzymes bar LiPFK 
was slightly reduced in the presence of AMP with respect to ADP titrations. This may be a 
competitive effect of AMP binding weakly in the ADP/ATP site, or a result of the AMP-PFK bound 
complex adopting a conformation that has little effect on ADP binding. It is clear however that 
increased F16BP binding is accommodated for with the addition of AMP, and improves the 
efficiency of PFK working in reverse – demonstrated by increases in the kcat/KhalfF16BP (table 5.2).  
The effect of reaction order was not as clear in the reverse reaction ; When added after the 
incubation of PFK with ADP, AMP had a consistent activating effect with respect to F16BP 
titrations. When added prior to ADP, AMP produced mixed effects on the enzymes – either 
showing activation through an increased Kcat/Km or not showing any effect (data not shown). 
Responses in the presence of AMP were more consistent when AMP was added after ADP, 
suggesting that prior binding of ADP is necessary for AMP binding or at least the observation of 
its activating effect on the enzyme in reverse. 
5.3.2 F26BP is not a regulator of the reverse PFK reaction. 
Fructose 2,6-bisphosphate (F26BP) was tested up to a concentration of 1 mM against the 
trypanosomatid PFKs in the PGI/G6PDH reverse activity assay. No significant effect of F26BP on 
PFK activity was observed (data not shown). Many PPi-dependant PFKs (‘PPi-PFKs) that are 
known to run in the reverse direction are regulated by F26BP. PPi-PFKs found in higher plants 
that also possess ATP-PFK and FBPase enzymes are stimulated by F26BP. Yeast and mammalian 
ATP-PFKs are activated by F26BP.  As discussed in Chapter 4, the trypanosomatid PFKs were not 
affected by F26BP, likely due to a separate evolutionary branching from yeast, plant and 
mammalian PFKs which developed an allosteric site for F26BP binding from an ancestral active 
site (section 1.4.1, Chapter 1). This is likely the same reason for why no regulation of the reverse 





5.4. Inhibition of the reverse PFK reaction. 
We have so far shown that trypanosomatid PFKs are able to run in the reverse direction; turning 
over ADP to produce ATP and behaving enzymatically under titrations of the reverse substrates 
ADP and F16BP. We have also established that the allosteric activator of the forward PFK 
reaction (AMP) is also an effector of the reverse reaction.  
The ‘CTCB’ inhibitors described in Chapter 6 inhibit trypanosomatid PFK by binding to a unique 
allosteric pocket and blocking the movement of a catalytically important loop (‘Asp229 loop’) 
that co-ordinates the transfer of a phosphate from ATP to F6P. If trypanosomatid PFKs are able 
to act in reverse and facilitate transfer a phosphate from F16BP to ADP, it is logical to assume 
that by blocking the mechanism responsible for this phosphotransfer we will also inhibit the 
reverse reaction.  
5.4.1 CTCB compounds inhibit trypanosomatid PFK running in reverse. 
Using the PGI/G6PDH linked assay, several CTCB compounds were titrated against the T. brucei 
PFK enzyme running in reverse to test for inhibition. The concentration that resulted in inhibition 
of 50% of the enzyme activity was measured. This is known as an ‘IC50’. IC50 values for CTCB 
compounds against TbPFK were measured using the LDH/PYK linked enzyme assay, as described 
in Chapter 6, section 6.1. Enzyme concentrations were optimised previously for the PGI/G6PDH 
assay, and were comparable with concentrations used in the forward reaction assay for 
measuring PFK inhibition (2 µg/ml in PYK/LDH assay and 4 µg/ml in LDH/PYK assay). Equimolar 
concentrations ( 3mM ) of F16BP and ADP were used in the assay. The reaction was carried out 
at 25 oC in reaction buffer (10 mM MgCl2, 50 mM TEA, 100 mM KCl, 10 glycerol, 0.005 % 
Tween20, 1% DMSO, pH 7.4). A full protocol can be seen in section 2.4.1.2. Figure 5.11 shows 





Figure 5.11 : Inhibition curves for CTCB compounds tested against T. brucei PFK in the reverse assay. 
CTCB compounds were titrated against TbPFK running in reverse in the PGI/G6PDH assay at 25 
oC. Compound concentrations are given in Log values on the X axis and enzyme activity on the Y 
axis – calculated as a percentage of the uninhibited enzyme activity using negative controls 
containing DMSO in place of compound. Error bars represent standard deviation (n=3). IC50 
values for each compound in the forward reaction (PYK/LDH assay) and reverse reaction 







The compounds tested show that the reverse TbPFK reaction can be inhibited, with IC50 values 
in the same order of magnitude as the forward reaction. IC50 values are not directly matching 
and it is difficult to pinpoint the reason; compounds were tested against the downstream 
enzymes in the reverse assay however no significant inhibition was observed. This does not rule 
out weak promiscuous binding to the downstream components however. This is investigated as 
a potential cause for similar discrepancies in IC50 values in two orthogonal assays and is discussed 
further in Chapter 6, section 6.2.3. The same buffer conditions, ‘non-binding’ 96 well plates and 
pipette tips were used compared to the forward assay (PYK/LDH assay). 
 It is clear however that the movement of the Asp229 loop is crucial for TbPFK to function in 
both directions. In the Apo-TbPFK crystal structure (2HIG), a leucine on the Asp229 loop docks 
into the site into which the CTCB compounds bind. Preventing the docking of this loop inhibits 
the enzyme as described in chapter 6, section 6.6. Furthermore, this is further evidence that the 
enzyme is carrying out the reverse phosphotransfer – from F16BP to ADP to produce ATP and 
F16BP, and that it is not simply spontaneous ATP or F6P formation that is responsible for the 
apparent reverse reaction signal. 
Since we showed that F16BP but not F6P can bind in isolation, it is possible that the Asp229 loop 
has affinity for F16BP and in the ADP/F16BP bound enzyme form, this may force the loop into 
the ‘closed’ apo-enzyme form with the leucine residue docked into the CTCB binding pocket 
(section 1.4.5, chapter 1). If this is the preferred conformation when ADP and F16BP are bound, 




5.5. Conclusions – trypanosomatid phosphofructokinase in 
reverse. 
In this chapter we investigated whether PFK could run in reverse, and if so what the conditions 
required are to run the enzyme in this direction. We present data showing that trypanosomatid 
PFKs can run in reverse in two orthogonal assays, and that the substrate kinetics for F16BP and 
ADP can be measured. We showed that trypanosomatid PFK behaved enzymatically in reverse, 
adhering to Michaelis-Menten kinetics and in some cases demonstrating cooperativity in F16BP 
binding. It was shown that AMP was an allosteric effector of the reverse reaction that improved 
the catalytic efficiency of the reverse reaction in trypanosomatid PFKs.   
Additionally, we showed that PFK could be inhibited in the reverse direction by inhibitors 
designed to allosterically block the catalytic activity of the forward enzyme.  
Trypanosomatid PFK appears to run in reverse under conditions that are arguably close to 
theoretical physiological values; Table 5.3 shows published ADP, ATP, F6P and F16BP 
concentrations within cells from various organisms. 
Organism [ATP] [ADP] [F6P] [F16BP] 
E.coli 1.35 mM1 0.82 µM2 0.95 mM3 
 
15 mM6 
Leishmania spp. ND ND >1mM4 >1 mM4 (check) 
H. sapiens 1.3 – 1.8 mM5  
(cytoplasmic) 
150 -390 µM5  
(cytoplasmic) 
ND 4 – 12 µM5 
(cytoplasmic) 
(Yaginuma et al., 2015) 2. (Albe, Butler, & Wright, 1990) 3.(Danchin, Dondon, & Daniel, 1984) 
4. (Akpunarlieva et al., 2017) 5. (Nakayama, Kinoshita, & Tomita, 2005) 6. (Bennett, Kimball, & 
Gao, 2009).  
Table 5.3 : literature values for measured cellular concentrations of PFK metabolites. 
 
In E. coli cells, where PFK is located in the cytosol, ADP and F16BP concentrations have been 
reported as 0.56 – 0.82 mM and 15 mM respectively in growing cell populations (Bennett et al., 
2009; Lowry, Carter, Ward, & Glaser, 1971). In trypanosomes PFK is compartmentalised into the 
glycosome, and so it is possible that these concentrations are even higher. F16BP concentrations 
in Leishmania promastigotes have been reported to be greater than 1 mM (Akpunarlieva et al., 




conditions.  The trypanosomatid PFK enzymes tested here can therefore run in reverse under 
conditions close to physiological concentrations. A question remains; If the concentrations of 
ADP and F16BP required for trypanosomatid PFK to run in reverse are achievable in vivo, is there 
evidence of trypanosomatids using PFK in reverse?  
To address this question it is necessary to look at a number of examples of PFK being able to run 
in reverse in vivo; E. coli cells possess two ATP-dependant PFKs (PFK-1 and PFK-2), and an FBPase 
enzyme. It has been shown that in E.coli cells with depleted ATP-kinases and FBPase enzymes, a 
recombinant PPi-kinase enzyme can replace the function of both ATP-kinases in glycolysis and 
run in reverse to perform the function of FBPase in gluconeogenesis (Kemp & Tripathi, 1993). 
The E. coli PFK enzyme has been shown to run in reverse in vitro in a pH-dependant manner 
(Auzat & Garel, 1992). 
Labelled hexose sugars derived from C13-labelled F16BP have been found via LC-MS of T. brucei 
cells (in which the FBPase is thought to be inactive), suggesting the reverse activity of T. brucei 
PFK in cells (Creek et al., 2015). The Lab of Dr Frédéric Bringaud at the University of Bordeaux, 
France has also recently shown that FBPase-null mutants of procyclic T. brucei parasites are 
capable of producing hexose 6-phosphates (in the absence of glucose) from amino acids, by 
gluconeogenesis (unpublished – Per. Comm. Dr P. Michaels). This suggests that PFK can fulfil the 
role of FBPase in the gluconeogenesis pathway by carrying out the conversion of F16BP to F6P. 
A sample of one of our CTCB compounds has been sent for use in this study to inhibit PFK and 













Chapter 6 : Inhibition of trypanosomatid PFK. 
 
The work in this chapter focuses on the Wellcome Trust funded ‘Seeding Drug discovery’ (SDD) 
project carried out by the Walkinshaw Lab at the University of Edinburgh in collaboration with 
the medicinal chemistry company Selcia Ltd based in Ongar, Essex. The aim of the SDD project 
was to design, synthesise and test small molecule inhibitors of Trypanosoma brucei PFK. The 
desired outcome being the development of new orally administered drug compounds against 
Human African Trypanosomiasis (HAT). Section 1.4.8, chapter 1 details why PFK was chosen as 
a target for anti-trypanosomatid drugs. The aim of the work reported in this chapter is to rank 
and characterise the inhibition of trypanosomatid (T. brucei and others) PFK by novel organic 
small molecules. 
6.1 Developing drug-like compounds against Human African 
Trypanosomiasis. 
An initial screening project of 340, 000 small molecules against T. brucei PFK enzyme activity was 
carried out in collaboration between the Walkinshaw lab and the National Institute for health 
(NIH)(Brimacombe et al., 2014). This study identified >1,000 small molecule inhibitors of T. 
brucei PFK. From here, the Walkinshaw lab undertook a structure-based design approach to 
developing compounds from these chemical series as part of the Wellcome-funded SDD project. 
Existing crystal structures of apo- and ATP-bound T. brucei PFK by Iain McNae allowed the 
identification of the unique pocket into which the initial inhibitors bound. This pocket will be 
referred to as the ‘CTCB compound binding site’.  
6.1.1 SDD project workflow. 
A structure-based design approach to drug discovery requires a constant feedback loop of 
compound design, testing, characterisation and crystallographic confirmation of binding in order 
to improve upon compound classes and chemical groups that enhance or hinder binding to the 
target protein. These characteristics must be in balance with optimising the pharmacokinetic 
properties of the compound to increase its bioavailability (entry through the blood-brain barrier, 
trypanosome and glycosome as well as potential metabolism and clearance by the host 
organisms) and specificity against the target organism. Division of labour and specialisation is 
therefore essential to ensure this information is generated in a timely manner. A summary of 





Figure 6.1: Workflow schematic for University of Edinburgh SDD programme. 
 
Initial compound series were based on the sulphonamide chemical class that was identified in 
the NIH screen. Later development resulted in sulphone, benzamidizole and pyrazole chemical 
classes. The best inhibitors from these were refined into the 3rd generation chemical scaffolds 






Figure 6.2: Evolution of CTCB compound chemical classes. 
Evolution of chemical scaffolds of CTCB compounds throughout the Wellcome Trust SDD project. 
EC50 relates to the concentration of compound required for 50% death of in vitro cultured T.b. 








6.1.2 Assays used in compound ranking and enzymatic characterisation. 
Compound testing and characterisation was carried out initially by ranking compounds 
according to their potency against the enzyme. This was quantified by measuring the IC50 of each 
compound – the concentration of compound at which the enzyme is at half maximal activity. 
These were measured for each compound in 2 orthogonal enzyme assays – the ADP-Glo™ assay 
and the PYK/LDH linked enzyme assay. Compounds were also ranked according to their binding 
response at single concentrations against a T. brucei PFK surface in SPR.  
Compounds with strong potency against the T. brucei PFK enzyme (IC50 < 20 µM) were selected 
for further characterisation: affinity measurements using SPR, characterisation of binding 
stoichiometry and binding thermodynamics in Isothermal Titration Calorimetry (ITC), specificity 
testing against human PFK isoforms and characterisation of competition with F6P and ATP. This 
workflow is summarised in figure 6.3. 636 ‘CTCB’ compounds (named after the Centre for 
Translational and Chemical Biology at the UoE) in total were tested at least twice in each 
orthogonal assay.  
 
Figure 6.3: CTCB compound testing flow diagram. 
Compounds tested in the 2 primary assays were tested in parallel against cultured GVR35 T. 
brucei brucei parasites and ranked by their EC50 (concentration at which half the trypanosome 
population is killed). A close comparison of potency against the enzyme and against the 




6.1.3 CTCB compound ranking against T. brucei PFK by orthogonal assays. 
CTCB compounds were primarily ranked based on IC50 measurements against T. brucei PFK in 
the PYK/LDH and ADP-Glo™ orthogonal assays (see section 2.3.1 and 2.3.4 respectively for 
protocols). The spread of potencies against TbPFK of the 636 compounds tested over the SDD 
project is represented in figure 6.4. Inhibitor potency ranged from 22 nM to >150 µM, with 13 












Figure 6.4: Distribution of CTCB compound potency against T. brucei PFK. 
Distribution of averaged IC50 values (µM) measured in PYK/LDH and ADP-Glo™ assays for 











6.2. Primary compound ranking by LDH/PYK and ADP-Glo™ 
assays. 
6.2.1 Ranking by PYK/LDH assay. 
The PYK/LDH enzyme-linked assay measures T. brucei PFK activity by linking the production of 
ADP to the downstream enzymes pyruvate kinase (PYK) and lactate dehydrogenase (LDH), as 
seen in figure 6.5. Activity is observed by reading the change in absorbance of NADH at 340 nM 











Figure 6.5: PYK/LDH linked assay reaction scheme. 
Compounds were titrated against a fixed concentration of PFK (4 µg/ml) and supplied with a 
fixed concentration of ATP (5 mM). Compound titrations were mixed with the PFK enzyme in 
the presence of ATP and incubated for 30 minutes before the reaction was started with a sub-
saturating concentration of F6P (0.6 mM). Reactions were carried out at 25 oC. For a full protocol 
please see section 2.3.1. Compound titration ranges were decided upon according to limits of 
solubility and/or predicted potency. The PYK/LDH assay allowed measurements to be taken in 
real-time – recording the absorbance at 20 second intervals over 12 minutes. The absorbance 
values were converted to NADH concentration using the Beer-Lambert law (A = Ɛcl). The initial 
velocity of the PFK reaction (µM NADH oxidised per minute) for each concentration of inhibitor 
was then taken and plotted as a function of the compound concentration in a dose-response 
curve as exemplified in figure 6.6. A sigmoidal curve was plotted using the positive control (5 
µM CTCB 001 or CTCB 405) as the minimum constraint (M1) and the negative control (DMSO) as 





Figure 6.6: Dose-response curve for CTCB 405 inhibition of TbPFK – measured using PYK/LDH assay. 
CTCB 405 series dilution of 13.3 µM – 6.1 nM. TbPFK concentration was 4 µg/ml final. F6P = 0.6 
mM, ATP = 5 mM final. ‘M1’ and ‘M2’ are the upper and lower constraints of the sigmoidal curve, 
representing the positive control (CTCB 001 - 100% inhibition) and negative control (DMSO – 0% 
inhibition). Experiments carried out in triplicate at 25 oC, error bars denote standard deviation. 
 
6.2.2 Ranking by ADP-Glo™ assay. 
The ADP-Glo™ assay produced by Promega was used as the orthogonal assay in CTCB compound 
ranking. The ADP-Glo™ assay is an end-point assay that measures the ADP produced in a kinase 
reaction after a set amount of time. This is achieved by first removing any unused ATP. Any ADP 
produced is converted back to ATP to be used in the luciferin/luciferase reaction, giving a 
luminescent output. A full protocol can be seen in section 2.3.4. 
 Serial dilutions of CTCB compounds were incubated with an optimised concentration of PFK (0.5 
µg/ml final) and a set concentration of ATP (0.1 mM final) in reaction buffer (50 mM TEA, 10 mM 
MgCl2, 5 mM KCl, 0.1% w/v bovine serum albumin (BSA), 0.005% Tween20, 1% DMSO, pH 7.4). 
The reaction was started with a 5X ATP/F6P mixture (0.1 mM and 0.5 mM final conc. 
respectively) and allowed to run at 25 oC for 30 minutes. The luminescence was measured and 
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Log [CTCB 405] (nM)
IC50 = 213 ± 10 nM 
M1 = 0.22 ± 0.7 µM-
1.min-1 





Concentrations of ADP produced were plotted as a function of CTCB compound concentration, 
and a sigmoidal curve was applied as shown in figure 6.7B. Curve fitting is explained in section 
2.3.4.2. Positive controls (5 µM CTCB 001 or ‘405) were used for the lower constraint (m1) and 















    
Figure 6.7: Dose-response curve for inhibition of TbPFK by CTCB 405 – as measured by ADP-Glo 
assay. 
A) ADP standard calibration curve for converting ADP-Glo kit Luminescence (RLU) to concentration of 
ADP produced (µM). ADP produced from the kinase reaction is converted to ATP and used in the 
luciferin/luciferase reaction by the ADP Glo kit. B) Dose-response curve for CTCB 405 against TbPFK. 
CTCB 405 serial dilution from 7 µM – 3.2 nM. TbPFK concentration was 0.5 µg/ml. 0.1 mM ATP, 0.5 
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Log [CTCB 405] (nM)
IC50 = 201 ± 14 nM 
m1 =  0.02 ± 0.09 µM-
1.min-1  
m2 =49 ± 0.8 µM-1.min-1 






6.2.3 Calculating Z-prime of primary assays. 
The ‘Z-factor’ coefficient is a measurement of the quality of high throughput assays. It represents 
both the dynamic range of the assay signal and the variation in the measurement of those signals 
(Zhang, Chung, & Oldenburg, 1999). The Z-prime of the PYK/LDH and ADP-Glo™ assays were 
calculated using the positive and negative controls. When using positive and negative controls, 
the Z-factor is defined by; 
𝑍 = 1 −  
(3𝜎𝑐  + 3𝜎𝑐 )
|𝜇𝑐 −  𝜇𝑐 |
 
Where 𝜇 = mean, 𝜎 = standard deviation, c+ = positive control (max. signal) and c- = negative 
control (min. signal). (Zhang et al., 1999) 
Z-factor Interpretation 
1.0 Ideal assay. Z-factor cannot be greater than 1. 
1 > Z ≥ 0.5 An excellent assay. 
0.5 > Z ≥ 0 A marginal assay. 
<0 There is too much overlap between the positive and negative controls for the 
assay to be useful. 
 
PYK/LDH assay Z-factor: 
Positive control (maximum signal) = DMSO in place of CTCB compound (0% PFK inhibition – 
maximum abs/min). 
Negative control (minimum signal) = 5 µM CTCB 405 (100% PFK inhibition). N = 73. Raw assay 
data were used – the gradient of the linear part of the plot of NADH absorbance over time 
(Abs/min). 
𝑍 = 1 − 
(3 ∗ 0.185 + 3 ∗ 0.009)
|1.137 −  0.0110|
 










ADP-Glo™ assay Z-factor: 
Positive control (maximum signal) = DMSO in place of CTCB compound (0% PFK inhibition – 
maximum RLU). 
Negative control (minimum signal) = 5 µM CTCB 405 (100% PFK inhibition). N = 74. Raw assay 
data was used – the luminescent signal produced (RLU).  
𝑍 = 1 −  
(3 ∗ 2708 + 3 ∗ 244)
|25254 −  1565|
 




𝑍 = 0.63 
Both assays have a Z-factor values of >0.5, and so both are excellent, reproducible assays for 
using in high throughput screening (Zhang et al., 1999). 
 
6.2.4 CTCB compound correlation between primary assays  
Correlation between the primary assays was measured using a Spearman nonparametric 
correlation test for non-normal data, In a correlation plot of 311 compounds with IC50 < 50 µM, 
data correlated reasonably well – giving a positive correlation coefficient of rs = 0.69 (figure 
6.8A). When only compounds with IC50 < 1 µM were included however, the correlation was 














Figure 6.8: Correlation of CTCB compound potency against T. brucei PFK as measured by 
PYK/LDH and ADP-Glo™ assays. 
A) Correlation of IC50 values < 50 µM B) Correlation of IC50 values < 1 µM. Data was tested for 
normality using the D’Agostino-Pearson omnibus normality test and was found to be non-normal 
(P<0.0001). Correlation was therefore tested using a spearman nonparametric correlation test for 






6.2.4.1 Discrepancies in IC50 values between primary assays. 
The IC50 values for CTCB compounds measured in the ADP-Glo™ assay were on average 2.7X 
lower than the PYK/LDH assay measured values (based on compounds with IC50 <50 µM. N = 
311). A number of compounds however showed significantly higher IC50 values when measured 
in the PYK/LDH assay. A selection of these ‘problem compounds’ is shown in table 6.1.  
The discrepancies in IC50 values between each assay did not appear to be attributed to a certain 
chemical class; While many of the ‘problem compounds’ belonged to the sulphonamide 
chemical class, the compounds in the azaindole chemical class had a range of discrepancies – 
from 1.4 - 10.7 X higher values in the PYK/LDH assay (table 6.1). The ADP-Glo™ and PYK/LDH 
experiments are orthogonal assays, and measurements are taken at different stages of the PFK 
reaction; In the PYK/LDH assay measurements are taken when the enzyme is at a constant rate 
(Abs/time taken at linear part of activity curve). The ADP-Glo™ assay was optimised so that the 
end-point measurements were taken when ~50% of the provided ATP was hydrolysed (figure 
6.7B). Some slight variation in the absolute IC50 values for compounds may therefore be 
expected, but not to the extent of some of the compounds listed in table 6.1. Other factors must 


















 Azaindoles     
CTCB 405 (Ctrl) 
 
0.27 ± 0.08 55 0.197 ± 0.07 56 1.4 X 
CTCB 339 
 
0.91 ± 0.25 5 0.24 ± 0.16 5 3.8 X 
CTCB 338 
 
8.71 ± 0.53 3 0.65 ± 0.2 3 13.4 X 
CTCB 293 
 
2.71 ± 0.88 6 0.47 ± 0.14 5 5.8 X 
CTCB 325 
 
2.88 ± 0.55 3 0.27 ± 0.08 3 10.7 X 
 Sulphonamides     
CTCB 002 
 
3.48 ± 0.41  3 0.98 ± 0.3 3 3.6 X 
CTCB 298 
 
6.36 ± 1.12 3 0.47 ± 0.14 3 13.5 X 
CTCB 308 
 
6.13 ± 0.40 3 0.66 ± 0.23 3 9.3 X 
Table 6.1: CTCB compounds with varying degrees of difference in IC50 values between primary 
assays. 
‘Difference’ refers to the factor by which PYK/LDH assay values differ from ADP-Glo™ assay. IC50 





























































6.2.4.2. IC50 discrepancy troubleshooting:  changing buffer and assay components in 
PYK/LDH assay.  
To examine further why some compounds had significantly higher IC50’s in the PYK/LDH assay, 
differences between the assay conditions were identified. Table 6.2A compares the running 
conditions between the two primary assays. These differences were the inclusion of bovine 
serum albumin (BSA), protein, KCl and substrate concentrations. To assess the impact of these 
differences, the running conditions of the PYK/LDH assay were altered to match the ADP-Glo™ 
assay. The compounds were tested again, and the effect on the IC50 compared to the previous 
assay conditions was measured – as shown in table 6.2B.  
A 
Component PYK/LDH assay ADP-Glo™ assay 
Buffer   
MgCl2 10 mM 10 mM 
T.E.A (triethanolamine) 50 mM 10 mM 
KCl 100 mM 20 mM 
Glycerol 10% - 
Bovine serum albumin (BSA) - 0.1 % (w/v) 
Tween20  0.005% 0.005% 
   
Protein   
TbPFK 4 µg/ml 0.5 µg/ml 
   
Substrates   
F6P 0.6 mM 0.5 mM 
ATP 5 mM 0.1 mM 
B 
Compound Lower F6P 
(0.1 mM F6P) 
Lower ATP 
(0.5 mM ATP) 
Buffer:  
- glycerol 
Buffer :  
+ BSA 
Buffer:  
- glycerol, + BSA 
CTCB 405 - - - - - 
CTCB 339 - - - - - 
CTCB 338 - 3.5 X 3 X 2 X 2 X 
CTCB 293 6 X - 3 X 3 X 1.5 X 
CTCB 325 - - - - - 
CTCB 002 - 2 X 2X  2X - 
CTCB 298 - 2 X 2 X - 1.5 X 
CTCB 308 6 X 2 X 2 X - 2 X 
Table 6.2: Altering buffer and assay components in PYK/LDH assay does not fully correct 
discrepancies. 
A) Summary and comparison of buffer and assay components in PYK/LDH and ADP-Glo™ assays. 
Differing conditions between the assays are highlighted. B) Results of changes in IC50 values for 
compounds in the PYK/LDH assay under different buffer and assay conditions. Values represent 




As seen in table 6.2B, no single change in the PYK/LDH assay conditions was responsible for the 
IC50 discrepancies for the ‘problem’ compounds tested. Lowering the concentration of F6P from 
0.6 mM to 0.1 mM had a large effect on CTCB 293 and CTCB 308, dropping the discrepancy in 
IC50 values 6-fold. This would suggest perhaps a degree of competition between F6P and these 
compounds, but as will be shown later in section 6.7.1, no CTCB compounds were found to be 
competitive with F6P.  
Including BSA and removing glycerol had a small effect on most compounds, but this effect was 
not cumulative. A change in the optimised PFK concentration had little effect on IC50 
discrepancies, and caused greater deviation in IC50 values in repeats of the same compound in 
the PYK/LDH assay – as this resulted in a poor signal: noise ratio (data not shown).  
With chemical classes and assay conditions being ruled out as the causative agents of the 
‘problem compounds’, it was decided to look at the chemical properties of the functional groups 
belonging to the compounds; Figure 6.9 shows the correlation between the basicity of a range 






Figure 6.9: Of the ‘problem compounds’, the less basic compounds have a higher IC50 discrepancy. 
Computed pKb values for a range of ‘problem’ CTCB compounds plotted against factor of 
difference between IC50 values generated by the PYL/LDH and ADP-Glo™ assays. CTCB numbers 
have been annotated to the right hand side of each data point. 
 
Figure 6.9 shows indeed that there is a relatively weak correlation (rs = 0.22) between the less 
basic compounds, and higher discrepancy in IC50 values. There are some exceptions to the rule 
however; CTCB 405 and CTCB 338, despite having the same pKb value, have significantly 
different IC50 discrepancies between assays. The varying basicity of the compounds will affect 
how they interact with other components in the assay such as BSA or downstream enzymes, 
which of course are different in each assay. While controls showed that no CTCB compound 
affected the downstream activity of the assays, it does not rule out the possibility of 
promiscuous binding to other assay components, effectively reducing the free inhibitor 
concentration in the assay.  
No single uniting factor appears to be responsible for the ‘problem compounds’ between assays. 
A combination of uncontrollable factors such as compound basicity and variable factors such as 
the concentration of F6P and inclusion of BSA contribute generally but not equally for each of 
the compounds. These variables cannot be altered without jeopardising the reproducibility 




in high throughput screening, to minimise on false positives or negatives throughout the 
process. 
6.2.5 Inhibition of PFK corresponds to parasite killing. 
For a structure-based drug design to be successful, any gains in potency against the enzyme 
must also be matched by increases in potency against the target organism. Figure 6.10 shows a 
good correlation between IC50 values for the CTCB compounds and the EC50 (concentration of 
compound at which 50% parasite killing is achieved) of the same compounds against cultured T. 
brucei brucei trypanosomes. Inhibition of the essential PFK enzyme is targeted by the CTCB 




Figure 6.10: Inhibition of PFK by CTCB compounds correlates with killing of trypanosome cultures. 
Correlation plot – CTCB compound inhibition of T. brucei PFK (IC50) (X-axis) against killing of 
cultured T. brucei brucei ‘427’ strain trypanosomes (EC50)(Y-axis). Basic compounds are labelled 
with stars (), compounds with neutral or acidic groups labelled as diamonds (). IC50 values 





A grouping of basic compounds (labelled) can be seen in figure 6.10 as the most potent 
compounds against both the enzyme and parasite. Basic compounds may allow greater 
penetration into the hydrophobic parasite cell and glycosome membranes - resulting in more 
potent killing of trypanosome.  
6.2.6 Compound ranking using SPR. 
The ADP-Glo™ and PYK/LDH assays were used primarily for ranking of potency against the 
enzyme on a week-by-week basis. Single point ranking through SPR was also carried out on a 
less regular basis, testing batches of ~30-60 compounds at a time. The single point screening by 
SPR was used to identify compounds for further characterisation by SPR – only compounds that 
showed potent, specific binding to the PFK surface at single point were chosen for further 
analysis. All PFK surfaces described in this chapter were made using the his6-tag capture and 
couple technique described in section 2.5.3.1. 
6.2.6.1 CTCB 405 is an excellent control for ranking in SPR. 
Single point screening in SPR involves measuring the response (in resonance units - ‘RU’) of each 
compound at a single concentration against the PFK surface. In order to rank compounds in 
single point using SPR, a control compound must be used as a reference. This control compound 
needs to bind tightly and specifically to the PFK surface, in a 1:1 stoichiometry and must be 
reproducible in its response and not interfere or bind promiscuously to the protein surface or 
SPR chip matrix. The lead compound identified from the NIH screen – ‘CTCB 001’ was used 
initially as a control for all assays as it was the original compound scaffold and was known to 
inhibit TbPFK with high potency (ADP-Glo™ IC50 = 220 nM) .  
Later however, CTCB 405 was identified as a much better candidate as a standard for all CTCB 
compounds. It has a similar potency against T. brucei PFK (ADP-Glo™ IC50 = 197 nM) but had 
‘cleaner’ binding profiles (flat equilibrium responses) and better reproducibility in SPR compared 
to CTCB 001. As shown in figure 6.11A CTCB 405 binds very cleanly to the T. brucei PFK surface 
in SPR; The sensorgram shows fast on rates and slow off rates, with the response reaching 
equilibrium at the higher concentrations. Also, the compound completely dissociates back to 
baseline. Furthermore, CTCB 405 gives excellent steady state plots such as that shown in figure 
6.11B. Its binding response has excellent reproducibility with an average standard deviation for 







Figure 6.11: CTCB 405 is an excellent control compound for measuring binding against TbPFK in 
SPR. 
A) SPR sensorgram for CTCB 405 titration against T. brucei PFK surface (Density = 1500 RU). 1:1 
binding model has been fitted to each sensorgram trace (black). Tested at 25 oC. B) Steady state 





6.2.6.2 Single point ranking by compound ‘binding response’ and ‘stability’. 
Single point ranking of CTCB compounds using SPR was carried out by measuring both the 
compound ‘binding response’ and ‘binding stability’ against a T. brucei PFK surface. All measured 
responses were reference subtracted and corrected for molecular weight. An explanation of SPR 
binding response measurements is given in section 2.5.3. Single concentrations of CTCB 
compounds were tested at 50 µM and later 10 µM as increasingly more potent compounds were 
developed.  
‘Binding response’ measurements look at the overall binding response (RU) of the compound, 
measured by the response at the ‘equilibrium’ phase of the sensorgram – measured 4 seconds 
before the end of the injection phase (figure 6.12). The concentration of the complex is 
proportional to the corrected response.  
  ‘Binding stability’ measures the binding response (RU) 5 seconds after the end of the injection 
phase, when the compound is dissociating from the PFK surface (figure 6.12). The binding 
stability and response of each compound was ranked against the response of the standard - 





Figure 6.12: Binding ‘response’ and ‘stability’ measurements taken in SPR single point compound 
ranking. 
Example sensorgram trace for a single concentration of compound. 1) Association phase – 
compound washed onto surface and binds as a function of concentration of compound. 2) 
Equilibrium phase – compound association and dissociation in equilibrium. ‘Binding response’ 
measurements taken during this phase. 3) Dissociation phase – compound no longer injected, 




The single point binding responses and stability measurements for a batch of 96 compounds 
against a low density TbPFK surface (1,500 RU) is shown in figure 6.14. The responses were 
grouped into 3 sections – ‘high’, ‘medium’ and ‘low’, relative to the repeats of the CTCB 405 
standard, shown in red. Generally, compounds within the ‘medium’ binding range were picked 
for further analysis. Compounds with responses much higher than CTCB 405 were assessed 
further; Very high binding responses suggest promiscuity in binding to the PFK surface. The 
maximum binding response ‘Rmax’ value relates to the binding capacity of the ligand surface – ie 
the response measured at saturation of the PFK surface. For a small molecule interaction with 
an immobilised protein the recommended Rmax is ~ 25 RU (GE Healthcare, n.d.). RUmax can be 
calculated by; 
𝑅𝑈𝑚𝑎𝑥 =  
𝑀𝑊𝑎𝑛𝑎𝑙𝑦𝑡𝑒
𝑀𝑊𝑙𝑖𝑔𝑎𝑛𝑑
∗ 𝑅𝑈 𝑜𝑓 𝑖𝑚𝑚𝑜𝑏𝑖𝑙𝑖𝑠𝑒𝑑 𝑙𝑖𝑔𝑎𝑛𝑑 ∗ 𝑛 
For CTCB 405 (MW = 364 Da) tested against a T. brucei PFK surface (monomer MW = 54 KDa) of 




∗ 1500 = 10 𝑅𝑈 
This theoretical response is accurate to the actual saturating response measured for CTCB 405, 
as seen in figure 6.14A. As an example, the compounds CTCB 501 and ‘552 have responses that 
deviate greatly from the theoretical RUmax for the compounds. According to the above equation, 
CTCB 501 and ‘552 (MW = 378 and 404 Da respectively) have a theoretical RUmax of 10 and 11 
RU. The actual measured responses of these compounds was much higher (figure 6.14A), 
suggesting either a >1:1 stoichiometry or promiscuous binding to the PFK surface. Other factors 
such as ‘carryover’ can also be assessed when single point responses demonstrate this 
behaviour. SPR single point binding measurements are a quick method of flagging ‘sticky’ or 
promiscuous binders of the target ligand. Both binding and stability responses are equally 
important to measure – an increase in stability relative to CTCB 405 suggests the PFK/inhibitor 
complex is more stable as a result of favourable binding interactions with the enzyme. The 
importance in measuring both parameters in single point screening is exemplified by the varying 
responses for compound CTCB 482 shown in figure 6.14. CTCB 482 had a strong binding 
response against TbPFK (figure 6.14A), but a poor stability score (figure 6.14B). CTCB 482 is a 
potent inhibitor of TbPFK – with an IC50 of 44 nM (ADP-Glo™ assay). Poor stability does not confer 




unfavourable changes in hydration upon compound binding, a lack of conformational freedom 











Figure 6.14: CTCB compound single point ranking in SPR. 
Batch of 93 CTCB compounds tested at a single concentration (10 µM) against low density (1,500 
RU) T. brucei PFK surface using SPR. CTCB 405 was used as a control at a concentration of 10 µM. 
A) Shows molecular weight-corrected binding responses. B) Shows the binding ‘stability’ 






6.3. Discussion : Ranking CTCB compounds using primary 
assays and SPR. 
We have described the development and use of two excellent primary assays for compound 
ranking against TbPFK. Both the PYK/LDH and ADP-Glo™ assays had excellent Z-prime values 
(0.57 and 0.63 respectively) resulting from reproducibility in IC50 measurements, reliable 
controls and good signal-to-noise ratios. Compound IC50 values correlated well with both PFK 
binding affinity (through SPR measurements) and parasite death (EC50 values), confirming that 
binding and inhibition of T. brucei PFK translated to effective parasite killing. Observed 
discrepancies in IC50 values between the orthogonal assays for some compounds did not result 
from a single controllable factor. Correlation between assays however was acceptable for the 
majority of compounds, and only a minority of compounds had significant discrepancies. 
Changing the protocol to account for potential discrepancies was unfeasible, considering there 
was not one unifying variable that was responsible for the discrepancies seen. The need for at 
least 2 orthogonal assays in inhibitor ranking is therefore important. Coupled with cross-
checking with other methods such as SPR, false positives or negatives can be avoided. This is 
paramount in a structure based approached to drug design, as information from initial testing 
of compounds against the target directly influences the next step in design of the compound. 
Single point ranking of compounds by both binding response and stability measurements is a 
quick and effective method of compound ranking provided a reliable ligand surface can be 
immobilised. As will be discussed in section 6.4.3, single point stability measurements can be 
used to estimate off rates. SPR therefore is an invaluable tool in the ranking and initial 
characterisation of binding for small molecules against a target. It allows large batches of 
compounds to be tested simultaneously. For smaller scale, week-to-week compound testing and 





6.4. Biophysical Characterisation of CTCB inhibitor compounds. 
Following ranking by potency against the enzyme and cultured parasites, biophysical 
characterisation of CTCB compound binding to T. brucei PFK was carried out. This work had 3 
main aims; To assess the kinetics of CTCB binding with PFK, determine the specificity of binding, 
and describe the mechanism of binding and inhibition.   
6.4.1 Compounds bind T. brucei PFK with high affinity in SPR experiments. 
SPR was used as the primary assay for measuring the binding kinetics of CTCB compounds to 
PFK. The following results were achieved by measuring compound binding against low density 
(~1500 – 3000 RU) surfaces of T. brucei and T. cruzi PFKs with N-terminal His6-tags. Initial SPR 
experiments were carried out with medium density surfaces (~12000 RU). It was found later 
however that with the low density surfaces, compound binding sensorgrams were significantly 
cleaner, fitted 1:1 binding models better, and fewer compounds showed ‘multiphasic’ binding 
behaviour. Higher density surfaces have a greater proportion of heterogeneous binding 
orientations. The binding response of these populations can add artefacts to the sensorgram, 
giving false evidence of multiphasic binding, affecting the fit of 1:1 models to the data.  
To measure the kinetic parameters in SPR, eight 2-fold serial dilutions of the compounds (12.5 
µM – 6 nM) were carried out in running buffer (10 mM HEPES, 150 mM NaCl, 0.05 % P20, 1 % 
DMSO, pH 7.4). Each concentration was run against a T. brucei His6-tagged PFK surface of 1500 
- 3,100 RU and a T. cruzi PFK surface of 1500 RU. Compounds were washed over the surface at 
30 µl.min-1 with a 15 second contact time before being washed off for 60 seconds with running 
buffer. Figure 6.15 shows a typical sensorgram trace with 1:1 binding model applied for CTCB 
531 against T. brucei. The Chi2 value gives an estimation of the goodness of fit of the 1:1 binding 

















Figure 6.15: CTCB 531 is a tight binder of PFK - as measured in SPR. 
CTCB 531 titration (12.5 µM – 6 nM) against a low density (~1500 RU) T. brucei PFK surface 
measured in SPR. A) Sensorgram for CTCB 531 titration with 1:1 binding model applied (black). 
B) Plot of steady state responses of CTCB 531 titration against T. brucei PFK surface. 0.46 µM 








The calculated binding parameters for a range of tight binding CTCB compounds against a low 
density (3100 RU) T. brucei PFK surface are given in table 6.3. Both steady state (SS) and kinetic 
Kd values from 1:1 binding fits have been given. IC50 values as measured by the ADP-Glo™ assay 
are also given. While not directly comparable, the affinities (Kd) of the compounds as measured 
by SPR closely match the IC50 values of the compounds. There are of course some exceptions; 
CTCB 486 for example is a potent inhibitor of T. brucei PFK (IC50 = 92 nM). It had a proportionally 
poor affinity (874 nM or 470 nM) as measured from either kinetic or steady state plots in SPR. 
This may be a result of comparing the inhibition of PFK in free solution against when it is 
covalently tethered to the SPR chip surface. However, as can be seen in table 6.3 each of the 
reported compounds are structurally similar, with only slight differences in the side chains, and 
each binds in a similar orientation (per. comm. Iain McNae UoE). TbPFK was uniformly orientated 
to the N-terminal his6-tag during surface generation. Despite a uniformity in PFK orientation on 
the SPR chip surface,  dynamic loops that may be sterically hindered or interrupted from 
tethering the PFK tetramer to the surface and thus may result in lower affinity when measured. 
CTCB 486 has the longest side chain of the compounds shown in table 6.3 - increasing the chance 
of interactions with these dynamic loops that form a lid over the CTCB binding pocket. This may 
explain the discrepancy between SPR-measured Kd and IC50 values for compounds such as CTCB 
486. Again the importance of a number of measures of inhibition and binding when selecting 















  SS   Kinetic   













0.197 0.093 0.05 0.082 0.958 0.079 0.41 
CTCB 531 
 
0.139 0.164 0.17 0.094 0.585 0.055 0.47 
CTCB 470 
 
0.216 0.203 2.84 0.173 0.156  0.027 1.34 
CTCB 540 
 
0.650 0.311 2.01 0.120 0.217 0.026 1.22 
CTCB 480 
 
0.199 0.217 1.07 0.154 0.265 0.041 1.63 
CTCB 460 
 
0.105 0.237 1.16 0.165 0.381 0.063 1.63 
CTCB 461 
 
0.319 0.330 1.80 0.301 0.595 0.179 1.48 
CTCB 486 
 
0.092 0.874 0.69 1.06 0.443 0.470 0.30 
 
Table 6.3: Kinetic parameters for a range of CTCB compounds against a T. brucei PFK surface in 
SPR. 
Kinetic values were measured from titrations of CTCB compounds tested against a low density 
(3,200 RU) T. brucei PFK surface. ‘SS’ = steady state measurements. Chi2 relates to goodness of 























































6.4.2 CTCB compound affinities are driven by dissociation rates. 
The range in affinities (Kd) of the CTCB compounds results from varying dissociation rates (koff). 
This is shown in figure 6.16, where association and dissociation rate constants have been plotted 
against affinity constants for a batch of CTCB compounds against T. brucei PFK as measured using 
SPR. The association constants of CTCB compounds with a range of affinities stay relatively 
constant (~0.5 µM-1.s-1), while the dissociation rate constants drop (dissociation of the PFK/CTCB 
complex is slower) as the affinity increases. Unlike association constants (kon), dissociation 
constants are not a function of compound concentration, but of the stability of the 
compound/protein complex in the absence of free compound. Provided the 1:1 interaction 
model is a good fit, decreasing kinetic Koff measurements from SPR are therefore a good measure 




Figure 6.16: CTCB compound affinities are driven by dissociation rates (koff). 
Association (kon) and dissociation (koff) rate constants plotted against compound affinities (Kd) for 
28 CTCB compounds tested against a low density (3100 RU) T. brucei PFK surface using SPR.  A 
line of best fit has been applied to both the association constant and dissociation constant data 





6.4.2.1 Properties determining slow and fast dissociation rates. 
No correlation was observed when SPR-derived dissociation rates (koff) were plotted against 
compound molecular weight, pKa or pKb (data not shown). An interesting observation was made 
however when comparing two compounds at opposite ends of the spectrum of dissociation 
rates shown in figure 6.16; CTCB 531 (koff = 0.055 s-1) and CTCB 431 (koff = 0.971 s-1) differ only by 
the replacement if a chlorine atom with a fluorine on the dihalo-benzyl ring (table 6.4). 
 kon (µM-1.s-1) koff (s-1) Kd (µM) 
CTCB 431 
 
0.460 0.971 2.110 
CTCB 531 
 
0.585 0.055 0.094 
CTCB 589 
 
0.490 0.052 0.106 
Table 6.4: Could the dilaho-benzyl ring define compound dissociation rates? 
 
Both CTCB 589 and CTCB 531 with the chloro-fluoro- group in place of chloro-chloro have 
significantly slower dissociation rates over CTCB 431. While chemically the chlorine and fluorine 
atoms will bind with similar Van der Waals interactions in the pocket, changes to the hydration 
shell in the pocket and/or the rotational degrees of freedom of the compound in the pocket may 
contribute to the differing dissociation rates due to the difference in atomic size. No other 
comparisons could be made due to insufficient SPR data to compare more than a pair of 


























6.4.3 Dissociation constants can be estimated from single point measurements in 
SPR. 
Estimated dissociation constants (koffest) were calculated for CTCB compounds using single point 
binding stability measurements and the known kinetic data for CTCB 405; Stability 
measurements are a measure of the response 5 seconds after the compound has started to be 
washed off the chip, during the dissociation phase. During this phase dissociation of the 
protein/inhibitor complex is not determined by concentration; koff can be estimated from a 
single concentration when compared to a known dissociation constant for a similar compound 
(CTCB 405). The ratio between stability measurements of the control compound CTCB 405 and 
another compound must be proportional with the ratio of dissociation constants, provided 
association rates are similar (which they are – see section 6.4.2).  The estimated dissociation 
constant for a compound ‘X’ is therefore given as: 
𝑘𝑜𝑓𝑓(𝑒𝑠𝑡) 𝐶𝑚𝑝𝑑 𝑋 =  
𝐾𝑜𝑓𝑓 𝐶𝑇𝐶𝐵 405
(𝑆𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝐶𝑇𝐶𝐵 405 ∶ 𝑆𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑐𝑚𝑝𝑑 𝑋)
 
As shown in figure 6.17, there is good correlation between estimated and measured dissociation 
constants for a range of CTCB compounds tested. This is a useful tool for accurately estimating 
dissociation rate constants for compounds, when time or other resources prevent full kinetic 
characterisation in SPR.  
 
Figure 6.17: Dissociation constants can be accurately estimated from single point measurements. 
Correlation plot of dissociation constants estimated from single concentration (10 µM) ‘stability’ 
measurements of CTCB compounds, plotted against measured dissociation constants from serial 




6.4.4 CTCB compounds are not promiscuous binders. 
HSA is a monomeric protein with multiple roles involving carrying, holding or transporting toxins, 
proteins and small biomolecules in the bloodstream (Fasano et al., 2005). HSA has a multitude 
of clefts, but two main drug binding sites – named ‘Sudlow’s sites’ I and II - bind a number of 
commonly known drugs such as Warfarin and Ibuprofen, respectively. The abundance and 
binding abilities of HSA in the blood make it an obvious first hurdle to clear when it comes to 
effective pharmacokinetic design of drug molecules – promiscuous compounds will be bound by 
HSA, reducing the bioavailability of the drug in the bloodstream. 
To test for general promiscuity in CTCB compound binding, an SPR chip was prepared with a 
reference cell, a T. brucei PFK surface and a surface of human serum albumin (HSA). See section 
2.5.3.4 for a full protocol. A homogenous HSA surface was made using fatty acid and globulin-
free human serum albumin, coupled using standard amine coupling methods (GE Healthcare, 
n.d.). The final HSA surface had a density of 12,600 RU. CTCB compounds were first tested 
against the HSA surface as single point concentrations (50 µM) in running buffer (10 mM HEPES, 
150 mM NaCl, 0.05 % P20, 1 % DMSO, pH 7.4), with CTCB 001 repeated as a standard control. 
Serial dilutions of selected compounds (titration of 50 - 0.39 µM compound) were then tested 
against the surface to generate steady state Kd values against the HSA surface. Warfarin was 
used as a positive control for HSA binding. Figure 6.18 shows the single point binding responses 
of 46 CTCB compounds, with steady state Kd values given in brackets as a reference.  
The standard compound (CTCB 001) had a surprisingly high affinity for the HSA surface (Kd = 48 
µM), however as can be seen in figure 6.18 the remainder of the CTCB compounds tested had 
very low affinities (>100 µM) for HSA. The calculated steady state affinity for the positive control 
Warfarin was 12 ± 3 µM, in agreement with published affinities for HSA (19 – 39 µM) 





Figure 6.18: CTCB compounds bind very weakly to human serum albumin (HSA). 
Molecular weight-corrected responses of CTCB compounds (black dots) tested at 50 µM against 
human serum albumin surface (12,600 RU). CTCB 001 (red squares) was repeated to test quality 
of surface. Numbers in brackets correspond to steady-state affinity (Kd) of compound when 
tested against the same HSA surface as a 2-fold serial dilution.  
Measured affinities of CTCB compounds for HSA were plotted against available mouse plasma 
protein binding data and showed a correlation between affinity for HSA and plasma protein 






Figure 6.19: CTCB compound affinity for HSA correlates with mouse plasma protein binding. 
Steady state affinity (Kd) values measured using SPR against an immobilised surface of human 
serum albumin (HSA). Corresponding plasma protein binding values measured at a concentration 






6.4.5 Thermodynamics of CTCB compound binding using SPR. 
The thermodynamics of binding for three tight binding CTCB compounds was investigated using 
SPR. This was achieved through titrations of compound against a T. brucei PFK surface (3,000 
RU) at 13 temperatures ranging from 5 – 41 oC. This was carried out for compounds CTCB 405, 
‘470 and ‘589. Kinetic Kd values were calculated from 1:1 binding models applied to the 
sensorgrams at each temperature. Figure 6.20 shows the data obtained for CTCB 405.   
The affinity constants Kd measured at each temperature are related to the enthalpy and entropy 
changes of the reaction through the equation for Gibbs free energy; 
𝛥𝐺 =  −𝑅𝑇𝐼𝑛𝐾 and ∆𝐺 =  ∆𝐻 − 𝑇∆𝑆 
Where K = Kd , R = gas constant (taken as 8.314 J/mol-K) and T = temperature (Kelvin). The 
temperature dependence on changes in free energy can described and plotted according to the 




∆ °)     van’t Hoff equation 
Where Kd = equilibrium  dissociation constant, R = universal gas constant, T = absolute 
temperature (K) ΔHo = entropy change and ΔSo = entropy change.  
A van’t Hoff plot, like that shown for CTCB 405 in figure 6.20 can then be used to calculate the 
enthalpic contribution (ΔHᵒ) – by taking the slope of the plot which gives ΔHo/R. The entropic 
contribution (ΔSᵒ) can be measured by taking the y-axis intercept, which gives ΔSo/R. With these 
parameters the free energy (ΔGᵒ) can be calculated. The enthalpic, entropic and free energy 



















Temp. (oC) 5 8 11 14 17 20 23 26 29 32 
Kd  
(nM) 
25.5 33.8 43.8 56.4 73.1 92.7 109 131 153 189 
Kon 
(µM-1.s-1) 
0.21 0.24 0.31 0.34 0.41 0.50 0.62 0.77 0.89 1.10 
Koff 
(x10-3 s-1) 
5 8 13.5 19.1 30 46.7 67.8 98.2 136 211 
 
Figure 6.20 Thermodynamics of CTCB compound binding measured by SPR. 
Thermodynamic profiling of CTCB 405 binding to T. brucei PFK surface in SPR. A) Van’t Hoff 
thermodynamic plot B) Sensorgram traces for CTCB 405 (red) measured at 26 oC with 1:1 binding 
model (black) fitted. C) Kinetic parameters for CTCB 405 at each temperature tested. Data for 



















































CTCB 405 113 -9.48 -10.77 -1.29 0.24 
CTCB 470 130 -9.40 -11.24 -1.84 0.26 
CTCB 589 106 -9.520 -11.72 -2.20 0.22 
 
Table 6.5: Thermodynamic parameters for CTCB compounds binding to T. brucei PFK in SPR. 
Data measured from CTCB compound titrations (5 µM – 62 nM) against low density T. brucei PFK 
surface (3100 RU) using SPR. Parameters calculated from van’t Hoff analysis curves. All 
parameters relate to thermodynamics of binding at 26 oC.  
 
As expected from a biological system, the ΔGᵒ values for all three compounds are the same (~9.5 
Kcal.mol-1), with different enthalpic and entropic contributions. As the CTCB compounds tested 
have similar affinities and bind in the same pocket, a constant ΔGᵒ value is expected. ΔCp is a 
measurement of the change in heat capacity for the system – it tells us how much heat is added 
to the system per unit temperature rise. For the compounds above, ΔCp has a positive value, 
suggesting that upon binding there is a movement of charged or polar groups. A negative ΔCp 
value suggests a hydrophobic group has been moved during binding (Perozzo, Folkers, & 
Scapozza, 2004b). This ΔCp value contributes very little, but is important to include when 
calculating the ΔGᵒ of the system. Taking ΔCp into consider the equation for calculating free 
energy becomes: 




Where ΔCpo = change in heat capacity and To is the reference temperature (298K) (Martin A. 





6.4.6 CTCB compounds bind T. brucei PFK in a 1:1 stoichiometry. 
CTCB compounds tested against TbPFK in SPR fitted 1:1 binding models well, with Chi2 values for 
the fit of <2.0. To comprehensively confirm this binding stoichiometry and to characterise the 
thermodynamics of binding, compounds were also tested using Isothermal Titration Calorimetry 
(ITC) experiments. ITC measures the change of heat upon the binding of analyte to ligand in a 
thermally isolated (adiabatic) cell. The apparatus includes two cells: a sample cell containing the 
macromolecule(PFK) and a reference cell. The ligand (CTCB compound) is held in a syringe and 
titrated into the sample cell. A constant power is applied to the reference cell and acts as a 
feedback circuit to the sample cell. This maintains the two cells at the same temperature (ΔT=0). 
Upon binding of ligand to protein, heat is given out or taken in. This temperature difference 
between the cells is detected by a calorimeter and the power applied to the sample cell is 
adjusted accordingly. The power used to maintain ΔT = 0 between the cells is the baseline. The 
change in reference power upon ligand and analyte interaction is measured as peaks (in 
endothermic reactions) or troughs (exothermic) showing the change in ‘reference power’ over 
time (µcal/sec). The heat evolved or absorbed during binding is quantified by integration of 
these peaks (figure 6.21)(Holdgate, 2001). ITC offers the ability to directly measure the enthalpy 
change from binding. As well as this ITC can be used to simultaneously measure the molar ratio 






To carry out thermodynamic characterisation of CTCB compounds binding to T. brucei PFK using 
ITC, compounds were titrated into a cell containing a solution of PFK (Figure 6.21).  
 
Figure 6.21 : ITC assay schematic. 
CTCB compound is titrated into a cell containing PFK. The change in temperature ΔT is accurately 
measured by measuring the power (µcal/sec) required maintain temperature between the 
sample and reference cells so that ΔT=0. Image adapted from Freyer & Lewis, 2008. 
 
The following ITC results were carried out in HBS buffer (10 mM HEPES, 150 mM NaCl, 0.005% 
p20, pH 7.4, 1% DMSO). Proteins stocks were desalted (HiTrap 5ml Desalting column, GE 
Heathlcare) with the above buffer to ensure minimal buffer mismatch between ligand and 
analyte when injected. Solubility limits for all compounds were tested in this HBS buffer system 
prior to ITC experiments. This buffer system matched that used in the SPR experiments. CTCB 
compound titrations consisted of 16 injections with 180 second delay between injections and 
750 rpm stirring at 25 oC. All solutions were degassed prior to use. A full protocol can be seen in 
section 2.5.4. Controls included: 
 Injection of each CTCB compound into buffer - to assess heat of dilution of ligand. 
 Injection of buffer into protein – measure heat of dilution of analyte (this is generally 







 Injection of buffer into buffer – an instrument blank. Generally negligible. 
For the data show below the heat of dilution is negligible. Data for the first injection in each 
experiment was omitted. Data was analysed using a ‘one-site’ model assuming one binding site 
(one compound molecule per TbPFK monomer) using the dedicated MicroCal analysis software. 
Details of ITC data analysis can be found in section 2.5.4.1. 
The CTCB compounds performed well in ITC. The compound titrations had minimal baseline 
noise, heat of dilution, no evidence of buffer mismatch and relatively large heat changes for 
noncovalent binding interactions - greater than the average value of 5 – 10 Kcal mol-1 (Perozzo 
et al., 2004b) . Figure 6.22 shows an example trace for CTCB 405 titrated against TbPFK. 
 
 
Figure 6.22: CTCB 405 binds PFK in a 1:1 stoichiometry as measured by ITC. 
ITC trace of titration of 150 µM CTCB 405 into 12.8 µM T. brucei PFK at 25 oC. Top panel shows 
raw ITC trace for each injection (thermogram), starting from highest to lowest injections of 
compound (left to right). Bottom panel shows integrated data of each injection (Kcal/mol) (Y-




Binding stoichiometry can be determined from the molar ratio of compound: protein at the 
equivalence point of the ITC curve.  For all of the CTCB compounds where a reliable trace was 
measured, the compounds bound with an almost perfect 1:1 stoichiometry with T. brucei PFK. 
Table 6.6 shows the results of all compounds plotted.  
Measured Kd values match nicely with those measured in SPR (see table 6.3, section 6.4.1 ). 
Measured free energy contributions (ΔGᵒ) are also in agreement with those calculated from SPR 
thermodynamic profiling for CTCB 405, ‘470 and ‘589 via van’t Hoff analysis (table 6.5), and 
within the typical range for drug-like molecules (-7 to -12 Kcal/mol)(Holdgate, 2001). All 
compounds tested bound with negative ΔHᵒ and ΔSᵒ contributions – suggesting CTCB compound 
binding with TbPFK has favourable hydrogen bonding and hydrophobic interactions (Freyer & 
Lewis, 2008). These also agreed with the average ΔHᵒ and TΔSᵒ values for drug-like molecules of 
-19 to +20 Kcal/mol and -14 to +10 Kcal/mol respectively (Holdgate, 2001).  All of the compounds 
tested in ITC possessed the azaindole scaffold and thus bind in roughly the same orientation, so 
the similarity in Gibbs free energy (ΔGᵒ) contributions is to be expected (see section 6.6.1).  
The thermodynamic parameters for CTCB 480 and 481, which represent the enantiomers of a 




















1.05 ± 0.02 0.092 ± 
0.002 
-13.6 ± 0.26 -4.03 -9.57 
CTCB 421 
 
1.12 ± 0.03 0.370 ± 
0.43 
-2.6 ± 0.17 6.17 -8.77 
CTCB 435 
 
1.01 ± 0.02 0.215 ± 
0.09 
-14.4 ± 0.13 -6.01 -8.6 
CTCB 470 
 
1.24 ± 0.02 0.218 ± 
0.06 
-9.53 ± 0.23 -0.44 -9.09 
CTCB 480 
 
1.04 ± 0.01 0.204 ± 
0.08 
-14.2 ± 0.18 -5.09 -9.11 
CTCB 481 
 
1.02 ± 0.01 0172 ± 
0.08 
-14.1 ± 0.17 -4.98 -9.12 
CTCB 531 
 
1.28 ± .01 0.158 ± 
0.05 
-11.5 ± 0.11 -2.24 -9.26 
CTCB 589 
 
1.20 ± 0.01 0.090 ± 
0.02 
-11.3 ± 0.17 -1.66 -9.64 
 
Table 6.6: Thermodynamic parameters of CTCB compounds measured by ITC against T. brucei PFK. 
All experiments carried out at 25 oC in HBS buffer (10 mM HEPES, 150 mM NaCl, 0.005% p20, pH 
7.4, 1% DMSO). Data calculated from ‘one site’ binding model plots (MicroCal™ Origin® analysis 
software). ΔGᵒ values have been calculated using the equation ∆𝐺 =  ∆𝐻 − 𝑇∆𝑆, given T = 





















































6.4.6.1 Normalised ITC thermodynamics are more accurate. 
To allow for a better comparison between compounds and with SPR-derived thermodynamic 
values, ΔHᵒ, ΔSᵒ and ΔGᵒ were normalised for a fixed stoichiometry of 1.0. This involved re-
plotting the ITC data and adjusting assumed syringe (compound) concentration until a 
stoichiometry of 1 ± 0.05 was achieved. This assumed that there was no error in TbPFK 
concentration between assays (likely as the same working stock of protein was used for all 
assays) but rather an error in the absolute compound concentration. All ITC assays were carried 
out over a 48 hour period. The normalised thermodynamic parameters for CTCB 405, 470 and 









CTCB 405 0.092 ± 0.002 -13.5 ± 0.25 -4.03 -9.58 
CTCB 470 0.588 ± 0.13 -14.9 ± 0.25 -5.66 -9.24 
CTCB 589 0.114 ± 0.02 -13.3 ± 0.20 -3.67 -9.63 
Table 6.7 : normalised ITC thermodynamic values for CTCB 405, 470 and 589. 
 
Normalising the ITC fits to achieve a stoichiometry of 1.0 had a significant effect on the ΔHᵒ value 
for CTCB 470 and 589. The thermodynamic parameters calculated for these two compounds 
shown in table 6.6 were calculated with fits showing stoichiometries of 1.24 and 1.20 
respectively. PFK monomers cannot have 1.2 binding sites, and so by correcting for potential 
errors in absolute compound concentration to achieve a fit with N fixed to 1.0, the 






6.5. Discussion: SPR and ITC as biophysical tools in structure-
based design. 
SPR proved to be a remarkably information rich method of analysing CTCB compound binding. 
Alongside the two primary assays, SPR was used in compound ranking, estimation of off-rates, 
steady state and kinetic affinity measurements, analysis of binding stoichiometry and 
thermodynamic profiling of the inhibitor compounds. Single point assays in SPR offer a fast and 
accurate method of affinity ranking large batches of compounds. Estimated off rates (koffest) 
described in section 6.4.3 were found to be accurate and reliable when compared to the actual 
data measured from compound titrations. Thermodynamic profiling was carried out for only 3 
CTCB compounds, but produced data on enthalpic and entropic measurements and free energy 
changes (ΔGᵒ) that agreed with those measured by ITC. Thermodynamic profiling is invaluable 
in structure-based drug design – giving further insights into compound binding beyond basic 
affinity measurements.  
Comparing CTCB 405 and CTCB 470 as an example, we can make further judgments on the drug 
candidates; CTCB 405 and ‘470 differ by a bromine replacing a chlorine on the dichloro-benzene 
ring, as can be seen in figure 6.23B. Looking at the thermodynamic profile of the two compounds 
(figure 6.23C) we can see that despite the free energy of binding (ΔGᵒ) being the same for each 
compound, there is a significantly more negative enthalpic contribution (ΔHᵒ)  for CTCB 470 (>1 
Kcal/mol, Std. dev. = 0.25 Kcal/mol). Enthalpic contributions result from the release of water 
molecules and/or from increased interactions such as hydrogen bonding, Van der Waals 
interactions or salt bridges. As we can see in figure 6.23D, the additional electron shell in the 
bromine of CTCB 470 gives a much larger density in the X-ray structure of the compound bound 
to T. brucei PFK. The Van der Waals radii of chlorine and bromine are 175 pm (1.75 Å) and 185 
pm (1.85 Å) respectively. Increased Van der Waals interactions from the bromine of CTCB 470 
compared with the chlorine of CTCB 405 may explain the slightly greater enthalpic contribution 
to binding for ‘470 over ‘405.  
Entropic changes can contribute either positively (+TΔSᵒ) or negatively (-TΔSᵒ) to the free energy 
of binding. Entropic changes can arise from a loss in the degrees of freedom in movement of all 
the molecules involved in the interaction. The more negative TΔSᵒ value for CTCB 470 may be a 
result of the larger bromine atom restricting movement compared to CTCB 405 due to steric 
bulk. Combined with the kinetic information given in figure 6.23C, we can make the judgement 




weaker binder and inhibitor of T. brucei PFK (KD = 173 nM over 82 nM, IC50 = 216 nM over 197 of 
CTCB 405), it has a much slower off rate (0.027 s-1 over 0.079 s-1), and will therefore have a longer 
half life when bound to the PFK target. Added to the thermodynamic information mentioned 
above, we can see that CTCB 470 is a marginally better drug candidate, with minimal enthalpic 
penalties to overcome to allow binding. Coupled with inhibition assays, this example shows the 











SPR thermodynamic profiles: 
  ITC/SPR ITC/SPR ITC/SPR  










CTCB 405 113 -9.48 / -9.58 -10.77 / 13.5 -1.29 / -4.03 0.24 
CTCB 470 130 -9.40 / -9.24 -11.24 / 14.9 -1.84 / 3.67 0.26 
 
 









CTCB 405 0.958 0.079 0.082 0.197 




Figure 6.23: Complete analysis of CTCB 405 and ‘470 compound binding. 
A) Chemical structures of CTCB 405 and ‘470. B) Thermodynamic parameters from compound 
binding against TbPFK measured by SPR and ITC. C) Inhibition and kinetic binding data of 
compounds against TbPFK derived from ADP-Glo™ assay and SPR. D) TbPFK crystal structure 
(lines) with CTCB 405 bound (Cyan sticks). Density maps for CTCB 405 (cyan mesh) and CTCB 470 


















Extra density due to 




6.6. Structural characterisation and mechanism of inhibition. 
6.6.1 Binding poses of CTCB compounds. 
A number of X-ray structures of T. brucei PFK with various CTCB compounds bound have been 
determined. All structures were solved by Iain McNae of the Walkinshaw Group at the University 
of Edinburgh. Crystals were obtained by either co-crystallisation or ligand soak methods (Hassell 
et al., 2006). Diffraction data was collected remotely at the Diamond Light Source synchrotron 
facility in Oxfordshire.  
Fragments 
The 3,4-dihalobenze group is fundamental to CTCB compound potency against T. brucei PFK. 
Figure 6.25 shows the binding position of a fragment – CTCB 012 within the binding pocket of 
TbPFK. The chlorine on the 4-position of the benzyl ring forms a particularly important ‘halogen 
bond’. Sirimulla et all describe halogen bonds as;   
“A short, noncovalent C−X···D−Z interac on, where D is a halogen bond donor, C−X is a carbon-
bonded chlorine, bromine, or iodine; D−Z is a carbonyl, hydroxyl, thiol, aroma c ring, charged 
carboxylate, phosphate group, or amine, and the X···D distance is less than or equal to the sums 
of the respective van der Waals radii.” (Sirimulla, Bailey, Vegesna, & Narayan, 2013).  
When covalently bound to a carbon atom, halogens possess a positive nuclear charge as well as 
a ring of electron density, this allows halogen binding to both an electron negative region and a 
region of positive electrostatic potential (Sirimulla et al., 2013). Figure 6.24 shows the electron 
density map of a halogen bound to carbon atom. 
 
 
Figure 6.24: When covalently bound, halogen atoms possess electrophilic and electronegative 
regions. 
Image adapted from Sirimulla et. al 2013. A) Representation of electron distribution in bound 
halogen atom. B+C) Electrostatic potential map of CH3I molecule. Prepared using ‘Gaussian 9’ 





As a consequence of halogen binding, the chlorine in the 4-position of the benzyl ring of CTCB 
compounds makes contacts both with the positively charged nitrogen of the backbone of 
ASP199, and the lone electron pair oxygen on the carbonyl group of GLY197. The chlorine 
atom in the 3-position of the dichlorbenzyl ring most likely makes purely Van der Waals 
contacts. Both halogens in the 3- and 4- positions are required and form the basis of CTCB 
compound binding. The small fragment 3,4-dichloroaniline, when tested against TbPFK had a 
remarkable IC50 of 3.3 µM as measured in the PYK/LDH assay.  
 
 
Figure 6.25: Binding of CTCB 012 as example of halogen binding in 3,4-dihalo ring of CTCB 
compounds. 
The chlorine atom in the 3-position of the dichlorbenzyl ring makes halogen bond contacts with 
ASP199 and GLY197 of TbPFK. Image made using Pymol ver. 2.0. Structure solved by Dr Iain 









IC50 = 0.8 µM 




Ligand efficiency (LE) describes the energy of binding per non-hydrogen atom of a ligand (CTCB 
compound) to a receptor (PFK enzyme)(Kuntz, Chen, Sharp, & Kollman, 1999). It can be 
calculated from IC50 values according to the equation: 
𝐿𝐸 = 1.37(− log 𝐼𝐶50)/𝑁 
Where N = the number of non-hydrogen atoms in the ligand structure. (Chen, Engkvist, & Kogej, 
2015) 
 Small fragments such as 3,4-dichloroaniline (CTCB 097) (162 Da) or CTCB 012 (227 Da) have 
extraordinary ligand efficiency – with LE values of 0.85 and 0.61 µM respectively. These are 
impressive given CTCB 360, one of the most potent CTCB compounds has an LE value of 0.49 
(table 6.8).  
Compound MW (Da) IC50 (µM) Ligand efficiency 





162 3.1 0.85 





227 0.8 0.61 






293 0.1 0.49 
Table 6.8: CTCB fragments demonstrate high ligand efficiency. 
Ligand efficiency calculated as described above. IC50 values measured in ADP-Glo assay.  
 
The binding position of the 3,4-dichlorobenzyl ring within TbPFK is sufficient to block the leucine 
residue that is normally docked in the CTCB binding pocket, as revealed in the apo TbPFK 
structure 2HIG. Figure 6.26 shows the position of CTCB 012 in the CTCB binding pocket of TbPFK, 

















Figure 6.26: Binding of CTCB 012 prevents normal docking position of Leu232. 
Apo-TbPFK structure (2HIG) shown in grey cartoon form. Binding position of CTCB 012 (sticks – 
cyan) in CTCB binding pocket (surface – pink). Asp229 loop of 2HIG structure has been coloured 
orange, with Leu232 shown (sticks – orange). Alignment of 2HIG to TbPFK-CTCB12 RMS = 0.792 
Å. Structure solved by Dr Iain McNae (2HIG)(CTCB 012 structure unpublished at time of writing). 
As can be seen in figure 6.26, the normal docked position of Leu232 overlaps with the 
dichlorobenzyl ring of CTCB 012.The binding of smaller CTCB compound fragments such as CTCB 
012 effects only the position of the Asp229 loop. In the crystal structures of similar fragments, 
no significant changes are made to the positions of the Arg173, inserted or N-terminal loops that 
also surround the active site (data not shown).  
Azaindoles. 
The azaindole family of compounds are the most numerous of the different scaffold types 
making up the 636 CTCB compounds designed against TbPFK. As well as the halogen contacts 
made by the 3,4-dichlorobenzyl ring (figure 6.25), the azaindoles make additional hydrogen 
bond contacts with one of two proximal aspartate residues – Asp199 or Asp275. Figure 6.27 











Figure 6.27: The azaindole CTCB 360 adopts 2 binding positions in TbPFK. 
A) Binding orientation 1: CTCB 360 makes hydrogen bond contacts (yellow dashes) with Asp199 
in TbPFK. B) Binding orientation 2: CTCB 360 makes hydrogen bond contacts with Asp275 in 










IC50 = 0.07 µM 







To gain potency through additional contacts with TbPFK residues out with the CTCB binding 
pocket, the next generation of azaindole compounds included groups branching off the 
azaindole ring. It was found that basic groups enhanced the potency of compounds against 
cultured T. b. brucei 427 strain parasites (data not shown).  
Second generation azaindoles. 
Second generation azaindoles added various basic groups to the azaindole ring in an 
attempt to pick up additional interactions outside the CTCB binding pocket. The crystal 
structure of CTCB 405 bound in TbPFK shown in figure 6.28 is a good example of the 
binding pose adopted by the second generation azaindoles; The amine group bends out 
of the pocket to make an additional hydrogen bond interaction with Asp199 residue 
(figure 6.28). Similar to the smaller fragments, the azaindoles binding pose only 
interfered with the Asp229 loop, and not any of the additional dynamic loops 
surrounding the active site. 
 
 
Figure 6.28: Second generation azaindole CTCB 405 makes additional hydrogen bond with Asp199. 
Azaindoles, like CTCB 405 shown here make 2 hydrogen bond contacts (yellow dashes) with 




IC50 = 0.19 µM 













These compounds adopt an orientation that pushes the N-terminal loop out of position. In Apo 
TbPFK structures, ATP-bound TbPFK structures and structures with the CTCB scaffold types 
mentioned above, the N-terminal loop forms a lid over the active site. The consequences of this 
binding orientation, and a more detailed description of the binding mode of pyrazoles in seen in 
section 6.4.3. 
6.6.2 CTCB compounds inhibit T. cruzi PFK with increased potency. 
To compare and contrast binding affinities of CTCB compounds for T. brucei and T. cruzi PFKs, 
high density (~12,000 RU) His6-TbPFK and His6-TcPFK surfaces were made and tested using SPR. 
Full experimental details can be found in section 2.5.3. As an example, a comparison of the 
sensorgrams for CTCB 360 titrated against T. brucei and T. cruzi PFK surfaces is shown in figure 
6.29.  
The differences in binding were striking; Compared to the TbPFK surface CTCB 360 has a much 
slower off-rate with TcPFK that can be observed from the sensorgram trace alone (figure 6.29). 
The slower off rate for the inhibitor against T. cruzi PFK translates to a ten-fold tighter binding 
constant (kinetic Kd = 7 µM against T. brucei PFK compared with 0.2 µM against T. cruzi PFK). 
Increased potency against the TcPFK enzyme activity compared with TbPFK was also observed; 
CTCB 360 was a stronger inhibitor against T cruzi PFK – with an IC50 of 22 nM compared with 120 
nM against the T. brucei enzyme, as tested in the PYK/LDH assay. 
Table 6.9 shows collated data comparing inhibition and binding affinity of a selection of CTCB 
compounds against T. brucei and T. cruzi PFKs. All SPR data given is from a high-density surface 
(12,000 RU), and so KD values are higher than those measured from the low-density surfaces.  







T. brucei T. cruzi T. brucei T. cruzi 
CTCB 001 
 
Sulph. 4.9 0.9 0.31 ± 0.1 0.03 ± 0.04 
CTCB 012 
 



















SPR Kd (µM)  Enzyme IC50 (µM) 
CTCB 097 
 
Frag. ND ND 1.99 ± 0.25 2.27 ± 0.18 
CTCB 189 
 
Pyra. ND ND 0.34 ± 0.18 0.27 ± 0.11 
CTCB 293 
 
Aza. 42.5 7.6 0.270 ± 0.17 0.05 ± 0.03 
CTCB 360 
 
Aza. 7.0 0.2 0.100 ± 0.03 0.020 ± 0.02 
CTCB 366 
 
Pyra. ND ND 2.59 ± 0.36 2.67 ± 0.22 
CTCB 374 
 
Pyra. ND ND 0.29 ± 0.06 0.26 ± 0.03 
CTCB 386 
 
Pyra. ND ND 0.41 ± 0.03 0.47 ± 0.03 
CTCB 405 
 
Aza. ND ND 0.270 0.05 
CTCB 589 
 
Aza. ND ND 0.96 ± 0.06 0.31 ± 0.01 
  
Table 6.9: CTCB compounds have greater potency and bind tighter to TcPFK than TbPFK. 
Enzyme IC50 values calculated using PYK/LDH assay. SPR-derived Kd values were calculated using 
high density (~12,000 RU) surfaces. ‘Frag.’ = fragment, ‘Sulph.’ = sulphonamide, ‘Aza.’ = 
































































The data in table 6.9 suggests that the chemical scaffold of the compound dictates the difference 
in affinities and potency of the CTCB compounds between TbPFK and TcPFK; The azaindole 
compounds show a much greater difference in affinity for TcPFK over TbPFK than the 







Figure 6.29: CTCB 360 demonstrates a remarkable jump in affinity to T. cruzi PFK over T. brucei PFK 
in SPR 
SPR sensorgram traces for CTCB 360 titrations against T. brucei (12,000 RU) and T. cruzi (8,000 
RU) surfaces. 1:1 binding models (black) have been fitted to each sensorgram. IC50 values for 




6.6.3 Increased inhibition of TcPFK may reveal opportunity for compound 
development. 
Data shown in table 6.9 demonstrates the increase in inhibitor potency and compound affinity 
for TcPFK over TbPFK. The two enzymes share 77% identity in sequences, and LiPFK, TbPFK and 
TcPFK are homologous in their ATP, F6P and CTCB binding pockets (section 3.2.1, chapter 3). 
Increased CTCB potency against T. cruzi PFK therefore must result from interactions outside the 
CTCB binding pocket.  
Four dynamic loops surround the trypanosomatid PFK binding site and CTCB pocket; The Arg 
173 loop (res. 170 – 178), Asp 229 loop (res. 225 – 235) and inserted loop (res.329 – 348) 
surround the active site and contribute to the catalytic activity of the PFK enzyme. An additional 
loop, the ‘N-terminal loop’ (res. 15 -23) forms a lid over the CTCB binding pocket and is observed 
in both the apo and ATP-bound structures of T. brucei PFK. 
A sequence alignment between T. brucei and T. cruzi PFK for the dynamic loops surrounding the 
trypanosomatid active site is shown in figure 6.30. The catalytically important Asp 173 loop, Asp 
229 loop and inserted loop are homologous between T. brucei and T. cruzi PFKs, however 
identity in the N-terminal loop is only 44%.  
The data shown in table 6.9 suggested that there was a greater increase in both affinity and 
potency against TcPFK for the azaindole compounds compared with the pyrazole type 
compounds. The binding poses of these two different scaffolds may explain this difference, in 
particular their interaction with the N-terminal loop; Figure 6.31 shows the crystal structures of 
CTCB 189 (pyrazole scaffold) and CTCB 293 (azaindole) bound to TbPFK. The binding orientation 
of the pyrazole compound (CTCB 189) appears to push the N-terminal loop out of the position 
it adopts in the ATP-bound PFK structure. In the azaindole (CTCB 293) bound structure the N-
terminal loop remains in the ‘normal’ position. It is possible that the increased affinity observed 
for CTCB compounds with the azaindole scaffold may be due to interactions with the dynamic 
N-terminal loop. In contrast the pyrazole scaffold compounds, which push the N-terminal loop 
out of position have much smaller differences in affinity and potency when comparing TbPFK 
and TcPFK. As the only difference in the TbPFK and TcPFK sequences was observed in the N-
terminal loop, it is reasonable to suggest that increased affinity for azaindole-like CTCB 





Figure 6.30: The N-terminal loop is not well conserved between T. brucei and T. cruzi PFKs. 








Cyan = TbPFK ATP bound (3F5M) Green = TbPFK + CTCB 189 
 
Cyan = TbPFK ATP bound (3F5M) Red = TbPFK + CTCB 293  
 T. brucei IC50  T. cruzi IC50 
CTCB 189 (pyrazole) 337 nM 267 nM 
CTCB 293 (azaindole) 320 nM 52 nM 
 
Figure 6.31: Binding pose of pyrazole compounds effects N-temrinal loop. 
 A) Pyrazole compound CTCB 189 bound to TbPFK overlaid on ATP-bound TbPFK structure 3F5M. 
B) Azaindole compound CTCB 293 bound to TbPFK. C) IC50 data for example CTCB 189 and CTCB 
293 compounds against TbPFK and TcPFK, measured using ADP-Glo assay. Structures solved by 






















6.7. CTCB compound specificity.  
6.7.1 CTCB compounds are not competitive with PFK’s substrates. 
To investigate if the CTCB compounds inhibited PFK without competing with the enzymes 
substrates, the PYK/LDH enzyme linked assay was used. ATP and F6P titrations were carried out 
in the presence of set concentrations (2x, 1x and 0.5x IC50) of inhibitor. As discussed in section 
4.2.1, the order of reaction is important for PFK – with ATP binding preceding F6P binding. To 
ensure all possibilities were covered, the competition kinetics experiments were carried out with 
and without incubation of the CTCB compound and TbPFK. The assays are summarised in table 
6.10. Full experimental procedures can be found in section 2.3.1.4.  
 ATP titration F6P titration 
‘Pre-incubated’ competition 
assays 
(TbPFK / cmpd. / F6P) + ATP (TbPFK / cmpd. / ATP) + F6P 
Non pre-incubated 
competition assays 
(TbPFK / F6P) + (ATP / 
cmpd.) 
(TbPFK / ATP) + (cmpd. / 
F6P) 
 
Table 6.10: Reaction order in compound competition assays. 
Brackets denote analytes that were pre-incubated together on ice for 10 minutes, then an 





Competition kinetics experiments were carried out using 5 CTCB compounds; A fragment (CTCB 
012), a sulphonamide identified from the original NIH screen (CTCB 123)(Brimacombe et al., 
2014) and three of the most potent inhibitors of T. brucei PFK (CTCB 360, ‘405 and 460)(figure 
6.32). Michaelis-Menten curves of the substrate titrations were used to look for evidence of 
competition. Table 6.11 outlines the classical hallmarks of different types of competition on 
enzyme kinetics. Figure 6.33 shows the plots for F6P and ATP titrations against T. brucei PFK in 
the presence of CTCB 360.  
 
 
CTCB 012 (fragment) 
 
CTCB 123 (sulphonamide) 
 
CTCB 360 (azaindole) 
IC50 = 0.8 ± 0.09 µM IC50 = 0.13 ± 0.05 µM IC50 = 0.10 ± 0.03 µM 
 
CTCB 405 (azaindole) 
 
CTCB 460 (azaindole) 
 
IC50 = 0.27 ± 0.08 µM IC50 = 0.08 ± 0.03 µM  
   
Figure 6.32: CTCB compounds used in PFK competition assays. 
IC50 values measured in PYK/LDH assay. 
 
Type of competition Effect on Vmax Effect on Km 
Uncompetitive    
Non-competitive  - 
Competitive -  
 
Table 6.11: Kinetic phenotypes of different types of competitive inhibitors. 




































TbPFK ATP titration vs Ctcb 360

































39.6 ± 1.6 36.5 ± 1.1 31.1 ± 0.8 27.9 ± 1.5 
Km (µM)   137 ± 8.3 181 ± 6.2 181 ± 6.9 199 ± 12.6 
 
 TbPFK only CTCB 360 0.5X 
IC50 
CTCB 360 1X 
IC50 





39.2 ± 0.5 31.7 ± 0.7 21.9 ± 0.4 13.2 ± 0.4 
Khalf (µM) 965 ± 30 1297 ± 92 2663 ± 151 4240 ± 276 
 
Figure 6.33: CTCB 360 inhibits T. brucei PFK without competing with ATP or F6P. 
A) ATP titrations (4 mM – 31 µM) against T. brucei PFK with set concentrations of CTCB 360 (0.5 
X, 1X and 2X IC50) (50, 100 and 200 nM respectively). 10 mM F6P, 4 µg/ml T. brucei PFK B) F6P 
titrations (40 mM – 310 µM) against T. brucei PFK. Fixed CTCB 360 concentrations as above. 5 







In the case of CTCB 360 shown in figure 6.33, mixed inhibition characteristics can be seen with 
both ATP and F6P; In both substrate titrations the Vmax is reduced and the KmATP or KhalfF6P is 
increased – showing a mix of the phenotypes outlined in table 6.11. The CTCB 360 compound 
therefore shows no evidence of competition with ATP or F6P. This was the outcome for all the 
compounds tested in these experiments: either producing ‘mixed inhibition’ or non-competitive 
phenotypes (data not shown). Pre-incubation of the compound had no effect on these 
conclusions. CTCB compounds are not competitive with the substrates of T. brucei PFK. The CTCB 
compounds also had no effect on the cooperative binding response with respect to F6P; The Hill 
coefficient (h) for 0, 0.5X , 1X and 2X CTCB 360 IC50 was between 1.7-1.8 ± 0.1 for the F6P 
titrations shown in figure 6.33. 
 
6.7.2 CTCB compound specificity between PFK from different species. 
The SDD project took a structure-based design approach to the development of the CTCB 
inhibitor compounds. The attraction of PFK as a target for trypanocidal drugs over other 
glycolytic enzymes was the binding pocket identified from crystal structures of T. brucei PFK. 
Crucially, this pocket is not present in the mammalian form of the enzyme – resulting in 
specificity for the trypanosomatid enzyme over the host. The aim of the work in this section was 
to investigate if the synthesised CTCB compounds were in fact specific over the mammalian form 
of the enzyme in vitro, and if they had comparable affinity between trypanosomatid PFKs.  
6.7.2.1 The most potent CTCB compounds do not inhibit human PFK. 
To test for specificity of CTCB compounds for T. brucei PFK over mammalian PFK, 8 of the most 
potent CTCB compounds were tested against the human muscle isoform of PFK (PFK-M) in the 
aldolase/TIM assay - see section 2.3.2.2 for experimental details. Human muscle PFK is the most 
abundant of the three human PFK isoforms PFK-P (platelet), PFK-L (Liver) and PFK-M (Muscle). 
No inhibition of human PFK-M was observed for any of the compounds tested. A titration of 
CTCB 405 against human PFK-M and T. brucei PFK is shown in figure 6.34. CTCB 405 has an IC50 





Figure 6.34: CTCB 405 shows no significant inhibition of human PFK-M. 
Data measured using the aldolase/TIM linked assay at 25 oC. Experiments carried out in 
triplicate, error bars denote standard deviation. T. brucei PFK and H. sapiens PFK-M at equimolar 
concentrations (80 nM). 1mM ATP and 0.6 mM ATP were provided. Sigmoidal curves have been 






6.8. Discussion – Mechanism and specificity of CTCB compound 
binding. 
We have shown in this section that the CTCB compounds bind tightly with specific interactions. 
The binding poses of the CTCB compounds within the ‘CTCB binding pocket’ of T. brucei PFK 
show how even small fragments can inhibit the normal docking of the catalytically important 
Asp 299 loop.  
We observed a striking increase in potency for the CTCB compounds against T. cruzi PFK 
compared to T. brucei PFK. This increased potency revealed further information on the 
relationship between the CTCB chemical classes and the binding mode; The pyrazole class of 
compounds destabilised the N-terminal loop, which normally forms a lid over the active site. 
The azaindole compound class demonstrated remarkable increases in potency against TcPFK, 
and in crystal structures did not interfere with the N-terminal loop. We showed through 
sequence alignments that the only significant differences in the active site and CTCB binding 
pocket between the TbPFK and TcPFK enzymes was within the N-terminal loop. While crystal 
structures of the CTCB compounds bound within TbPFK do not show interactions with any other 
dynamic loops within the active site, some evidence was presented for the azaindole class of 
CTCB compounds making contacts with the ‘N-terminal loop’.  
We have also shown in this chapter the specificity of the CTCB compounds; firstly we showed 
that the binding and inhibition by the CTCB compounds was not competitive with PFKs 
substrates. Mixed inhibition phenotypes were observed when CTCB compounds were tested 
against titrations of F6P and ATP, showing a lack of direct competition with these compounds. 
This is an obvious advantage in drug design, as the CTCB compounds will not be competing with 
high concentrations of substrates within the trypanosomes. F6P concentrations have been 
found to be >1mM in Leishmania spp. for example (Akpunarlieva et al., 2017). 
Secondly and perhaps more importantly, we have shown that the CTCB compounds are specific 
to the trypanosomatid PFK over the Human enzyme. No significant inhibition was observed 
when CTCB compounds were tested up to a concentration of 100 µM against the human muscle 
isoform of PFK. The CTCB binding pocket is incomplete in the human PFK structure, as discussed 
in section 7.4, chapter 7. Coupled with the observations described in this chapter that CTCB 
compounds are not promiscuous binders, we have shown that the CTCB compounds are highly 
specific and potent inhibitors of the T. brucei PFK enzyme, and have the potential as specific 




Chapter 7 : Conclusions. 
7.1. Trypanosomatid PFK is an essential, yet simply regulated 
glycolytic enzyme. 
In chapter 4 we observed that phosphofructokinase from T. brucei, T. cruzi and L. infantum 
trypanosomatids is regulated by the physiological effector AMP (and the structurally similar 
GMP). No other physiological effector of other eukaryotic PFKs or metabolic intermediate tested 
had any significant effect on our enzymes, however other, less obvious regulatory mechanisms 
may exist. AMP was an activator of the PFK enzyme; increasing the catalytic efficiency of the 
trypanosomatid PFKs (kcat/Km) with regards to both substrates ATP and F6P by factors between 
1 – 7X and 3 – 15X respectively. 
7.1.1 Trypanosomatid PFKs are not sensitive to allosteric ADP or ATP inhibition. 
ADP is an activator of the ancestral bacteria-like PFK, yeast PFK and mammalian PFK enzymes 
(section 4.5, chapter 4). Section 1.4.1, chapter 1 shows the evolution of eukaryotic PFKs from 
their bacterial ancestor. Yeast and mammalian PFKs retained an effector site imparting 
inhibition by PEP and activation by ADP. ADP did not regain its regulatory activity when 
trypanosomatids changed back to the use of ATP as phosphodonor, later in evolution (Bapteste, 
Moreira, & Philippe, 2003). We did observe weak inhibition of TbPFK by ADP (IC50ADP = 7.2 mM), 
though we propose that this may be in competition with ATP in the active site rather than 
allosteric inhibition. The binding orientation of AMP in an unpublished structure of T. brucei PFK 
with AMP bound (Montserrat Valdivieso and Iain McNae, UoE) suggests that the extra 
phosphate of the ADP molecule could be accommodated within the AMP binding site (section 
1.4.7, chapter 1)(per. Comm. I. McNae). 
ADP was shown to bind all three enzymes in SPR – giving steady state Kd’s of 0.56, 0.73 and 0.16 
mM for TbPFK, TcPFK and LiPFK respectively. AMP had no effect on the affinity of TbPFK for ADP 
in SPR, suggesting a lack of competition for the ADP or AMP binding sites. We propose therefore 
that ADP binds as a product in the active site or as a substrate for the reverse PFK reaction as 
discussed further in Chapter 5. We have no evidence of ADP binding within the allosteric AMP 
site, and the weak inhibition of ADP on TbPFKs activity is likely due to competition with ATP in 
the active site. 
We did not observe any binding response or inhibition of any of the three trypanosomatid PFKs 




enhancing the ATP inhibition effect on the enzyme. It does this as high citrate (a TCA cycle 
intermediate) signals that biosynthetic intermediates are readily available, and no further 
glucose is required to be broken down. The effector site responsible for the sensitivity (as well 
as ATP sensitivity) of mammalian and yeast PFK resulted from an acquisition of an extension that 
developed a citrate binding site (G. A. Dunaway, 1983; Heinisch et al., 1989). Therefore whereas 
a loss in allosteric ADP sensitivity by trypanosomatid PFKs resulted from a loss of an effector 
site, the lack of ATP/Citrate sensitivity is attributed to the lack of a event resulting in a new 
effector site (see section 1.4.1, chapter 1). The TCA cycle is also repressed in the BSF T. brucei 
parasites, and so regulation by citrate would seem unlikely (Zikova et al., 2017). 
Compartmentalisation of trypanosomatid PFK means that the enzyme does not sense the overall 
cellular (i.e. the cytosolic) ATP concentration; Feedback inhibition through ATP is an important 
regulatory feature of yeast and mammalian PFK and hexokinase enzymes (those using ATP as a 
substrate in glycolysis) as they are located in the cytosol. As glycolysis results in the net 
production of 2 ATP molecules per molecule of glucose consumed, inhibition of the enzyme 
activity by ATP or hexose phosphates (G6P, F6P and F16BP) is required. Preventing the auto-
stimulation of these enzymes by the surplus ATP produced by the process (‘turbo-effect’) could 
result in the build-up of intermediates to toxic levels when the catalytic capacity of the first 
enzymes of the pathway exceeds that of the downstream enzymes (figure 7.1). Trypanosomatid 
PFK and hexokinase, and the other enzymes involved in the first seven steps of glycolysis are 
compartmentalised within glycosomes, where the ATP:ADP ratio is held constant – there is no 
net production of ATP within the glycosomes, only in the cytosol where pyruvate kinase (PYK) is 
localised. The turbo-effect by ATP build up is therefore not possible regarding the enzymes in 
the glycosomes and sensitivity to ATP is not required (Haanstra et al., 2008). We did not find 
G6P, F6P or F16BP to be inhibitory against T. brucei PFK either. Under the conditions used, 





Figure 7.1: Feedback inhibition by ATP in glycolysis. 
The net production of ATP in glycolysis (4 x ATP) can act as fuel for the ATP consuming reactions 
upstream (dotted lines) and lead to build-up of metabolic intermediates of the capacity of the 
upper part of the pathway exceeds that of the lower part). Most eukaryotic organisms prevent 
this through negative feedback inhibition of hexokinase by hexose phosphates (G6P, F6P and 
F16BP) (Haanstra et al., 2008). In trypanosomatids net production of ATP occurs outside the 
glycosomal membrane which is impermeable to nucleotides. Several kinases within the 
glycosomes maintain the balance between ATP consumption and production (Deramchia et al., 
2014). 
7.1.2 AMP is the low energy signal and activator of trypanosomatid glycolysis. 
In mammalian glycolysis, AMP activates PFK by binding to an allosteric site and reversing the 
inhibitory effect of high ATP concentrations on the enzyme. When energy supplies are low (i.e. 
a low ATP:AMP ratio) the enzyme is stimulated and more ATP is produced through glycolysis. 
ADP is not used as the low energy signal as it can be converted into additional ATP by adenylate 
kinase (ADP + ADP = ATP + AMP).  
This offers a much more resource efficient method of signalling. AMP binds to an allosteric site, 
and allows more sensitivity as a regulator than ADP – small changes in ATP concentration result 
in large changes in AMP concentration – the breakdown of 2 ATP molecules results in a net loss 
of 1 ATP but a gain of 1 AMP molecule (figure 7.2). This is a resource-efficient way of recouping 
an ATP molecule while producing a signal molecule to stimulate glycolysis. 
 





In contrast to the important regulatory role PFK plays in mammalian glycolysis, we know from 
flux control analysis that while there is no single rate limiting step of glycolysis, PFK plays a lesser 
role in the control of glycolysis in trypanosomatids (section 1.3.5, chapter 1) (Haanstra et al., 
2017). Unlike all other eukaryotic PFKs, trypanosomatid PFKs are not stimulated by F26BP, but 
instead this activation of the pathway is facilitated via stimulation of pyruvate kinase (PYK) in 
the cytosol. Nonetheless AMP was an activator of all three of our trypanosomatid PFK enzymes. 
A glycosomal adenylate kinase produces AMP from ADP in T. brucei parasites (Ginger et al., 
2005). Similar to activation of PFK in mammals, it is likely that AMP is the low-energy signal in 
the trypanosomatid glycosomes, activating the PFK enzyme and stimulating glycolysis. PFK in 





7.2. A mechanism for trypanosomatid PFK enzyme activity. 
Various assays and biophysical methods described throughout this thesis have allowed us to 
accumulate evidence for a more complete understanding of trypanosomatid PFK activity. Figure 
7.3 describes a mechanism for PFK activity and regulation by AMP. The evidence used to build 
this model is summarised in table 7.1. 
7.2.1 A model for trypanosomatid PFK activity and regulation. 
The model for trypanosomatid PFK activity shown in figure 7.3 assumes two ‘activated’ enzyme 
conformations – the first upon ATP binding and the second upon subsequent AMP binding. In 
the ATP-bound state a conformational change in the loops surrounding the active site allows for 
F6P binding. AMP binding to this activated ATP-bound state results in the second ‘locked’ active 
state – affinity for both ATP and F6P is increased but the mechanism conferring cooperativity in 
F6P binding is lost. This AMP-induced loss of cooperativity is perhaps due to a conformational 
change or locking of the C-terminal reaching arms that span across adjacent subunits, and under 
which the putative AMP binding pocket lies. A crystal structure with both ATP and AMP bound 
would help answer this hypothesis, investigating in particular the effect AMP binding has on the 
conformational state of the C-terminal reaching arms. 
In the ATP-bound active conformation, cooperativity in F6P binding can best be described as 
following the KNF or ‘sequential’ model for cooperativity (see section 1.4.6, chapter 1); Provided 
ATP has bound to all subunits within the tetramer first, the binding of a molecule of F6P to one 
of the subunits induces a conformational change in the neighbouring subunit that increases 
affinity for the binding of another F6P molecule. We cannot consider the MWC ‘symmetry’ 
model as the rules governing this model dictate that the change between inactive and active 
enzyme states is independent of ligand binding. In our model the active state is only formed 
when ATP binds first. Some features of the MWC symmetry model however can be applied: The 
binding of F6P was found to be cooperative, but how is this cooperativity signalled across the 
tetramer? One possibility is the large dynamic ‘inserted loop’ feature. This large unstructured 
loop could potentially make contacts with the neighbouring inserted loop upon F6P binding, 
signalling a conformational change in the neighbouring F6P site to increase affinity for another 
F6P molecule (figure 7.4). With this in mind, the PFK subunits would work in pairs within the 







(A) ATP binds to PFK first in the reaction 
scheme, inducing an active enzyme state. 
1. A comparison of apo- and ATP-bound 
T. brucei PFK crystal structures shows 
ATP binding induces a 
conformational change to open up 
the active site and accommodate F6P 
(section 1.4.5, chapter 1). 
2. A binding response for F6P against T. 
brucei PFK surface in SPR was only 
possible when ATP was present 
(section 4.4.4, chapter 4). 
3. Pre-incubation of PFK with ATP 
resulted in greater affinity for F6P 
(lower KmF6P) (section 4.2.4, chapter 
4). 
(B) F6P binds PFK in a cooperative manner 
in the presence of ATP. 
1. F6P titrations against 
trypanosomatid PFKs result in dose-
response curves with sigmoidal tails 
at lower [F6P]. 
2. Hill coefficients are >2.0 with regards 
to F6P titrations against the PFK 
enzymes (Section 4.2.3, chapter 4) 
(C) ATP must be bound for AMP to elicit its 
activating effect. 
1. The activating effect of AMP on PFKs 
activity was only observed when the 
enzyme was pre-incubated with ATP 
first (section 4.5.3, chapter 4). 
(D) AMP binding induces a second 
conformation. This is a ‘locked’ active state 
with high affinity for substrates.  
1. The observed activation by AMP 
results in increased affinity for both 
ATP and F6P (section 4.5.2, chapter 
4). 
2. Cooperativity in F6P binding is lost 
when AMP is present (section 4.5.2, 
chapter 4). 
3. AMP also activates the reverse 
reaction, suggesting a second 
conformational state independent of 
ATP activation (section 5.3.1, 
chapter 5).  
 
Table 7.1: Evidence used for formation of our trypanosomatid PFK activity model. 
Showing the observations used to develop our PFK mechanism model and the evidence for each 










Figure 7.3: Model for trypanosomatid PFK enzyme mechanism. 
























Figure 7.4: Could the ‘inserted loop’ feature communicate cooperativity in F6P binding? 
ATP-bound (3F5M) TbPFK structure. Two neighbouring subunits within a dimer have been 
coloured pink and purple. Other dimer has been coloured grey. Inserted loop feature is coloured 
in red in both subunits and ATP shown as orange sticks in both subunits. Maximal distance 








F6P binds to one subunit within a dimer.  
F6P binding induces a conformational change in inserted loop 
structure. Inserted loop of neighbouring subunit senses this and 
promotes conformational change in F6P pocket to increase 




7.3. Enzyme kinetic assays revealed unique properties of 
trypanosomatid PFKs 
 
7.3.1 Measuring PFK activities for various trypanosomatid species is vital for 
accurate metabolic control analysis. 
As discussed in section 1.3.5 in chapter 1, metabolic control analysis is a powerful method of 
characterising and ranking glycolytic targets according to their effectiveness in controlling 
overall glycolytic activity in the system. Computer modelling of these systems requires accurate 
and representative kinetic data for each enzyme (Haanstra et al., 2017). The data we have 
gathered for PFK activity in the three trypanosomatid species in this thesis will add the species-
specific information required to build up a specific model of glycolysis in each organism.  
While maximal activity and affinity constants for ATP and F6P were comparable between T. 
brucei and T. cruzi  PFKs,  L. infantum PFK had a considerably lower affinity for F6P, as well as a 
lower maximal activity. While perhaps a simplified approach, the cell and tissue type in which 
these parasites linger during their infective stage may help to answer why we see such variances 
in the enzyme activity between species; These environments are summarised for each 
trypanosomatid species in their human infective life cycles in table 7.2. Unlike T. cruzi and L. 
infantum parasites, T. brucei’s life cycle, both in the insect and mammalian host stages is entirely 
extracellular. T. cruzi survives intracellularly in heart and digestive muscle tissues and 
Leishmania parasites evade immune detection by proliferation inside the phagolysosome of 
macrophages. The window of opportunity for maximal PFK inhibitor efficacy against 
trypanosomes is mainly in the bloodstream – where both drug bioavailability and 
trypanosomatid reliance on glycolysis will be at its highest. Glucose concentrations will vary 
according to extracellular fluid levels, insulin levels and the metabolic state of the host tissue of 
course, but even in their stage II tissue environments, T. brucei and T. cruzi parasites are in 
relatively high glucose environments in the brain, heart and digestive muscle tissues whether 
intracellular or extracellular (table 7.2).  This may explain why both overall enzyme activity and 
affinity for substrates is comparable between T. brucei and T. cruzi PFKs. Leishmania parasites 
in contrast enter macrophage cells as promastigotes, where they proliferate and transform into 
an amastigote form and invade other cell types of the immune system intracellularly. Data for 
glucose levels within phagolysosomes could not be found at the time of writing. It is fair however 




muscle tissue cells. It is known that Leishmania spp are able to use sugars, but undergo 
metabolic quiescence (a slowing of the metabolism) in these environments (McConville, 
Saunders, Kloehn, & Dagley, 2015).  As Leishmania PFK was most affected by AMP, it is possible 
that the metabolic environment in which Leishmania parasites proliferate may be energy 
deficient – i.e. have high levels of AMP. AMP therefore, more than in T. brucei and T. cruzi 
parasites, may act as a potent signaller for a metabolic switch for Leishmania spp. – significantly 
stimulating glycolysis within the trypanosomatid cell. The control of overall metabolic properties 
of trypanosomes is likely to be dictated mostly through regulation of the expression of the 
enzymes making up the metabolic pathways – reviewed by (Zikova et al., 2017). Still, AMP 
appears to play a significant role – greatly increasing the trypanosomatid PFK catalytic efficiency 
at times when glucose supplies may start to run low. The recent observation of T. brucei  
parasites in adipose and skin tissue adds another metabolic environment in which there may be 
a switch on the reliance of various metabolic pathways for survival (Capewell et al., 2016; 
Trindade et al., 2016). The PFK enzyme kinetic parameters gathered for these three disease 
causing trypanosomatid species in this thesis may provide up-to-date and reliable information 
for species-specific metabolic modelling studies. It is clear that despite their high sequence 
identity (69 – 72%) and homology in F6P and ATP binding sites, there are still differences in the 
overall enzyme activity between the trypanosomatid species.  
We have tested trypanosomatid PFKs with gene sequences optimised for expression and 
purification from bacterial cells. The conclusions we draw from in vitro testing of these enzymes 
therefore must be limited; Post-translational modifications on the enzymes when expressed in 
the trypanosomatids for example may significantly affect their true in vivo activity. A more 
accurate analysis may require purification of PFK from whole cell lysates of the various 
trypanosomatid species. Although difficult to carry out due to lab safety requirements (Cat. 3 
lab required even for non-human pathogenic T. b. brucei strains for example) and lower 
purification yields compared to E. coli expression, gathering kinetic values from in vivo PFK 









Parasite Stage I environment Stage II environment 
T. brucei sspp. Bloodstream. [Glucose] 18+ 
yr. old male = 4 – 5 mM1 
Lymph and spinal fluids 
(extracellular). 
[Glucose] CSF = and 2.9 – 5.4 
mM2. 
Skin and adipose tissues also 
reported3,4. 
T. cruzi Bloodstream. [Glucose] 18+ 
yr. old male = 4 – 5 mM1 
Heart + Digestive muscle 
tissue (intracellular) 
[Glucose] muscle tissue = 70 – 
320 µM5. 
Leishmania spp. Bloodstream. [Glucose] 18+ 
yr. old male = 4 – 5 mM1 
Macrophages (intracellular, 
inside the phagolysosome). 
[Glucose] in phagolysosome 
of macrophages = no data 
available. 
 
Table 7.2: Fact file for glucose concentrations in trypanosomatid human infective stage 
environments. 
1. (Darzy et al., 2006) 2. (Wishart et al., 2008) 3. (Tanowitz, Scherer, Mota, & Figueiredo, 2017) 
4. (Capewell et al., 2016)  5. (Cline, Jucker, Trajanoski, Rennings, & Shulman, 1998). 
 
7.3.2 A physiologically relevant reverse PFK reaction. 
In chapter 5 we showed evidence for the ‘reverse’ PFK reaction carried out by trypanosomatid 
PFKs. We showed that the production of F6P and ATP from F16BP and ADP was catalysed by the 
PFK enzyme. Titrations of both ADP and F16BP showed hyperbolic or sigmoidal responses 
against the enzymes, and the reverse reaction could be inhibited by the CTCB compounds. As 
we have described in chapter 6, the mechanism of trypanosomatid PFK inhibition by these 
compounds involves the blocking of a dynamic loop that aids in the phosphotransfer from ATP 
onto F6P in the forward direction. By showing that this same mechanism can be blocked by the 
compounds in the reverse direction, we have accumulated evidence that indeed the PFK enzyme 




kinetic parameters for the trypanosomatid PFKs in the reverse direction were feasibly close 
enough to expected F16BP and ADP concentrations to run in reverse under certain physiological 
conditions. We also discussed how in FBPase null mutants of T. brucei, indications of  PFK running 
in reverse was recently observed by the lab of Dr Bringaud at the University of Bordeaux 
(unpublished, pers. comm.). Unless the FBPase enzyme is somehow inhibited or downregulated, 
it is still difficult to imagine under what conditions trypanosomatid PFKs would need to carry out 
the reverse reaction to produce F6P from F16BP in vivo. As many plant PPi-PFKs are known to 
run in reverse, it is tempting to postulate that the ability to run in reverse may be a consequence 
of trypanosomatid PFKs ancestral divergence to a PPi-PFK and back again (section 1.4.1, chapter 
1). This is not likely the case however – we have shown through collaborative work with Dr Peter 
Fernandes within the Walkinshaw lab group, that human muscle, platelet and liver PFK isoforms 
can too be run in reverse under the correct in vitro conditions (data not shown). As mammalian 
PFKs did not have an evolutionary divergence to PPi-dependence, it is unlikely that the ability to 
run in reverse is due to this PPi-enzyme lineage.  
Showing that the reverse reaction is possible and that it can be inhibited allowed us to reveal 
more detail into the catalytic mechanism carried out by trypanosomatid PFKs; As shown again 
in figure 7.5, the mechanism for T. brucei PFK phosphotransfer has been modelled based on 
bacterial PFK structures (Evans, 1992; McNae & Martinez-Oyanedel, 2009). The Asp229 residue 
is responsible for holding the F6P substrate in place, to facilitate the phosphotransfer reaction 
between it and ATP. This is the catalytic loop that is blocked by CTCB compounds binding to a 
pocket into which the loop sits. The fact that we can inhibit the reverse reaction shows that this 
loop is also responsible for the reverse phosphotransfer from F16BP back onto ADP to produce 
F6P and ATP. If this is the case, the interactions of F6P and F16BP with this Asp229 residue must 
be the same, allowing the binding of F6P or F16BP with similar affinity. It is interesting that in 
SPR we were able to record a binding response for F16BP alone against T. brucei PFK, but not 
F6P on its own (section 4.4.2, chapter 4). We have explained that ATP binding promotes a 
conformational change in PFK to an ‘active’ conformation, capable of binding F6P, and indeed 
when ATP was present a response for F6P binding in SPR could be recorded (section 4.4.4, 
chapter 4). In the presence of ATP a binding response for F16BP could not be measured. This is 
not surprising considering the phosphates would overlap. As the affinity for ATP is much greater 
than for F16BP (table 7.3), ATP will be bound preferentially. This suggests that the ‘active’ PFK 
enzyme state induced upon ATP binding promotes specificity for F6P as a substrate for the 





 ADP ATP F6P F16BP 
SS Kd (µM) 558 ± 80 16 ± 2 No response 4600 ± 122 
SS Kd (+ATP) 
(µM) 
1677 ± 194 NA Weak (>10 mM) No response 
 
Table 7.3: Dissociation constants for PFK substrates against TbPFK. 
 
 
Figure 7.5: catalytic mechanism of bacterial ATP-dependant PFK.  
Adapted from Evans et al(Evans, 1992). A) From E. coli crystal structure. Corresponding T. brucei 
PFK residues shown in grey B) from B. stearothermophilus structure.  
 
Enzymes can speed up the rate of a reaction, but cannot alter the equilibrium of the reaction. 
Considering this, the thermodynamics of the forward and reverse reactions, and not the kinetics 
of the reaction may answer if the reverse reaction is feasible or not. The free energy change 





reverse reaction involving PPi, less of an energy cost is required. This may be the reason why 
most PFKs that are known to run in reverse in vivo (plant PPi-kinases) are able to do so. 
ΔGo (PPi + F6P → F16BP + Pi) = -2.1 Kcal/mol 
ΔGo (ATP + F6P → F16BP + ADP) = -4.4 Kcal/mol. 





7.4. CTCB compounds are excellent drug candidates against 
HAT. 
The main driving force behind the work carried out in this PhD project has stemmed from the 
overall goal of the Seeding Drug Discovery program; to design novel small molecule inhibitors of 
T. brucei PFK as drug candidates against Human African Trypanosomiasis. We have shown in this 
thesis that inhibition of T. brucei PFK translates to equally potent killing of cultured T. b. brucei 
parasites. As PFK holds a lower ranking position in terms of flux control in T. brucei (section 1.3.5, 
chapter 1), it is important that inhibitors designed against the enzyme are selective against the 
parasite and not the human host enzyme. We have shown that the CTCB compounds are exactly 
that; they bind in a 1:1 stoichiometry to a unique allosteric pocket found proximal to the active 
site of T. brucei PFK. They are not promiscuous binders , do not compete with the physiological 
substrates of the enzyme, and are small molecules – the average size of the 636 CTCB 
compounds was 320 Da. The selectivity of the compounds over the human PFK enzyme is clearly 
due to the CTCB binding pocket, which is incomplete in the human PFK structure (figure 7.7) 
These attributes make the CTCB compounds very promising ‘druggable’ compounds. Effective 
drugs however must have many other attributes despite a specific and tight interaction with 
their target; 
Out of the six CTCB compounds taken forward into dose-tolerance assays in mice, three showed 
cure of stage I HAT models in mice – CTCB 405, CTCB 470 and CTCB 508. 
 
Figure 7.7 : The CTCB binding pocket is not present in Human PFK platelet isoform. 
Overlay of TbPFK (pink) with CTCB 405 (sticks) bound (unpublished structure) with human PFK-P 
(4XYJ) (Blue). TbPFK-CTCB 405 structure resolution = 2.8 Å (per. comm I. McNae, UoE), human 





7.4.1 CTCB compounds were rapid killers of T. brucei parasites. 
During in vitro assays to establish the EC50 (“effective concentration” required for 50% death of 
parasites) for CTCB compounds against cultured T. b. brucei parasites it was found that CTCB 
compounds killed the parasites much quicker than existing treatments such as Suramin and 
other compounds in development (Fexinidazole and SCYX-7158) (Jacobs et al., 2011). Figure 7.8 
shows the parasite killing profiles of CTCB 405 alongside these existing compounds against ‘T. b. 
brucei parasites of the GVR35Luc2 cell line. This cell line is derived from the GVR35 strain; it  
produces a luciferase enzyme that emits a luminescent signal with the addition of luciferin – 
showing the presence of ATP and thus providing an indication of cell viability. As we can see in 
figure 7.8, CTCB 405 rapidly blocks ATP production and kills cells within 30 minutes, compared 
to the other compounds which take at least 12 hours to elicit complete killing of the parasite 
culture. It is clear that the inhibition of the T. brucei PFK enzyme is a highly effective killer of the 
bloodstream form parasites, and validates our finding that CTCB potency against the enzyme 
correlates well with parasite death. 
 
Figure 7.8: CTCB 405 blocks leads to a rapid cell death of T. b. brucei GVR35 trypanosomes. 
GVR35Luc2 T. b. brucei cells modified for luciferase expression (gives luminescent signal when 
ATP is being produced. All cells tested in modified HMI-9 medium with 20% FCS. Data collected 
by L. Yen (UoE).  
 
Time to kill experiment using GVR35 cells
























7.4.2 CTCB compounds had promising pharmacological profiles. 
‘ADME’ (Absorption, Distribution, Metabolism and Excretion) profiles were generated for all 
CTCB compounds that were considered for testing in mice. Table 7.4 shows the pharmacological 
profiles for the three CTCB compounds taken forward to show cure of stage I HAT in mice. 
The CTCB compounds have strong target selectivity – with high potency against both the enzyme 
(IC50 / 0.2 µM) and cultured parasites (EC50 ~ 0.3 µM), the compounds in table 7.4 show no 
inhibition of the human muscle PFK isoform (‘hPFK) and kill human liver hepatocytes (HepG2 
cells) at much higher concentrations. This is reflected in the high ‘cellular selectivity’ indices 
given – the ratio of EC50 (HepG2 cells) : EC50(T. b. brucei cells).  
CTCB compounds also show good metabolic stability – half-life in mouse liver microsomes 
(MLM) range from 15 – 25 minutes. Half-life values for existing drugs (in Human Liver 
Microsomes – HLM) range from 4 minutes (Midazolam) to as much as 66 minutes (Amobarbital) 
(Obach, 1999). Drug metabolism and clearance occurs predominantly in the liver and kidneys – 
many existing drug compounds are known to be cleared by liver hepatocytes (Obach, 1999). The 
CTCB compounds shown in table 7.4 have moderate intrinsic clearance rates of 56 – 70 
µL/min/mg in mouse liver microsomes. This sits in the middle of the range of known clearance 
rates of existing drugs in human microsomes – ranging from 0.52 – 189 µL/min/mg for the drugs 
Warfarin and Verapamil, respectively (Obach, 1999). 
As we showed in section 6.4.4, chapter 6, the majority of CTCB compounds had very weak or no 
affinity for human serum albumin (HSA). This is shown indeed by the low binding rate of the 
CTCB compounds to both human and mouse plasma protein as shown in table 7.4. This ensures 
a high bioavailability of the inhibitor in the bloodstream – the environment which offers the 
window of opportunity for most effective killing of the trypanosomes due to their metabolic 
reliance on glycolysis. The IC50 and EC50 values for CTCB 405, ‘470 and ‘508 are all ~ 0.2 and ~0.3 
µM respectively (table 7.4). With even a single dose of compound, the plasma concentration is 
~3X higher than the EC50 requirement for each of the compounds – under these concentrations 
the parasite population in the blood should be completely killed. With a 3x 100 mg/Kg dose over 
2 days the plasma compound levels for both 405 and 470 are greater than 4 µM at 2 hours 
following the last dose. Considering the compounds kill parasites in vitro in under 30 mins at this 
concentration (figure 7.8), there is an ample window of opportunity to clear the parasites from 
the blood considering all of these measured parameters. Again the IC50 and EC50 measurements 











   
TbPFK IC50 (µM) 0.19 0.21 0.20 
hPFK IC50 (µM) > 100 > 100 > 100 
Tbb EC50  (µM) 0.37 0.31 0.3 
HepG2  EC50  (µM) 20.8 12.3 33.4 
Cellular Selectivity 56 39 111 
METABOLIC 
STABILITY 
   
MLM Clint 
(µL/min/mg) 
70 91 56 
MLM t1/2 (min) 19.6 15.2 24.6 
HLM Clint (µL/min/mg) <8.6 - - 
BINDING AND EFFLUX 
   
Mouse PPB 
(%unbound) 
94.2% 94% 82% 
Human PPB 
(%unbound) 
93.7% 96.8% 79.3% 
 
Table 7.4: ADME profiles for CTCB compounds that lead to a cure of stage I HAT in mice. 
TbPFK = T. brucei PFK. hPFK = human muscle PFK. MLM = mouse liver microsomes. HLM = human 








Highest tolerated dose (HTD) studies were carried out in mice with five of the CTCB compounds 
and the plasma concentrations of compound were measured 2 hours after each dose. The blood 
concentration levels of CTCB 405, ‘470 and ‘508 in mice under various dosing regimens are given 
in table 7.5.  
 
 
  Plasma conc. (µM) 
(2hr after final dose) 
 
Dose scheme CTCB 405 CTCB 470 CTCB 508 
1 x 50 mg/Kg 
dose 
0.86 0.89 0.78 
3 x 50 mg/Kg 
doses daily for 2 
days 
6.8 1.8 5.0 
3 x 100 mg/Kg 
doses daily for 2 
days 
9.8 4.8 ND 
 
Table 7.5: Mice blood plasma concentrations of CTCB compounds after oral administration. 
Powdered stocks of CTCB compounds were administered using oral gavage to C41 strain mice. 






7.4.3 CTCB compounds resulted in cure of stage I HAT. 
The overarching focus of the SDD was to design small molecule inhibitors of T. brucei PFK as 
novel drug candidates against Human African Trypanosomiasis. All three of the CTCB compounds 
described in table 7.4 resulted in a cure of stage I HAT in mice infected with T. b. brucei Lister 
427 strain parasites. A relapse of parasites was observed when the same drugs were used in 
studies involving mice infected with T. b. brucei Lister-427 infected mice, however figure 7.9 
shows the clearance of fluorescent GVR35Luc2 T. b. brucei parasites from mice through oral 
dosing with CTCB 470 and CTCB 508. The relapse of parasites in the stage II HAT mice models 
was seen by a return of luminescent signal in the brain region, followed by the abdomen (data 
not shown). This suggests both that insufficient amounts of CTCB compound were available in 
the brain for a complete cure of the parasite population, and that perhaps a number of parasites 
were dormant in the adipose tissue of the abdomen or skin, as suggested by recent findings 















Figure 7.9: CTCB 470 and CTCB 508 result in a cure of stage I HAT in mice. 
Imaging of stage I T. brucei brucei infected C41 mice at day 7 post treatment. Melarsoprol is an 
existing HAT treatment with high mortality rates and toxic side effects. Efficacy monitored using 
transgenic luminescent parasites (GVR35Luc2 strain). [BP] = concentration of compound in blood 
plasma. Data measured by D. Malik (UoE) using facilities provided by University of Glasgow. 
Untreated  + Melarsoprol  
+ CTCB 470 
[ 2x (3x 
100mg/Kg) ]  
[BP] = 4.8 µM 
 
+ CTCB 508 
[ 2x (3x 
100mg/Kg) ]  




7.4.4 Future directions for SDD project. 
Going forward, the main focus of the SDD work will be to optimise the lead compound to 
increase penetration of compound into the brain, in order to kill parasites in the stage II form of 
the disease. The average molecular weight of the CTCB compounds was 319.9 Da, and the most 
successful azabenzimidazole scaffold series (like those shown in table 7.4) has scope for 
increased groups to be added or modified. The more basic compounds generally performed 
better when tested against the in vitro cultured T. b. brucei parasites (section 6.2.5, chapter 6) 
and the lead compounds taken forward for mice studies clearly have a suitable balance in affinity 
against the target enzyme (IC50PFK) and characteristics to effectively enter the parasite (EC50). 
More work therefore will need to be carried out to improve the characteristics of the 
compounds for crossing the blood-brain-barrier. This is possible, as shown by the revisiting of T. 
brucei N‑Myristoyltransferase Inhibitors  from a group in Dundee, who managed to improve the 
brain penetration of their lead series to better improve its stage II HAT characteristics (Bayliss et 
al., 2017). 
The latest implementation of Fexinidazole as an orally administered treatment of stage II HAT 
by the DNDi (Drugs for Neglected Diseases initiative) has been a remarkable success story 
(Pollastri, 2017). Despite this, it is still important to feed more potential drug compounds into 
the ‘pipeline’ of drug development against HAT – to ensure a range of possible treatments can 
be used to attempt to tackle drug resistance and availability. It would be extremely 
advantageous therefore to continue development of the CTCB compounds since they are tight 
and specific inhibitor compounds, have shown no toxicity in mice models, show excellent ADME 
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